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Abstract 
Oral cancer is one of the most common malignancies worldwide, with over 350,000 to 
400,000 new cases reported each year. Early detection, followed by appropriate 
treatment, can increase cure rates to 80 or 90%, and greatly improve the quality of life by 
minimising extensive, debilitating treatments. 
Usually, the clinical diagnosis of most head and neck neoplasms, including oral cancer, 
is performed through time-consuming and invasive biopsies followed by histological 
examination of the excised tissue and may present psychological trauma and risk of 
infection to patients. In addition, histological grading can be subjective, as it is based on 
subtle morphological changes. In this context, saliva is gaining interest as a diagnostic 
fluid, since it represents a non-invasive, safe, cheap source of complex biomolecular 
information that can easily be obtained from the oral cavity. In parallel, increased effort 
is being devoted to developing less invasive early diagnostic modalities for oral cancer, 
of which novel optical systems, such as Raman spectroscopy, hold great promise. 
The overall aim of this study is to develop methodologies for analysis of human saliva 
using Raman spectroscopy with a future applicability for oral cancer diagnosis. In order 
to optimise the measurement protocol, a number of different microscope configurations, 
source lasers, and substrates were trialled. Once the measurement protocol was optimised, 
it was validated using artificial saliva and real human saliva. The individual saliva 
constituent components as well as the artificial saliva itself were characterised and 
recorded. Following the standardisation protocol, real human whole saliva samples 
collected using two different collection methods were subjected to centrifugal filtration. 
The Raman signal from whole saliva was acquired and analysed through statistical tools, 
demonstrating the potential for diagnostic applications. Then, the Raman spectroscopic 
profiles of patients with saliva samples of different oral dysplastic pathologies, such as 
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epithelial oral dysplasia and oral cancer, were further analysed and spectroscopically 
assessed. To finalise, confounding factors, such as smoking habits and alcohol 
consumption, were also assessed in terms of their influence on the Raman classification 
of these pathologies. 
This research showed that, Raman spectroscopy was able to successfully discriminate 
stimulated saliva samples from healthy volunteers and patients with oral cancer or 
potentially malignant lesions, highlighting the weak influence of confounding factors, 
such as gender, age, smoking and alcohol consumption. However further studies are still 
required to improve classification among the different dysplasia grades.  
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Chapter 1: Introduction - Thesis Outline, Oral Cancer and 
Saliva 
 
1.1 Thesis Outline  
This thesis describes the investigation of Raman spectroscopy as an alternative/adjuvant 
method for early detection of oral cancer on the basis of the biochemical fingerprint from 
saliva samples. The study entails initially establishing protocols for the routine 
measurement of human saliva samples, which was carried out using water and artificial 
saliva, before applying the protocol to human samples.  
The broad objectives of the thesis were to: 
1) develop and optimise the methodology for analysis of liquid whole human saliva using 
Raman spectroscopy, based on artificial saliva formulation; 
2) discriminate qualitatively the nature of collection of saliva samples (e.g., Stimulated 
versus Non stimulated saliva) by Raman Spectroscopy; 
3) develop models for classification of oral potentially malignant and malignant oral 
lesions using multivariate statistical methods; 
4) evaluate the influence of confounding factors and clinical features from healthy 
volunteers and patients on the Raman spectra of saliva samples. 
Healthy volunteers were consented and their samples collected at Technological 
University Dublin (TU Dublin) in order to form the control group. Patients with oral 
cancer/potentially malignant lesions were consented during their check-ups at the 
Dysplasia Clinic of Dublin Dental University Hospital (DDUH). All the saliva samples 
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were assessed with Raman spectroscopy and their individual biochemical profiles were 
analysed, taking into consideration the dysplastic profile of each sample.  
The first chapter of this thesis is a general description of the background related to oral 
squamous cell carcinoma (OSCC) and potentially malignant lesions. It also details current 
methods for treatment and the importance of early detection of oral cancer. Chapter 2a 
describes the potential of Raman spectroscopy as a novel method for cancer detection and 
its current state of the art for oral medicine diagnostics. Chapter 2b of this thesis is a 
systematic review paper on the diagnosis of oral cancer through saliva samples by Raman 
spectroscopy, accepted for publication in Translational Biophotonics (DOI: 
10.1002/tbio.201900001).  
The subsequent chapters address the aims/objectives of this thesis. Chapters 3, 4, 5 and 6 
specifically address objectives 1, 2, 3 and 4, respectively. Chapter 4 has been submitted 
for publication at Analyst. 
Chapter 7 constitutes a summary of the work carried out, and furthermore considers the 
future perspectives and the potential clinical relevance of the current findings. 
 
1.2 Oral Cancer 
1.2.1 Definition and Epidemiology 
Cancer is a general term for diseases in which abnormal cells divide without control and 
can invade nearby tissues. Cancer cells can also spread to other parts of the body through 
the blood and lymph systems1. 
Oral cancer is a malignant neoplasia which is manifest on the lip or in the oral cavity and, 
in 90% of the cases, and is histologically classified as Squamous Cell Carcinoma (OSCC) 
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due to an origin from oral squamous cells. This type of lesion is one of the most common 
malignancies worldwide, over 350,000 to 400,000 new cases being found each year, and 
was responsible for more than 170,000 deaths in 2018. Demographically, oral cancer has 
its highest incidence in South Central Asia, Eastern Europe and some regions in Asia 
(Figure 1.1)1, 2. 
 
 
 
 
 
 
 
 
Figure 1.1: Map showing the incidence of oral cancer worldwide. Source: GLOBOCAN, 2018 
(IARC)1. 
 
The risk of developing oral cancer increases with age and the majority of cases occur in 
people aged 50 or over. However, in high-incidence countries of the world, many cases 
are reported before the age of 40 and, for those cases, Human Papilloma Virus (HPV)-
positive status seems to be a determinant. The reported sex differences are attributable to 
heavier indulgence in associated risk habits and exposure to sunlight (for lip cancer) as a 
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part of outdoor occupations, for men. The ratio of males to females diagnosed with oral 
cancer, however, has declined over the decades and is now about 1.5:13. 
1.2.2 Aetiology and Major risk Factors  
OSCC is considered a multifactorial entity. Several factors may contribute to the 
development and progress of this neoplasia, and the main and best understood ones in this 
carcinogenic process are described below. 
 
Smoking  
There is ample evidence suggesting that tobacco in various forms, including smoking, 
chewing and in betel quid etc., have carcinogenic impact in the oral cavity. The 
complexity of the mixture of carcinogens (over 60 in a cigarette, for example) in tobacco 
smoke means that, in different individuals, different carcinogens might cause different 
types of damage4. The different tobacco smoke compounds may exert carcinogenic, co-
carcinogenic, or tumour promoting effects in an organ and tissue specific manner, 
depending on the rate of accumulation and metabolism at various sites in the body, 
coupled with the possibility that these compounds may damage the tumour suppressor 
gene P535. 
Statistically, smoking is estimated to account for about 71% of deaths from oral cavity 
cancer (including pharynx) in high-income countries and 37% of deaths in low- and 
middle-income countries6. In terms of gender aspects, female smokers are more likely to 
develop oral cancer than male smokers when smoking is the only risk factor taken into 
consideration7. Also, the risk of carcinogenesis increases with increased tobacco 
consumption7. 
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Alcohol 
There is a certain degree of controversy concerning whether alcohol alone may have 
carcinogenic impact but, although through as yet uncertain mechanisms, alcohol is 
associated with 3.5% of all the cancer deaths worldwide8. Studies have shown that 
individuals consuming more than 170 g of whiskey daily have ten times higher risk of 
oral cancer than light drinkers8,9. Notably, anatomical sites in closest contact, on ingestion 
of alcohol, such as the mobile part of the tongue, present a high risk for developing this 
kind of neoplasm10.  
The most accepted theory regarding the carcinogenic capability of alcohol is the one 
correlated with the process of acetaldehyde production11. After alcohol intake, 
acetaldehyde is locally formed in the oral cavity by oral mucosal alcohol dehydrogenases 
(ADHs) and by the oral microflora and this chemical has been previously related to the 
carcinogenesis process in vitro 12. Furthermore, alcohol is believed to act as a solvent for 
other carcinogens which would explain the synergistic relationship between its 
consumption and smoking in the development of oral cancer13. 
 
Smokeless tobacco (SLT) 
Tobacco products which are used in a way other than smoking are called smokeless 
tobacco. The most common smokeless tobacco products are chewing tobacco, naswar, 
snuff, snus, gutka, and topical tobacco paste. There are more than twenty-five compounds 
in smokeless tobacco which have cancer causing activity14. The most harmful compounds 
in smokeless tobacco (SLT) are tobacco-specific nitrosamines (TSNAs) and their levels 
are directly related to the risk of cancer14. People using different forms of chewing SLT, 
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such as loose leaf, have an almost five times higher risk of developing oral cancer as 
compared to non-chewers15. 
Used in combination with SLT or on its own, betel quid, a substance, or mixture of 
substances, placed in the mouth, is usually wrapped in betel leaf (derived from the Piper 
Betel vine) with/without tobacco and sliced fresh or dried areca nut (Areca catechu)15. In 
contrast to the SLT by itself, the genotoxicity and mutagenicity seems to come from the 
areca nut extract along with areca alkaloids in betel quid16,17.  
 
Human Papilloma Virus (HPV) 
The human papillomavirus (HPV), transmitted through conventional and oral sexual 
contact, is an important risk factor for certain types of oral cancer. In fact, HPV is now 
the major cause of oropharyngeal cancer in developed countries, detected in 45–90% of 
cases, but it has also been detected in a smaller subset of oral cavity cancers (23%)18. 
Among all the HPV subtypes (more than 100), the 16 and 18 subtypes are recognised as 
high-risk due to their relevance in a possible association with oral pre-cancer lesions and 
cancer itself19. Two proteins, in particular, of the early genomic region of high-risk HPVs 
are capable of forming specific complexes with vital cell-cycle regulators: E6, which 
binds to p53 and induces its degradation, and E7, which interacts with pRb and blocks its 
downstream activity. Functional deregulation of these key oncosuppressors results in 
uncontrolled DNA replication and apoptotic impairment and explains the increased 
tumorigenic ability of high-risk types20. 
1.2.3 Clinical features of Oral Cancer 
The most common locations of occurrence of oral cancers are the tongue and the floor of 
the mouth, in over 50% of cases1. Other areas of involvement are the buccal mucosa, 
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retromolar area, gingiva, soft palate and, less frequently, the back of the tongue and hard 
palate21. These specific anatomic occurrences might be related to their own aetiology, as 
smoking could be associated with those malignant lesions in the retromolar area and floor 
of the mouth, while alcohol is mostly associated with the floor of the mouth only21. 
Clinically, OSCC has an extensive clinical variability, but very often it presents as an 
ulcer with fissuring or raised exophytic margins. It may also present as a lump, as a red 
lesion (erythroplakia), as a white or mixed white and red lesion, as a non-healing 
extraction socket or as a cervical lymph node enlargement, characterised by hardness or 
fixation21,22. 
Regarding symptomatology, usually, at the initial stages, oral cancer is painless but may 
develop a burning sensation or pain when it is advanced. This may be one of the principal 
reasons for diagnosis delay23. 
1.2.4 Diagnosis 
Usually led by a doctor or a dentist, the process of diagnosis begins with a conventional 
oral examination followed by a scalpel/punch biopsy/histology. This procedure still 
remains the gold standard and most medical/dental schools worldwide have adopted and 
disseminated it as the protocol of management of suspicious oral lesions24.   
Histological stratification determines the risk, according to tissue abnormalities and 
cellular morphology of premalignant lesions and squamous cell carcinoma. The 
histopathological grading describes the invasiveness, biological nature and behaviour of 
the tumour25. 
Despite providing valuable morphological information, both methods have raised 
questions regarding their applicability and general capability in oral diagnostics. Not only 
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risky and invasive in surgical terms, the biopsy may also not be effective when incorrectly 
performed, or even processed during the histological treatment of the specimen25. 
Other complementary diagnostic methods currently available for oral cancer also include 
toluidine blue staining and oral brush biopsy.  
Toluidine blue is a cationic metachromatic dye that may selectively bind to free anionic 
groups and it has been used for decades as an aid to the identification of mucosal 
abnormalities in the oral cavity. It has been valued by surgeons as a useful way of 
demarcating the extent of a lesion prior to excision, as toluidine blue stains 
deoxyribonucleic acid and/or may be retained in intracellular spaces of dysplastic 
epithelium. However, the high rate of false positives and the low specificity in staining 
dysplasia are very well known limitations of the technique24,26. 
Exfoliative cytology was first designed for early detection of cervical cancer and it has 
been primarily applied in oral medicine practice to detect early changes in oral mucosa 
related to malignancy. Exfoliative cytology is performed with cytobrushes, so as to obtain 
a good-quality smear that includes cells from deeper layers of the epithelium, especially 
of squamous intraepithelial lesions. However, this technique has been criticised for 
adding time and cost to the diagnosis of oral lesions without additional benefit to the 
patient once results must be confirmed with biopsy for a definitive diagnosis24,27.  
Concomitantly, or after the first diagnosis for oral cancer, a panoramic radiograph of the 
mandible, Computed tomography or Magnetic resonance imaging of the region may be 
done, each of which is useful in assessing the extent and stage of the cancer. Also, a chest 
radiograph and pre-treatment dental evaluation are recommended. For patients with 
advanced disease who will receive concurrent chemotherapy and radiation, blood counts 
and chemistries may be performed to assess critical organ function including renal and 
hepatic function28. 
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1.2.5 Clinical Staging and Histopathological grading 
Clinically, OSCC is often classified under the TNM system (T: Extent or size of the 
primary tumour, N: Absence or presence of regional lymph node involvement, M: 
Presence or absence of distant metastasis), widely applied by clinicians based on 
anatomical involvement29. 
Sub classifications of each factor previously cited into the TNM classification are also 
present and essential for further general staging. For T, TX, T0, Tis, T1, T2, T3, T4a and 
T4b are available as subclasses. TX characterises that the tumour could not be assessed. 
T0 represents tumour absence while Tis is used when a carcinoma in situ (CIS) is present. 
Tumours up to 2cm are clinically defined as T1. T2 and T3 tumours are primary tumours 
between 2-4cm or greater than 4cm, respectively. Furthermore, T4a and T4b designate 
nearby structures, such as cortical bone, muscles of the tongue and skin of the face, for 
T4a; and pterygoid plates, skull base or internal carotid artery, when T4b29.  
In the same way, NX, N0, N1, N2 and N3 are used for N classification. NX is the 
impossibility of assessment of the tumour. N0 is the tumour absence while N1 is the 
involvement of a single ipsilateral lymph node, no larger than 3cm. N2 is a single or 
multiple ipsilateral or contralateral lymph nodes, bigger than 3cm but less than 6cm. 
When bigger than 6 cm, the lymph node involvement can be classified as N329. 
Regarding the distant metastasis assessment, M1 indicates the presence of distant 
metastasis, while M0 is the absence and MX refers to distant metastasis that cannot be 
assessed29. 
Finally, the TNM classification further determines the scores inherent to each one of the 
cancer stages, which are: 
Stage 0: Tis N0 M0; 
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Stage I: T1 N0 M0; 
Stage II: T2 N0 M0; 
Stage III: Either T3 with N0 M0 or T1, T2, or T3 with N1; 
Stage IV: Locally invasive neoplasm (T4a/T4b) with N0 M0 or any T with N2/N3 or any 
T with M1. 
All these stages are extremely important for treatment strategy and to predict the survival 
probability. Furthermore, in 2018 other features were also added to the staging system in 
order to alter the clinical staging of these tumours, such as P16 positivity and the depth 
of invasion29. These guidelines were altered by the WHO, aiming for a better management 
of these different cases29. 
Complementary to the clinical staging, the histopathological grading for cancer in the oral 
cavity is also a determinant for the patient prognosis. Anneroth et al.30 proposed the most 
common grading system adopted among Oral and Maxillofacial pathologists (Table 1-1) 
for oral tumours. It takes into consideration morphological patterns related to the tumour 
cell population and tumour-host relationship and translates these data to numbers (1 to 4) 
that have to be used for the final grade calculation30. 
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Table 1-1: Anneroth et al. histological grading system for oral squamous cell carcinoma30. 
 
 
 
 
 
 
 
* High power field 
 
There are 4 grades in the histological classification and the total points scored by each 
patient are calculated by adding the points of each parameter31. The grades are: 
Grade I:  5-10 points; 
Grade II: 11-15 points; 
Grade III: 16-20 points; 
Grade IV: 21 or more. 
1.2.6 Management and Treatment  
Most oral cancers are treated with wide (radical) surgical excision, radiotherapy, or a 
combination of surgery and radiation therapy (multimodal treatment). Moreover, 
chemotherapy with platinum-containing compounds (e.g., cisplatin), 5-fluorouracil and 
texanes (e.g., paclitaxel) can integrate the range of therapy options29,32.  
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The factors that influence the choice of initial treatment are those related to the 
characteristics of the primary tumour, those related to the patient and those related to the 
treatment team33.   
The tumour factors that affect the choice of initial treatment of oral cancer are primary 
site, size (T Stage), location (anterior versus posterior), proximity to bone (mandible or 
maxilla), status of cervical lymph nodes, previous treatment, and histology (type, grade 
and depth of invasion). When diagnosed early, only a single therapy is required; 
radiotherapy or surgical removal for small tumours and a surgical approach for larger 
neoplasms. On the other hand, advanced cases require a multimodal approach of surgery 
followed by radiation and/or chemotherapy32,33. 
Likewise, several factors relative to patient characteristics are crucial in the selection of 
initial treatment for oral cancer and the course of the treatment, such as the patient’s age, 
general medical condition, tolerance of treatment, occupation of the patient, acceptance 
and compliance by the patient, lifestyle (smoking and drinking) and other socioeconomic 
considerations32.  
Also, the multidisciplinary approach is crucial in bringing about a successful outcome of 
the therapeutic program. Expertise in various disciplines including surgery, radiotherapy, 
chemotherapy, rehabilitation services, dental and prosthetic support, and psycho-social 
support are essential in making the individualised and correct selection of initial definitive 
treatment for oral cancer32. 
Follow up is mandatory for all oral cancer cases. The prognosis for survival from oral 
cancer depends on tumour stage. The great majority of deaths occur within the first 5 
years after treatment. The 5-year relative survival rate for intraoral carcinoma is 53% to 
68% if the tumour is relatively small and metastasis has not occurred by the time of 
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diagnosis. However, some patients die of their disease as many as 10 years after initial 
treatment29,32,33.  
 
1.3 Potentially malignant Oral lesions and disorders  
1.3.1 Potentially malignant oral lesions 
First used in 1875 by Romanian physician Victor Babeş, the term ‘premalignant lesion’, 
or potentially malignant lesions, is used to define a morphologically altered tissue in 
which cancer is more likely to occur than its apparently normal counterpart. Also, this 
sort of lesion– (disease, syndrome, or finding) is relatively common, appearing in about 
2.5% of the general population34,35. 
Defined by the World Health Organisation (WHO) as “a white patch or plaque that cannot 
be characterised, clinically or pathologically, as any other disease”, leukoplakia is by far 
the most common clinical presentation of premalignant oral lesions, representing around 
80% from all pre-cancerous lesions in the anatomical region. This clinical term does not 
take into consideration any histopathologic tissue change but it is known that 60% of oral 
mucosa carcinomas are present as white, keratotic lesions34,36. 
Oral leukoplakia is also clinically classified in two main types: homogeneous type and 
non-homogeneous type. The homogeneous leukoplakia is a uniform, thin white area 
alternating or not with normal mucosa. Alternatively, non-homogeneous type includes 
also sub classifications: speckled, nodular and verrucous leukoplakia. A high risk of 
malignant transformation is associated with non-homogeneous lesions37. 
In contrast to leukoplakia, erythroplakia and/or erythroleukoplakia is a red or 
erythematous patch of the oral mucosa. This lesion is defined as a red patch that cannot 
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be clinically or pathologically diagnosed as any other lesion and is associated with 
significantly higher rates of dysplasia, CIS, and invasive carcinoma than leukoplakia38. 
1.3.2 Oral Dysplasia 
While leukoplakia, erythroplakia and leukoerythroplakia are terms used to designate 
clinical features of potentially malignant lesions, dysplasia reflects histological changes 
which are followed by the loss of uniformity or of the architecture of the epithelial cells. 
Thus, the diagnosis and grading of oral epithelial dysplasia are based on a combination 
of architectural and cytological changes/atypia39: 
- Mild dysplasia (grade I): Characterised as a proliferation or hyperplasia of cells 
of the basal and parabasal layers which does not extend beyond the lower third of 
the epithelium; 
- Moderate dysplasia (grade II): Defined as a proliferation of atypical cells 
extending into the middle one-third of the epithelium; 
- Severe dysplasia (grade III): Abnormal proliferation from the basal layer into the 
upper third of the epithelium with cytological and architectural changes usually 
very prominent. Carcinoma in situ (CIS), the most severe form of epithelial 
dysplasia, has been recently included in grade III along with severe dysplasia by 
recommendation of the WHO. CIS is characterised by full thickness cytological 
and architectural changes. 
The presence and histopathological severity of dysplasia are often regarded as an 
indicator of the risk status of a precancerous lesion (some studies have shown as many as 
36.4% of dysplasia cases transforming to cancer) and these histopathological 
determinants are present in 5-25% of oral leukoplakias39. Erythroplakia also carries a 
much higher transformation rate and is often associated with severe dysplasia, or even 
carcinoma in situ39,40. 
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1.3.3 Potentially malignant oral conditions 
Defined as generalised states associated with a significantly increased risk of cancer, the 
most common potentially malignant oral conditions are: oral submucous brosis, actinic 
cheilitis, lichen planus, sideropenic dysphagia (Plummer-Vinson syndrome), discoid 
lupus erythematosus, syphilis, and xeroderma pigmentosum. The fact that a 
“precancerous condition” can affect other parts of the body is of no concern to the 
increased risk of oral cancer, only the “precancerous lesions” that these conditions can 
produce in the oral cavity may occasionally undergo a malignant transformation41. 
1.3.4 Progression 
Oral squamous carcinogenesis is a multistep process in which multiple genetic events 
occur that alter the normal functions of oncogenes and tumour suppressor genes. It is 
believed that OSCC follows a stepwise involvement of important cancer genes during the 
various stages of tumour progression, and thus, pre-malignant lesions, such as 
leukoplakia, erythroplakia, may precede malignancy42. The loss of chromosomal 
material, for example, is thought to result in changes leading to dysplasia (9p21, 3p21, 
17p13), CIS (11g13, 13g21, 14g31) and invasive tumours (4q26-28, 6p, 8p, 8q). 
However, P53 and P16 expression levels and loss of heterozygosity (LOH) are considered 
very important predictors of progression in oral carcinogenesis43. 
Dysplastic changes are one of the signs of premalignant progression in oral lesions that 
can be observed in histopathology. However, although it is a strong determinant in the 
early diagnostic process of OSCC, the histological grade from premalignant lesions may 
not be the only factor or concern for determination of the progressive malignant nature of 
it; severe dysplastic changes might not develop further to a CIS, for example44. 
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1.3.5 Diagnosis 
The diagnostic procedure adopted as gold standard to detect premalignant lesions and/or 
conditions is the physical examination followed by a biopsy and histopathological 
examination. Similar to those designed for OSCC, other diagnostic systems are also 
available, such as Toluidine blue, cytology, etc. However, their specificity and sensitivity 
is not as reliable as biopsy and histology45. 
1.3.6 Management  
All leukoplakic lesions should undergo biopsy if there is a strong suspicion of malignancy 
or when they do not respond to conservative therapy. For small areas of leukoplakia, 
excisional biopsy is usually appropriate. Erythroplakia is managed in much the same 
fashion as leukoplakia. Lesions characterised by dysplasia and CIS should be completely 
excised to clear margins when possible46. 
 
1.4 Saliva 
1.4.1 Origin and Anatomy 
Saliva is a clear, slightly acidic mucoserous exocrine biofluid produced in the oral cavity 
by three major (parotid, submandibular and sublingual) (Figure 1.2) and around 450-750 
minor salivary glands (situated on the tongue, buccal mucosa and palate except the 
anterior part of the hard palate and gums)47. Saliva components have also a non-glandular 
origin, so oral fluid cannot be considered exclusively as the product of salivary glands, 
because it also contains fluids originating from oropharyngeal mucosae (oral mucosal 
transudate cells, bacteria, fungi, virus, upper airways secretions, gastrointestinal reflux) 
mucosal transudations, gingival crevicular fluid, serum and blood derivatives from oral 
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wounds, desquamated epithelial cells, expectorated bronchial and nasal secretions, 
bacteria and bacterial products, viruses and fungi, other cellular components, and food 
debris. It is a complex fluid containing an entire library of hormones, proteins, enzymes, 
antibodies, antimicrobial constituents, and cytokines47,48.  
Each salivary gland contributes differently to the final composition of whole saliva. 
Furthermore, stimulation, by for example mastication, can also change the performance 
of the group of salivary glands resulting in a unique composition. 
The parotid glands are the largest of the salivary glands and lie wedged between the 
sternocleidomastoid muscle and the masseter, covering the ramus of the mandible and 
overflowing these structures behind and in front49. Hence, these glands are structurally 
associated with the peripheral branches of the facial nerve (seventh paired cranial 
nerve)50. Their ducts, also called Stensen’s ducts, arise from the anterior aspect of these 
glands, run over the masseter and penetrate the buccinator to open in the mouth at the 
level of the second upper molars, where they primarily deliver a watery seromucous saliva 
type49,51.  
The submandibular gland, about half of the size of the parotid gland, occupies most of 
the submandibular triangle area which is delineated by the anterior and posterior bellies 
of the digastric muscle and the mandible. Anteriorly, the floor of the triangle is the 
mylohyoid muscle; posteriorly it is the hyoglossus muscle39. The submandibular duct, or 
’’Wharton’s duct’’, arises from the anterior portion of the gland and traverses the floor of 
mouth and opens at the base of the frenulum of the tongue, just posterior to the inferior 
incisors on the submandibular caruncle via one to three orifices where a mixture of 
mucous and serous fluids are liberated52,53. 
The sublingual gland is the smallest of the major salivary glands, about one fifth the size 
of the submandibular glands, and lies in the submucosal plane of the floor of the mouth 
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superior to the mylohyoid muscle and lateral to the genioglossus muscle. It is 
predominantly a mucous gland. The sublingual (Bartholin’s) duct has several smaller 
tributaries, up to 20 salivary ducts, that subsequently open into Wharton’s duct, the main 
duct of the submandibular gland. It is predominantly a mucous gland54. 
Finally, the minor salivary glands are distributed throughout the human oral cavity. These 
glands can be found on the lower and upper lips, the cheeks, much of the palate, and the 
salivary secretions from these glands are primarily mucous55. 
 
Figure 1.2: Dissection, showing salivary glands of right side. Note: “submaxillary" refers to 
present day submandibular gland.  (Taken from the 20th U.S. edition of Gray's Anatomy of the 
Human Body, originally published in 1918)56. 
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1.4.2 Histology of the Salivary Glands 
Different types of cells constitute the salivary glandular tissue: acinar cells, various duct 
system cells, and myoepithelial cells (Figure 1.3 and Figure 1.4). The secretory end 
pieces (or acini), in which saliva is first secreted, are formed by accinar cells arranged in 
a roughly spherical shape. Hence, this primary secretion can be classified as serous 
(mainly from parotid gland), mucous (from minor salivary glands), or mixed (from 
sublingual and submandibular glands)51. 
Regarding the salivary duct system, three types of duct are present in all salivary glands, 
according to cell type: intercalated, striated, and excretory ducts. Having low cuboidal 
epithelium and a narrow lumen, the intercalated ducts maintain the network connecting 
acinar secretions to the rest of the gland. The cells from the intercalated duct are not 
involved in the modification of electrolytes, as the remaining duct cells. Columnar cells 
with many mitochondria line the striated ducts, second in the network, and regulating 
electrolytes by resorbing sodium. Finally, the excretory ducts, constituted by cuboidal 
cells and the last part of the duct network before saliva reaches the oral cavity, contribute 
by continuing sodium resorption and secreting potassium50. In addition, myoepithelial 
cells, which are long cell processes wrapped around acinar cells, contract on stimulation 
to constrict the acinar. This function, secreting or “squeezing out” accumulating fluid, is 
the result of a purely neural process57. 
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Figure 1.3: Structure of the salivary glands. Diagram of the secretory end piece (acini) and the 
branched ductal system. Source: Lalwani AK: Current Diagnosis & Treatment in Otolaryngology 
– Head and Neck Surgery, 2nd Edition: http://.www.accessmedicine.com58 
 
 
 
 
 
 
 
Figure 1.4: Histological image from parotid gland H&E stained. Source: Kumar GS. Orban's 
Oral Histology and Embryology. St Louis: Mosby, 201159.  
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1.4.3 Composition  
Whole saliva refers to the complex mixture of fluids from the salivary glands, the gingival 
fold, oral mucosa transudate, in addition to mucous of the nasal cavity and pharynx, non-
adherent oral bacterial, food remainders, desquamated epithelial and blood cells. Saliva 
is composed of more than 99% water. Saliva also contains a variety of electrolytes, 
including sodium, potassium, calcium, magnesium, bicarbonate, and phosphates (Table 
1-2). Also found in saliva are immunoglobulins, proteins, enzymes, mucins, and 
nitrogenous products, such as urea and ammonia60. 
Proline-rich proteins (PRPs) (acidic PRPs: 20%, basic PRPs: 12% and glycosylated PRPs: 
5%), mucins = 20%, amylase = 20%) constitute the most abundant proteins in human 
saliva. Immunoglobulin (A and G), cystatins, statherins and all others represent 23% of 
salivary proteins. In conjunction with other organic molecules, such as vitamins and 
lipids, they perform crucial roles in oral mucosal immunity (anti-viral, anti-bacterial and 
anti-fungal), protection of teeth and food digestion61. 
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Table 1-2: Main saliva composition60. 
  Composition of saliva  
Parameter Characteristics 
Volume 600-1000mL/day 
Electrolytes Na+, K+, Cl-,HCO3-,Ca2+, Mg2+,HPO42-, 
SCN-, and F-  
Secretory proteins/peptides Amylase, proline-rich proteins, mucins, 
histatin, cystatin, peroxidase, lysozyme, 
lactoferrin, defensis, and cathelicidin-
LL37  
Immunoglobulins Secretory immunoglobulin A; 
immunoglobulins G and M 
Small organic Glucose, amino acids, urea, uric acid, and 
lipid molecules 
Other components  Epidermal growth factor, insulin, cyclic 
adenosine monophosphate-biding 
proteins, and serum albumin 
 
1.4.4 Secretion 
Acinar cell secretion can be classified as serous (produced mainly from the parotid gland), 
mucous (minor glands) or mixed (sublingual and submandibular glands). Accumulation 
of ions in the lumen generates an osmotic gradient driving water through the apical 
aquaporin-5 channels leading to an isotonic plasma-like fluid. The acinar cells are 
connected by ducts and the secreted saliva is drained to oral cavity through striated and 
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excretory ducts. While saliva passes through salivary ducts, Na+/Cl- are reabsorbed and 
K+/HCO3- are excreted by active transportation through ion channels62. Due to the relative 
impermeability of the ducts to water, the resulting saliva has a hypotonic characteristic in 
relation to blood. Some saliva components are locally produced in salivary glands, thus 
they are not related to plasma concentrations. In this case, the salivary flow rate can 
influence their salivary concentration45.  
1.4.5 Function of Saliva 
Saliva is considered a mirror of body health and is composed of a variety of analytes from 
systemic sources that reach the oral cavity through various pathways. Saliva plays a key 
role in the lubrication and repair, formation and swallowing of food bolus, digestion, 
facilitation of food tasting and control of microbial population. All this versatility is better 
described in the following sections, while Figure 1.5 describes the main functions of 
saliva along with some important of the salivary constituents. 
 
 
 
 
 
 
 
Figure 1.5: The functions of saliva according to specific areas of action and related major 
components. Source: Kumar GS. Orban's Oral Histology and Embryology. St Louis: Mosby, 
201159. 
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Protection 
Saliva provides a washing action that flushes away bacteria and debris. In particular, the 
clearance of sugars from the mouth limits their availability to acidogenic plaque 
microorganisms. Also, the mucins and other glycoproteins provide lubrication, 
preventing the oral tissues from adhering to one another and allowing them to slide easily 
over one another. The mucins also form a barrier against noxious stimuli, microbial 
toxins, and minor trauma63. 
 
Buffering 
The bicarbonate and, to some extent, phosphate in saliva act as an excellent buffer helping 
to protect the teeth from demineralisation caused by bacterial acids produced during sugar 
metabolism64. Some salivary proteins also may contribute to the buffering action of 
saliva. The metabolism of salivary proteins and peptides by the native microbiota 
produces urea and ammonia, which help to increase the pH65. 
 
Pellicle Formation 
Many of the salivary proteins bind to the surfaces of the teeth and oral mucosa, forming 
a thin film, the salivary pellicle. The composition of the oral mucosal pellicle will 
presumably determine the types of microorganisms which can attach to the oral mucosa. 
More recently, several salivary proteins, including the mucins MUC5B and MUC7, have 
been identified in mucosal pellicle66. 
Regarding the saliva participation in the formation of the enamel pellicle, it is known that 
several proteins bind calcium and help to protect the tooth surface as well as other proteins 
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may bind to sites for oral bacteria, providing the initial attachment for organisms that 
form plaque67. 
 
Maintenance of Tooth Integrity 
Saliva is a bioliquid supersaturated with calcium and phosphate ions. The solubility of 
these ions is maintained by calcium binding proteins, especially the acidic proline-rich 
proteins and statherin. At the tooth surface, the high concentration of calcium and 
phosphate results in a posteruptive maturation of the enamel, increasing surface hardness 
(mineralisation) and resistance to demineralisation. The concentration of fluoride, 
responsible for the remineralisation enhancement process, in saliva is only just over 1 
mmol/L, but is sufficient to keep the saliva supersaturated with respect to any fluorapatite 
formed in the tooth as a result of intake of food, drink or oral health products containing 
fluoride68. 
 
Antimicrobial Action 
Saliva has a major environmental influence on the microorganisms that colonise oral 
tissues. Associated with the barrier effect provided by mucins, saliva contains several 
proteins with antimicrobial activity. For example, -amylase is a growth inhibitor of 
Porphyromonas gingivalis, well known periodontal pathogen69. Lysozyme, lactoferrin, 
peroxidase, and secretory leukocyte protease inhibitor complete the group of main 
salivary proteins with antibacterial activity70. A number of peptides that act by inserting 
into membranes and disrupting cellular or mitochondrial functions are present in saliva. 
These include α-defensins and β-defensins, cathelicidin-LL37, and the histatins71.  
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In addition to antibacterial activity, several of these proteins and peptides also exhibit 
antiviral and antifungal activity. The main salivary immunoglobulin, secretory 
immunoglobulin A (IgA), causes agglutination of specific microorganisms, preventing 
their adherence to oral tissues and forming clumps that are swallowed, thereby facilitating 
their removal by swallowing and possibly inhibiting their attachment to oral surfaces. 
Mucin MUC7, proline-rich proteins, and salivary agglutinin have the same agglutination 
property72. 
 
Tissue Repair 
The main protein and also digestive enzyme in saliva is -amylase (1,4-glucan 4-
glucanohydrolase), present as six isoenzymes which can split starch into maltose, 
maltotriose, maltotetrose, and some higher oligosaccharides. A variety of growth factors 
and other biologically active peptides and proteins are present in small quantities in saliva. 
Under experimental conditions, many of these substances promote tissue growth and 
differentiation, wound healing, and other beneficial effects. However, the role of most of 
these substances in protection of the oral cavity is presently unknown73. 
 
Digestion 
Saliva plays an important early role in digestion in that during the initial chewing of a 
portion of food, the solubilisation of food substances and the actions of enzymes such as 
amylase and lipase begin the digestive process. Saliva then contributes to the formation 
of a cohesive food bolus, covered by a mucin film, which facilitates the swallowing 
process74. 
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1.4.6 Non stimulated versus stimulated saliva 
The qualitative and quantitative aspects of saliva vary according to many factors, 
including the gland type from which it is secreted and another variables such as age, 
health, diurnal considerations, or sex of individuals. Most studies have focused on 
individual proteins under specific conditions, with the type of stimulation varying greatly. 
The average compositions of both non stimulated and stimulated whole saliva can be seen 
in table 1-351. The contribution of each salivary gland in the different method of 
collections is also further described in Table 1-4. 
 
Table 1-3: Major composition of non stimulated and stimulated whole saliva by Edgar et al.51.  
 Non stimulated Stimulated 
Water 
Solids 
99.55% 
0.45% 
99.53% 
0.47% 
 Mean ± S.D. Mean ± S.D. 
Flow rate 
pH 
0.32 ± 0.23 
7.04 ± 0.28 
2.08 ± 0.84 
7.61 ± 0.17 
Inorganic Constituents   
Sodium (mmol/L)  
Potassium (mmol/L)  
Calcium (mmol/L)  
Magnesium (mmol/L)  
Chloride (mmol/L)  
5.76 ± 3.43 
19.47 ± 2.18 
1.32 ± 0.24 
0.20 ± 0.08 
16.40 ± 2.08 
20.67 ± 11.74 
13.62 ± 2.70 
1.47 ± 0.35 
0.15 ± 0.05 
18.09 ± 7.38 
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Bicarbonate (mmol/L) 
Phosphate (mmol/L) 
Thiocyanate (mmol/L)  
Iodide (μmol/L)  
Fluoride (μmol/L) 
5.47 ± 2.46 
5.69 ± 1.91 
0.70 ± 0.42 
Not available 
1.37 ± 0.768 
16.03 ± 5.06 
2.70 ± 0.55 
0.34 ± 0.20 
13.8 ± 8.5 
1.16 ± 0.64 
Organic Constituents 
  
Total protein (mg/L)  
Secretory IgA (mg/L)  
MUC5B (mg/L)  
MUC7 (mg/L)  
Amylase (U=mg 
maltose/mL/min)  
Lysozyme (mg/L)  
Lactoferrin (mg/L)  
Statherin (μmol/L)  
Albumin (mg/L)  
Glucose (μmol/L)  
Lactate (mmol/L)  
Total Lipids (mg/L)  
Amino Acids (μmol/L)  
Urea (mmol/L) 
Ammonia (mmol/L) 
1630 ± 720 
76.1 ± 40.2 
830 ± 480 
440 ± 520 
317 ± 290 
28.9 ± 12.6 
8.4 ± 10.3 
4.93 ± 0.61 
51.2 ± 49.0 
79.4 ± 33.3 
0.20 ± 0.24 
12.1 ± 6.314 
780 
 3.57 ± 1.26 
6.86 
1350 ± 290 
37. 8 ± 22.5 
460 ± 200 
320 ± 330 
453 ± 390 
23.2 ± 10.7 
5.5 ± 4.7 
Not available 
60.9 ± 53.0 
32.4 ± 27.1 
0.22 ± 0.17 
13.6 
567 
2.65 ± 0.92 
2.57 ± 1.64 
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Table 1-4: Saliva contribution of each gland in non stimulated and stimulated whole saliva 
collection by Edgar et al.51 
Salivary gland Unstimulated contribution 
(%) 
Stimulated contribution 
(%) 
Submandibular 65% 35% 
Parotid  20% 50% 
Sublingual 5% 7% 
minor mucous glands 10% 8% 
 
One of the most comprehensive studies comparing whole saliva protein composition 
using different tastants was performed by Neyraud et al75. This experiment analysed 
protein abundance changes from four healthy subjects in whole and parotid saliva 
following stimulation with different tastants at low concentration and high concentration 
using two-dimensional gel electrophoresis and mass spectrometry. The respective 
numbers of differentially expressed proteins in different concentration of tastants (from 
lower to higher concentration) were 2, 9, 10, and 16. All of the differentially expressed 
proteins were low in abundance in comparison to total spot volumes and the vast majority 
of the salivary proteome was, in fact, unchanged by different concentrations of stimulants. 
However, only the few differently expressed spots were assessed so it is difficult to 
confirm the validity of these results75. 
Other studies have also examined the effect of changes in the oral environment on 
unstimulated vs. stimulated protein secretion. An interesting study examined the levels of 
parotid and submandibular/sublingual salivary IgA in response to experimental gingivitis 
in humans. They found a statistically significant increase in the IgA secretion rate in 
stimulated parotid saliva after 6 and 12 days without oral hygiene. This change was not 
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seen in resting saliva, or in any of the submandibular/sublingual saliva samples. A 
proposed reason was perhaps that the accumulation of plaque-derived substances or 
inflammatory products triggered salivary secretion via neural pathways76. 
Also, another study found histatin concentrations in resting saliva to be much higher for 
parotid than submandibular/sublingual saliva, and upon stimulation, the histatin 
concentrations decreased in parotid and increased in submandibular and sublingual saliva. 
Thus, the stimulation was proven to be an influencing factor regarding the saliva quality77. 
It was determined that unstimulated vs stimulated saliva sampling critically affects the 
amount and composition of detected salivary proteins. Nevertheless, even facing various 
methodological aspects and preanalytical variables that can affect saliva, these 
experiments could neither qualify nor specify proteins78.  
In contradiction of the major expected conclusions about the differentiation of stimulated 
saliva and unstimulated saliva, some studies found no significant time effect during 
resting and stimulated conditions. As an example, Becerra et al. carried out a 
characterisation of the influence of gustatory stimulation and duration of stimulation on 
the secretion pattern of salivary mucins and non-mucin glycoproteins in 
submandibular/sublingual saliva. Samples were analysed using SDS-PAGE, followed by 
Western blot analysis using polyclonal antibodies against MG 1, MG2, lactoferrin, 
amylase, and carbonic anhydrase. As final conclusions, both types of saliva did not show 
quantitative or qualitative differences79. 
Considering the present literature regarding the differences between stimulated and 
unstimulated saliva, a proper molecular definition for the two sorts of oral fluids still 
remains uncertain, due to the limitation of the techniques applied for this purpose to date.  
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1.4.7 Saliva as a diagnostic biofluid  
Saliva is gaining increasing interest as a diagnostic fluid, since it represents a non-
invasive, safe and cheap source of complex biomolecular information which can easily 
be obtained from the oral cavity80. Furthermore, the past few years have seen the 
development of salivary diagnostic tools to monitor various oral diseases ranging from 
periodontal diseases, dental caries to infections and autoimmune diseases. The main 
challenge of salivary diagnostics is to discover its potential and optimise analytical 
techniques for the use of this biofluid. The challenge of making salivary diagnostics a 
clinical reality is in establishing the scientific foundation and clinical validations needed 
to position it as a highly accurate and feasible technology that can achieve definite point 
of care assessment of health and diseases states81. 
Saliva may be used not only to detect oral diseases but also systemic ones, showing 
versatility and merit in diagnostic scope. Salivary biomarkers have already shown 
promising results in the diagnosis of many diseases, such as periodontitis82, HIV83, Hep 
B84, and even measles85. Immunoassays have been developed to detect secretory IgA and 
serum-derived IgG (from crevicular fluid) found in saliva for various diseases as well as 
saliva has shown potential for hormone and drug screening86. 
Proteome-based approaches have been applied over the last three decades to monitor 
changes in protein expression87. Generally, protein expression is primarily analysed by 
one or two-dimensional polyacrylamide gel electrophoresis (PAGE) which allows 
separation not only of different molecules with similar molecular weights, but also of 
different modification patterns or isoforms of the same protein. Along with the 
development and introduction of mass spectrometry (MS), the PAGE-separated proteins 
can be more accurately characterised and identified, leading to a wider range of 
applications for proteomic assays. Proteins that are primarily identified by MS can be 
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further characterised by ionization methods such as electrospray ionisation (ESI) and 
matrix-assisted laser desorption ionization (MALDI)87,88. Unfortunately, all these 
techniques usually require labour-intensive sample-preparation procedures and long 
analysis time.  
Other technologies that have been also employed for diagnostics include Enzyme Linked 
Immunoadsorbent Assay (ELISA), Micro-satellite Analysis, and High-Performance 
Liquid Chromatography (HPLC), but these techniques suffer from the same limitations.as 
MS89. 
In contrast, optical methods, such as Raman spectroscopy, are quantitative and more 
economic in terms of cost and labour89. It has been reported that Raman spectroscopy of 
saliva can be applied for detection of narcotics90, in forensic medicine91, cancer92 and 
periodontal disease detection93. However, all these studies have developed quite costly 
and complex methodologies using nanoparticle signal enhancers (when performed 
through surfaced enhanced Raman spectroscopy (SERS)) or modifying the physical form 
of saliva (dried saliva), leading to undeniable salivary quality loss93.  
The use of Raman spectroscopy for potentially malignant oral lesions and OSCC 
diagnosis is further discussed in chapter 2a and chapter 2b. 
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Chapter 2a: Raman Spectroscopy and Diagnostic Applications 
 
2a.1 Raman Spectroscopy 
Raman spectroscopy was named in honour of its discoverer, C.V. Raman, who, along 
with K.S. Krishnan, published the first paper on this technique in 19281. Raman 
spectroscopy is a versatile method for analysis of a wide range of samples. It resolves 
most of the limitations of other spectroscopic techniques. It can be used for both 
qualitative as well as quantitative purposes. Qualitative analysis can be performed by 
measuring the frequency of scattered radiation while quantitative analysis can be 
performed by measuring the intensity of scattered radiation2. 
2a.1.1 Diagnostics by Raman Spectroscopy 
Raman spectroscopy has been applied in numerous scientific fields, from chemistry and 
biochemistry to arts and archaeology, as a powerful spectroscopic technique which yields 
a spectral fingerprint capable of identifying and characterising the structure and function 
of molecules, materials, cells or tissues 3,4.  
Raman spectroscopy, with its molecular specificity and various signal enhancement 
techniques for increased sensitivity, has been extensively utilised in biomedical and 
clinical applications5. Both in vivo and in situ measurements have been demonstrated with 
minimum or no sample preparation6. 
Recent studies with Raman spectroscopy have shown its applicability in the identification 
of bacterial infection in the urinary tract as well as antibiotic pharmacokinetics for 
treatment7. Furthermore, Raman spectroscopy has been utilised to track nanomaterials 
moving through the circulation and to detect inhaled nanoparticles in the respiratory 
tract8,9. Coronary atherosclerosis along with blood components have also been 
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investigated for diagnostic purposes, with promising results10. Low level detection of 
viral pathogens has been also achieved with application of Surface-enhanced Raman 
scattering (SERS)11. 
2a.1.1.1 Cancer Diagnosis by Raman Spectroscopy 
Quantitative Raman spectroscopy has also been used for grading the severity of various 
cancers12. The phenomenon of Raman spectroscopy makes it ideal for assessing/probing 
samples because numerous biological molecules undergo some Raman scattering, 
allowing one to detect small molecular and architectural changes in the sample that might 
be associated with cancer, such as an increased nucleus-to-cytoplasm ratio, disordered 
chromatin, higher metabolic activity, and changes in lipid and protein levels13. 
When aimed at oncological diagnostics, Raman spectroscopy is usually applied through 
in vitro, ex vivo and/or in vivo approaches, without disrupting the cellular environment. 
Several studies using in vitro cultures have shown encouraging results for the application 
of Raman spectroscopy for improving the detection and screening of cervical cancer as 
well as investigating the biochemical changes associated with HPV infection14,15. 
Furthermore, normal and neoplastic lymphocytic cell lines could be distinguished by 
Raman spectroscopy based on DNA and protein changes16. Ex vivo essays, which include 
analysis of histological and cytological specimens, could achieve over 99.5% sensitivity 
and specificity of classification between normal and malignant in gastrointestinal 
samples, for example17. Similarly, Lyng et al. investigated tissue samples from 40 patients 
using Raman spectroscopy, and a principal components analysis associated with linear 
discriminant analysis (PCA-LDA) model to classify the samples as normal, cervical 
intraepithelial neoplasia (premalignant) or invasive carcinoma18. 
The use of in vivo Raman detection is still in the exploratory stages with the majority of 
work being conducted on animal models19. However, some researchers have applied this 
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technique to study a number of in vivo health related phenomenon of human tissue 
samples, such as non-invasive assessment of human corneal hydration, estimation of 
stratum corneum thickness, and monitoring drug penetration depth inside the skin20,21,22. 
When it comes to cancer diagnostics, skin cancer is arguably one of the most studied 
forms of neoplasia in vivo, via Raman spectroscopy, primarily due to the ease of access 
of suspicious lesions. Clinical studies conducted have already confirmed the ability to 
distinguish malignant and pre-malignant skin lesions from benign ones, melanomas from 
nevi (benign pigmented lesions, commonly referred to as moles), and melanomas from 
seborrheic keratosis23. However, the in vivo application of Raman spectroscopy is not 
confined to skin cancer diagnosis. A variety of endoscopic systems/fiber-based probes 
have also been developed for investigative work on breast24, brain25, colorectal26, 
esophageal27, gastric28 and lung cancers29.  
The assessment of surgical margins and cancer infiltration has also been investigated 
using in vivo Raman spectroscopy with promising results and easy clinical applicability, 
although, the small number of subjects involved in these studies may affect the 
reproducibility and, consequently, can decrease the diagnostic potential of the 
classifiers30. 
Also, new methodologies of Raman spectroscopy applied for liquid samples have been 
studied as proposed Bonnier et al.31. This approach applied an inverted geometry to 
improve the quality of the measurements of concentrated serum. The size and shape of 
the human serum drop analysed had little impact on the data collected using the 
methodology proposed. Thus, they were able to show that the use of centrifugal filtration 
devices to remove of low molecular weight proteins, enhances signals and intrinsic 
spectral reproducibility31. 
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2a.1.1.2 Oral Cancer and Raman Spectroscopy 
Regarding oral cancer specifically, the very first application of Raman spectroscopy 
started with the analysis of normal and dysplastic tissue in a murine model32. Dysplasia 
was chemically induced in the palate of mice resulting in 100% of both sensitivity and 
specificity. More recent studies have developed a Raman spectroscopy method with 
specificity and sensitivity better than 95%, for discrimination of normal and malignant 
tissues in oral cancers in formalin fixed oral tissues or even epithelial sections 33. 
In vivo approaches have been also developed, aimed at the diagnosis of oral dysplasia and 
oral malignancies. Singh et al. have shown the discrimination of normal control, 
premalignant, and cancerous oral sites from 104 patients with prediction accuracies 
between 72–96%34. In a more recent study, the same group assessed the potential of 
Raman spectroscopy to detect malignancy changes/cancer field effects in a cohort study. 
The comparison of non-cancer locations in a smoking and non-smoking population 
demonstrated prediction accuracies from 75–98%. This work further demonstrates the 
sensitivity of Raman scattering to subtle biochemical changes which may precede clinical 
disease35. Another group reported the discrimination of normal oral tissue from three 
separate lesion categories by probing with per-class accuracies ranging from 82–89% in 
199 patients and 96% sensitivity and 99% specificities for normal versus malignant and 
99% and 98% respectively, for normal versus potentially malignant36.  
Raman spectroscopic analysis of blood samples has also been applied to oral cancers. It 
has been proven that Raman spectroscopy can be used to distinguish between serum 
samples from patients that had been diagnosed with buccal mucosa and tongue cancer, 
and those from healthy volunteers37. Amino acids and lipids were the most significant 
Raman bands affected in the analysis. An efficacy of 85% was found when all spectra 
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were independently analysed. Also, Raman spectroscopy of serum samples was able to 
predict a potential reoccurrence of oral cancer37.  
An innovative study for oral diagnosis based on bodily fluids has been also performed38. 
Voided raw urine was collected from 167 patients and evaluated for its chemical 
components. Molecular vibrations associated with uric acid, specifically C–C stretching 
at 558 and 649 cm−1 and N–H stretching at 798 cm−1, showed elevated intensities in 
cancer patients compared to healthy volunteers. Four Raman bands related to creatinine 
also showed increases, while the band at 692 cm−1 was only present in cancer patients. 
Statistical analysis resulted in a diagnostic accuracy of 93.7%38.  
Oral cancer detection has been extended to saliva analysis through SERS. Using a 
discrimination threshold of 0.5, 23 normal samples (23/30), and 57 cancer samples 
(57/62) could be discriminated correctly, yielding the diagnostic sensitivity of 91.9%, 
specificity of 76.7%, and accuracy of 87.0%39. Nevertheless, the process to obtain spectral 
information requires a complex sample preparation of the associated nano particles39. 
2a.1.2 Principle of Raman Spectroscopy 
When light interacts with matter, the photons which make up the light may be absorbed 
or scattered, or may not interact with the material and may pass straight through it. Much 
of the scattered radiation has a frequency which is equal to the frequency of the incident 
radiation and constitutes Rayleigh scattering. The Rayleigh scattering process will be the 
most intense, since most photons scatter this way. However, the scattered light having a 
frequency different from that of incident light (inelastic scattering) may be used to 
construct a Raman spectrum. This latter phenomenon was first described by the Indian 
physicist C.V. Raman in 1928 as a rare process, in that only one in every 106–108 photons 
are Raman scattered40,41.  
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Raman spectroscopy uses a single frequency of radiation to irradiate the sample and it is 
the radiation scattered from the molecule, one vibrational unit of energy different from 
the incident beam, which is detected (Figure 2a.1). The Raman scattering process from 
the ground vibrational state (m) leads to absorption of energy by the molecule and its 
promotion to a higher energy excited vibrational state (n)42. 
 
 
Figure 2a.1: Diagram of the Rayleigh and Raman scattering processes. The lowest energy 
vibrational state m is shown at the foot with states of increasing energy above it. Source: Hollas 
JM. Modern Spectroscopy. West sussex, England: John Wiley and Sons, 200442. 
 
When the frequency of the incident radiation is higher than that of the scattered radiation, 
Stokes lines appear in the Raman spectrum. But, when the frequency of the incident 
radiation is lower than that of the scattered radiation, anti-Stokes lines appear in the 
Raman spectrum. The Raman scattered light can be collected by a spectrometer and 
displayed as a Raman spectrum, in which peaks (bands) correspond to Raman frequency 
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shifts (measured in wavenumbers cm-1) caused by the characteristic vibrations in the 
molecules of a sample42. 
A change in net molecular polarisability must occur for a molecular vibration to be Raman 
active. The polarisability (α) represents the ability of an applied electric field, E, to induce 
a dipole moment, μ0, in an atom or molecule; a process represented mathematically by 
the following equations: 
 
𝜇𝜊 = 𝛼Ε  
Equation 2a.1  
 
At the molecule’s equilibrium nuclear geometry, the polarisability has a value, α0. In the 
case of displacement, Δr, away from the molecule’s equilibrium geometry, the 
instantaneous polarisation α is given by: 
𝛼 = 𝛼𝜊 [
𝜕𝛼
𝜕𝑟
] Δ𝑟  
Equation 2a.2 
 
If the molecule is vibrating in a sinusoidal fashion, Δr can be written as a sinusoidal 
function in terms of the frequency of the vibration, νs, and the time, t: 
Δ𝑟 = 𝑟𝑚𝑎𝑥cos (2Δ𝑟 = 𝑟𝑚𝑎𝑥 cos(2𝜋𝜈𝑡) 𝜋𝜐𝑠𝑡) 
Equation 2a.3 
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Light of a particular frequency, νo, has an associated electric field, E, which also has 
sinusoidal behaviour: 
Ε = Ε𝑚𝑎𝑥cos (2𝜋𝑣𝜊𝑡) 
Equation 2a.4  
Equations 2.1 to 2.4 can thus be written in the form of equation 2.5, in which the first 
term represents the scattered phenomenon of Rayleigh scattering. The second term 
represents the Raman scattering of frequency v0+vs (anti-Stokes scattering), when the 
frequency of the scattered photon increases by molecular motion, vs; and the third term 
represents Stokes scattering of light of frequency v0-vs (Stokes scattering), when the 
frequency decreases43. 
 
𝜇𝜊 = 𝛼𝜊Ε𝑚𝑎𝑥 cos(2𝜋𝜐𝜊𝑡) + Ε𝑚𝑎𝑥𝑟𝑚𝑎𝑥 [
𝑑𝛼
𝑑𝑟
] cos(2𝜋𝜐𝑠𝑡) cos(2𝜋𝜐𝜊) ⇔  
⇔ 𝜇𝜊 = 𝛼𝜊Ε𝑚𝑎𝑥 cos(2𝜋𝜐𝜊𝑡) +
Ε𝑚𝑎𝑥𝑟𝑚𝑎𝑥
2
[
𝜕𝛼
𝜕𝑟
] {cos[2𝜋𝑡(𝜐𝜊 + 𝜐𝑠)]
+ cos[2𝜋(𝜐𝜊 − 𝜐𝑠)]} 
Equation 2a.5 
 
2a.1.3 Instrumentation 
The common Raman microspectrometer components are detailed in the schematic 
diagram (Figure 2a.2). The laser applied is the source of the monochromatic incident 
light that can be of different wavelengths, from ultra violet to near infra-red, and its choice 
is inherent to the application desired. The pin holes, or even sometimes neutral density 
filters, determine the intensity of the incident light and may be adjustable. Along with 
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this, the interference filter is a clean-up tool that only allows the laser output through. A 
microscope coupled to the system holds the sample and makes possible the analysis of 
samples as the focusing is facilitated with this. Furthermore, the objective lenses deliver 
the laser as well as collect the backscattered light. The Notch (or Edge) filter reflects the 
same wavelength as the incident light to remove all the Rayleigh scattered light and 
everything outside this range is taken as Raman scatter, to be transmitted further. The 
spectral resolution is determined by the groove density (measured in grooves/mm) of the 
grating, whereby a higher groove density corresponds to higher resolution. The grating 
or spectrograph is used to disperse the light and it is generally available in a setup between 
300 to 1800 groves / mm. Apart from that, other factors that can influence the spectral 
resolution are the wavelength and the spectrometer length, which is the distance between 
the grating and the detector. Very often used in Raman spectroscopy because of its light 
sensitivity, the charge coupled device (CCD) allows multichannel operation which 
permits a Raman spectrum be detected in a single acquisition (Figure 2a.3). 
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Figure 2a.2: Schematic diagram of a Raman microspectrometer based on the Horiba Jobin Yvon 
LabRAM HR800. 
 
 
 
 
 
 
 
 
Figure 2a.3: Example of Raman spectrum of unstimulated saliva sample acquired using the 
instrument setup described above. 
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2a.1.4 Statistical tools for Raman analysis  
2a.1.4.1 Pre-processing procedures 
Smoothing 
Smoothing techniques are commonly used to reduce spectral noise. These noise reduction 
practices also rely on the fact that spectral noise occurs at high frequency and therefore 
its transition from point to point on a spectrum is abrupt and random44. When utilising the 
moving average technique, each individual point of a spectrum is averaged with a chosen 
number of adjacent points. Savitzky–Golay polynomial smoothing can alleviate spectral 
distortion, as this methodology fits a polynomial function to a section of points around 
the point of interest. This allows for spectral features, such as a band’s height and width, 
to be conserved44,45. 
 
Baseline correction  
Rubberband baseline correction finds a convex polygonal line whose edges are 
‘‘troughs’’ within the spectrum. This method fixes the endpoints of the dataset in order 
to avoid any such alterations from occurring44. 
 
Normalisation  
Another important pre-processing procedure for Raman spectra is intensity normalisation, 
as this allows for intensities acquired from different spectral acquisitions to be compared. 
Vector Normalisation (Euclidean or L2-norm) is often used after differentiation, when 
there is no apparently consistent peak across the spectra in Raman spectroscopy46. 
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2a.1.4.2 Background Removal by Non negative constrained least squares 
(NNLS) analysis 
Non-negatively constrained least squares analysis (NNLS) is a technique similar to that 
of Classical least squares (CLS) method developed by Lawson and Hanson47. The CLS 
fitting is a supervised technique used to estimate the weighted contributions of a set of 
input spectra to a sample spectrum. It assumes that any complex spectrum is the weighted 
sum of all the base components that contribute to the spectrum48. 
NNLS is used to estimate the weighted contributions of a set of input spectra in a sample 
spectrum. However, unlike CLS, NNLS introduces non-negative constraints on the 
weighting co-efficients of the input spectra aiming to minimise the error in fitting the 
sample spectrum48. 
2a.1.4.3 Principal Components Analysis (PCA) 
Developed in 1901 by Karl Pearson, principal components analysis (PCA) is a statistical 
method widely used in exploratory analysis and model prediction. It is an unsupervised 
data reduction technique used to identify variances within the dataset that may be used to 
classify objects into groups49. 
PCA involves the calculation of the eigenvalue decomposition of a data matrix, usually 
after mean centring the data for each attribute. The results of a PCA are usually discussed 
in terms of component scores and loadings50. 
In Raman spectroscopy, PCA is used to reduce the matrix of spectral data in which objects 
(individual spectra) are measurements of a large number of variables (wavenumbers), 
whilst retaining most of the variation within the dataset. It works by (1) subtracting the 
mean of the dataset to obtain the mean centred matrix, (2) calculating the covariance 
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matrix (linear relationships between the individual spectra) of the mean centred matrix 
and (3) finding the eigenvectors and eigenvalues of the covariance matrix51. 
The eigenvector with the highest eigenvalue explains the most variance in the data set 
and is called the first principal component (PC). The first PC therefore describes the 
largest source of variance across all the spectra, the second PC the next largest source of 
variance and so on, all PCs describing mutually independent sources of variance in 
decreasing proportions of spectral variance51,52. 
2a.1.4.4 Partial least squares-discriminant analysis (PLSDA) 
PLSDA is considered a supervised technique of multivariate analysis which works as a 
linear classifier that aims to separate any data into groups using a hyperplane53. This form 
of analysis, similar to PCA, maximises the variance between groups and minimises the 
variance within groups53. It is based, however, on partial least squares regression (PLSR), 
a method used for constructing predictive models when the factors are many and highly 
collinear54. Conventionally, in the classic PLSR, y is a matrix of continuous variables, 
while in PLSDA it is categorical and used to assign the observations into classes53,54. The 
loadings of the discriminate hyperplanes or latent variables (LVs) can be visualised to 
provide more information about the source (component) of the variance53. 
2a.1.4.5 Leave one patient out cross validation (LOPOCV) 
Cross validation of any spectral classification models is an essential step to avoid over or 
under-fitting the model due to inappropriate selection of the components used as well as 
to determine the prediction error of the model. 
Leave one patient out cross validation (LOPOCV) is based on the leave one out cross 
validation (LOOCV) technique. In LOOCV one observation is excluded at a time from 
the training set and the resulting model is evaluated on the left out observation. The 
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procedure is repeated for all observations in the data set and the average performance 
across all interactions is considered the performance of the classification model51. 
However, in LOPOCV, instead of leaving one spectrum out, one patient is left out so that 
all the spectra of the patient are left out and predicted. 
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Chapter 2b: Raman Spectroscopic Analysis of Saliva samples 
for the Diagnosis of Oral Cancer: A Systematic Review 
 
Adapted from ‘Calado, G., Behl, I., Daniel, A., Byrne H. J., Lyng, F. M. Raman 
Spectroscopic Analysis of Saliva samples for the Diagnosis of Oral Cancer: A Systematic 
Review’ accepted for publication in Translational Biophotonics (DOI: 
10.1002/tbio.201900001). 
 
Genecy Calado conducted all the systematic analysis and was primary author of the 
article, with contribution and guidance from the other authors.  
 
2b.1 Abstract 
Oral squamous cell carcinoma (OSCC) is one of the most common malignancies 
worldwide, and new protocols for routine and early detection are required. Raman 
spectroscopy is an optical based method that can provide sensitive and non-invasive real 
time detailed information on the biochemical content of a sample like saliva, through the 
unique vibrations of its constituent molecules and this is sensitive to changes associated 
with disease. A comprehensive systematic review of the available scientific literature 
related to Raman spectroscopy of human saliva for diagnosis of OSCC was performed. 
The 785 nm laser line was most applied wavelength along with principal components 
analysis (PCA) associated with linear discriminant analysis (LDA). The main salivary 
components possibly associated with the presence of OSCC were proteins and lipids. 
Measurement in the liquid physical state, and with no addition of nanoparticles for signal 
enhancement, seemed to best conserve the salivary integrity. However, in terms of 
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sampling protocols, no differentiation was generally made between stimulated and non 
stimulated saliva. Raman spectroscopy of saliva holds a promising future for clinical 
applications such as early detection of OSCC. However more systematic analyses are still 
required for a better elucidation regarding sampling procedure, storage and degradation. 
 
2b.2 Introduction 
Oral Squamous cell carcinoma (OSCC) is one of the most frequently encountered 
malignant tumours worldwide, and its incidence is expected to reach around 350,000 new 
cases per year1. In 2018, OSCC, the histopathological variant present in more than 95% 
of tumours of the head and neck region, was also responsible for more than 150,000 
thousand deaths1. Furthermore, an exponential growth of the mortality rate related to this 
pathologic entity can be foreseen for the coming years1-3. 
OSCC, along with other head and neck tumours such as oropharygeal cancer, is the 6th 
most common malignant tumour worldwide2. This neoplasm seems to be more prevalent 
in males, in a ratio of 1.5 male:1 female2. This gender difference could be explained by 
the more frequent exposure to predisposing factors (such as tobacco and alcohol) and 
those associated with occupational conditions2,3. 
Early detection followed by appropriate treatment can increase cure rates in 80-90% of 
OSCC cases and significantly improve patient quality of life, minimising the need for 
extensive and debilitating treatments4. In addition, the medical and scientific community 
currently recognises that, without the development and implementation of new 
standardised screening procedures, the vast majority of cases of oral cancer are found in 
the late stage, often presenting peripheral metastases and infiltration of the regional 
liphonodal chain5,6. 
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Usually, the clinical diagnosis of head and neck neoplasias, including oral cancer, is 
performed through invasive biopsies followed by an expensive histological examination 
of excised tissue. This may result in psychological trauma and risk of infection for 
patients. In addition, it is well accepted that this type of diagnostic method is limited as it 
is a subjective histological gradation of the pathology in question, as represented by 
morphological abnormalities in the tissue7. In addition, clinically innocuous premalignant 
lesions, or even "hidden" lesions (such as lesions located in the retromolar region), can 
easily go undetected by routine clinical examination. 
Adjuvant techniques for the early detection and diagnosis of oral cancer include 
exfoliative cytology, toluidine blue staining, chemiluminescence and optical mapping8,9. 
Although some of these diagnostic aids show some promise for clinical everyday 
application, none have yet demonstrated better performance than conventional visual 
examination9. Thus, the accepted gold-standard method for diagnosis of oral cancer and 
potentially malignant lesions is still clinical examination and histopathological 
examination of the biopsied tissue10-12. However, given the difficulty of early detection 
of oral cancer and the increased prevalence of this type of neoplasm worldwide, any 
method that improves or contributes to the diagnostic process should also improve 
screening capacity across a large population. Significant efforts have been devoted to 
development of less invasive and at the same time effective diagnostic modalities for the 
early diagnosis of oral cancer13,14. In this context, optical techniques that are efficient, 
precise, low-cost, portable and easy to handle seem to overcome most of the present 
difficulties in this process and are of great value in clinical applications15,16. 
Raman spectroscopy is a technique that consists basically of the analysis of light 
scattering17. It has been known as a means of studying molecular structural properties of 
solids, liquids and gases since its discovery in 1928 by C. V. Raman and K. S. Krishnan. 
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The impact of the light onto molecules results in either elastic scattering (same frequency 
as that of the incident light and known as Rayleigh) and inelastic scattering (frequency 
different from that of the incident light). By interacting with vibrations in the material, 
the dispersed photon can either lose energy (a phenomenon known as Stokes scattering) 
or gain energy (known as anti-Stokes) (Figure 2b.1). Finally, the Raman spectrum shows 
the energy difference between incident photons and dispersed photons as a variation in 
intensity associated with the range of vibrational modes in the material16,17. 
 
 
 
 
 
Figure 2b.1: Schematic illustration of Rayleigh and Raman scattering processes.  
 
The Raman spectroscopic signature is a set of several characteristic peaks that represent 
the most important and specific spectral variations of the sample being studied. The 
application potential of these multidimensional signatures obtained is almost unlimited 
and may also be used for the spectral typing of a heterogeneous sample, such as saliva 
samples. Furthermore, newer modalities of Raman analysis, such as Surface-Enhanced 
Raman spectroscopy (SERS), have been applied recently, aiming to obtain a better 
performance regarding spectral acquisition as well as to increase the sensitivity and 
specificity of this technique13. SERS takes advantage of the enhancement of the local field 
in the regions of surface plasmon resonances on the surfaces of many metals, such as 
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gold, silver or copper, which can result in increases in the Raman signals by many orders 
of magnitude13. 
A Raman spectrometer, coupled to a light microscope, is capable of characterising the 
molecular structure of the salivary components through the incidence of light (laser) at a 
specific wavelength, and detecting the energy that is dispersed due to the vibration of the 
respective salivary molecules16. As a result, a specific spectral signature (or fingerprint) 
is acquired containing peaks/bands (shown in cm-1 or nm) which, as a whole, could be 
taken into account for the development of a multivariate analysis algorithm for the 
classification of saliva from, and consequent diagnosis of, patients with OSCC, for 
example16. 
Recent Raman spectroscopic studies have achieved specificity and sensitivity of > 90% 
for differentiating normal and neoplastic specimens of malignant tumours of the mouth 
in oral tissues based on the water content values from OSCC18. Also, Hole et al.20 
established a confusion matrix that enables the correct classification of 82% and 92% of 
tumour and oral cell spectra, respectively, when a spectra-wise cross validation was 
performed. In a subject-wise cross validation, 100% of oral normal cells and 90% of oral 
tumour cells spectra were correctly classified. These results are based on a large number 
of plasma and tissue proteins indicative of malignancy, supporting the application of 
Raman spectroscopy for the diagnostic purpose for this type of malignant neoplasm21,22. 
While spectroscopic analysis of tissues and cells for clinical applications has been 
explored over at least two decades, analysis of bodily fluids has emerged more 
recently23,24. In this sense, human saliva has gradually gained interest from researchers 
and scientists as a means of diagnosis because it represents a non-invasive source of safe, 
low-cost complex biomolecular information that can easily be obtained from the oral 
cavity25. Recent studies have shown that saliva can be used as a diagnostic medium not 
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only for diseases of the oral cavity, but also for systemic diseases, exhibiting versatility 
and merit in the diagnostic field26. However, although the development of diagnostic tools 
for salivary analysis to monitor diseases of the oro-maxillo-mandibular complex has been 
witnessed in recent years, the main challenge of clinical diagnosis from saliva is the 
discovery of the varied potential of this type of sample and the 
standardization/confirmation of analytical techniques for the correct use of this biofluid27.  
Knowing the importance and urgency of the implementation of more accurate and less 
expensive diagnostic methods such as Raman spectroscopy, and the clinical versatility of 
the salivary sample, it is important to develop methodologies for this type of sample. 
However, studies involving spectral analysis of human saliva through Raman 
spectroscopy for the diagnosis of oral cancer are still limited and diverse in terms of 
methodology and results. Therefore, this work aims to perform a systematic review of the 
literature on the application of Raman spectroscopy for human saliva analysis for the 
diagnosis of OSCC. It also aims to describe aspects that concern the instrumentation and 
preparation of saliva which could translate to a better standardised and reproducible 
protocol, a better assessment of the technique itself, as well as to describe spectral salivary 
components of verifiable significance for the applicability of this technique for routine 
clinical diagnosis. 
2b.3 Methodology 
The parameters adopted for this systematic review were based upon the PRISMA 
(Preferred Reporting Items for Systematic reviews and Meta-analyses) system28. An 
extensive electronic search was conducted in the Pubmed, B-On and other domains (eg. 
Scopus, Google, Google Scholar, etc.) using the following terms: “Raman Spectroscopy”, 
“Oral Cancer”, “Oral dysplasia” and “Saliva”. In addition, the Boolean terms "AND" and 
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"OR" were used to combine keywords. Only scientific articles in English were considered 
for this bibliographic review.  
All the identified articles were initially assessed by title and respective abstract. When 
such elements were unclear or not available, full articles were retrieved and examined. 
Studies that appeared in more than one database, or appeared more than once in the same 
database, were considered only once. Titles/abstract screening was performed by one 
reviewer and full text articles collected. Full text articles were independently assessed for 
eligibility by two reviewers. The bibliographic research was carried out between August 
2018 and February 2019. 
Review articles, opinion articles, and articles that were not related to oral cancer/oral 
epithelial dysplasia diagnosed with Raman spectroscopy through salivary samples were 
initially excluded from the proposed systematic review. Theses of any nature were also 
considered in this systematic review. Due to the scarcity of the literature on the proposed 
theme, no criteria of temporal restriction of the publication of the chosen articles were 
applied. 
Scientific articles involving the use of saliva as a biological sample in the diagnosis of 
some type of cancer through the use of Raman spectroscopy were included for the 
systematic analysis of the treatment (methodology) of the sample (saliva). However, only 
studies that aimed at the diagnosis of oral cancer or oral epithelial dysplasia were analysed 
in relation to the biological component of the salivary spectral profile as well as to the 
sensitivity, specificity and/or classificatory efficiency (also known as accuracy and 
described as the capability of efficiently detect the true positive and true negative samples 
over all observations)29 of the mathematical models. 
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2b.4 Results 
The bibliographic search identified a total of 828 scientific articles (Figure 2b.2). 
Duplicate studies were then excluded (n = 65), resulting in a total of 763 articles. After a 
thorough review of the title and/or abstracts, a total of approximately 525 articles were 
excluded because they were not consistent with the systematic review topic. Associated 
with this, literature reviews of any nature were also excluded from the final systematic 
analysis (n=230). Finally, only eight studies were deemed to be fully consistent with the 
proposed theme30-37, including those that did not specifically diagnose oral cancer (n=3) 
but used salivary samples for Raman spectroscopy33,35,36. 
 
 
 
 
 
Figure 2b.2: Flowchart showing the results of the research and the selection procedure of the 
papers included for analysis. 
Important aspects of each study were also analysed, including the year of the study, 
sample size, the nature of saliva collection, the physical state of the sample at the time of 
analysis, the laser wavelength used as source, the use of nano particles as enhancers for 
Raman analysis (SERS), the type of statistical analysis adopted, whether principal 
components analysis associated with linear discriminant analysis (PCA-LDA), partial 
least squares discriminant analysis (PLSDA) or support vector machines (SVM) were 
used, and the size of the spectral range analysed (Table 2b-1). Further details related to 
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the type of nanoparticles, and the incorporation state (colloid or substrate) of these 
particles listed by each of the groups was also noted and are presented in the same table 
(Table 2b-1). Statistical results related to the differentiation between the group of patients 
with OSCC and control group of each study (Table 2b-2) were defined as sensitivity and 
specificity and/or classification efficiency (accuracy) (not necessarily present in every 
analysis, but mandatory when sensitivity and specificity were not mentioned) and were 
also noted as important features of each study. In addition, the spectral profile of the 
predominant salivary components responsible for differentiation of the same groups 
(Table 2b-3) were also indicated and, based on the spectral profile of isolated 
components, were correlated with possible biochemical salivary associations found in the 
current literature. 
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Table 2b-1: List of articles that formed this systematic review, according to the year of publication and the number of participants in each study. Also, information 
was collected regarding the type of collection of the salivary sample (stimulated or non stimulated), the physical state of the sample at the time of collection, the 
wavelength of the laser source applied, the use or not of nanoparticle enhancers (SERS), the statistical method used by each study and the spectral range selected for 
analysis. 
Authors Year Participants 
(patients/ 
controls) 
Saliva 
collection type 
Physical state 
of the sample 
Laser-
line 
(nm) 
Type of Raman 
technique 
Type of nanoparticle  
(incorporation) 
Statistical 
method 
Fingerprint 
region 
 (cm-1) 
Kho et al. 2005 10 (5/5) Not mentioned  Dry 632.8 SERS Gold (colloid) No statistical 
tool was used 
400-1800  
Feng et al. 2014 92 (62/30) Not mentioned  Liquid  785 SERS Silver (colloid) PCA-LDA 500-1750  
Feng et al. 2015 64 (31/33) Not mentioned  Liquid  785 SERS Silver (colloid) PLSDA 500-1800  
Qiu et al. 2015 62 (32/30) Not mentioned  Dry 785 SERS Silver (colloid) PCA-LDA 400-1750 
Connolly et al. 2016 36 (18/18) Not mentioned  Dry 785 SERS Silver (substrate) PCA-LDA 400-1,750 
Jaychandran, 
Meenapriya and 
Ganesan 
2016 158 (137/21) Not mentioned  Not mentioned  785 Conventional  No particle was 
applied 
PCA-LDA 600-1000 
Rekha et al. 2016 83 (61/23) Non 
stimulated 
Liquid 785 Conventional No particle was 
applied 
PCA-LDA 800-1800 
Quian et al. 2018 127(61/66) Not mentioned  Dry 785 SERS Gold (substrate) SVM 400-1800 
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Table 2b-2: Statistical results of the mathematical models in the salivary sample classification 
process of patients with OSCC/ oral epithelial dysplasia. 
Authors Sensitivity/Specificity (%) Classification efficiency (%) 
Connolly et al.  89 / 57 Not mentioned 
Jaychandran, Meenapriya and Ganesan  Not mentioned 91.3 
Rekha et al.  Not mentioned 55.4 
 
 
Table 2b-3: Main peak positions and tentative vibrational mode assignments of saliva 
components associated to OSCC/oral epithelial dysplasia. 
Wavenumber (cm-1) Biological Assignments  Reference 
444 Protein Jaychandran, Meenapriya and Ganesan 
752 Glycoproteins Jaychandran, Meenapriya and Ganesan 
870 Amino acid Rekha et al. 
885 Protein Connolly et al. 
918 Glycoprotein Rekha et al. 
948 Proline rich proteins Rekha et al. 
969 Proline rich proteins Rekha et al. 
986 Amino acids Rekha et al. 
1015 Phenylalanine (proteins) Rekha et al. 
1126 Protein Connolly et al. 
1158 Lipids Jaychandran, Meenapriya e Ganesan 
1204 Phenylalanine (proteins) Connolly et al. 
1224 Amide III Connolly et al. 
1275 Amide III Connolly et al. 
1288 Amide III Rekha et al. 
1409 Glycoproteins Connolly et al. 
1417 C=C stretching Connolly et al. 
1525 Lipids Jaychandran, Meenapriya and Ganesan 
1636 Amide I (glycoproteins) Rekha et al. 
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In general, the work of Kho et al. was the only one to mention the method of collection 
of the saliva samples (non stimulated)30. Saliva in the liquid state was used by Feng et 
al.31,32 and Rekha et al.33 while dried saliva (after evaporation of water) was used in four 
studies, Kho et al.30, Qiu et al.34, Connolly et al.35 and Quian et al.37 (Table 2b-1). One 
of the groups did not mention the physical state of the samples that were analysed33.  
The wavelength of 785 nm was chosen for sample excitation in almost all salivary sample 
studies (Table 2b-1). Kho et al. was the only group to apply a laser source of 632.8 nm 
for spectral analysis30.  
In relation to the use of nano particles for spectral enhancement (SERS), Kho et al.30, 
Feng et al.31,32, Qiu et al.34, Connolly et al.35 and Quian et al.37 used metal nanoparticles 
to enhance the vibrational signal from saliva, while Jaychandran, Meenapriya and 
Ganesan36 and Rekha et al. 33 did not use SERS to enhance the Raman signal of their 
samples (Table 2b-1).  
The type of nano particles varied in the different studies, as well as how they were 
incorporated (Table 2b-1). Silver nano particles were the most common spectral enhancer 
and were used in four studies31,32,34,35 while gold nano paticles were used in two studies 
30,37. The particles were used as a colloidal solution in four of the studies30,31,32,34 while 
only two studies used nanoparticles incorporated in the substrate35,37. Notably, however, 
none of the studies indicated whether the choice of the type of metal nanoparticle and/or 
the wavelength were correlated. 
The choice of PCA-LDA was almost common amongst all studies involving analysis of 
saliva for the diagnosis of cancer through the use of Raman spectroscopy (Table 2b-1). 
Only Feng et al.31 and and Quian et al.37 used PLSDA and SVM, respectively, as the 
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statistical method of choice. Kho et al. perfomed a simple visual comparison between 
mean spectral profile of saliva from healthy people and patients with oral cancer30. 
The spectral range of analysis, however, was quite diverse across all studies (Table 2b-
1). Kho et al.30 and Quian et al.37 used a broad fingerprint region (between 400-1800 cm-
1), while Jaychandran, Meenapriya and Ganesan36 used the smallest range in fingerprint 
region of all the studies analysed (600-1000 cm-1). 
Studies involving the use of saliva samples for the diagnosis of oral cancer through 
Raman spectroscopy were restricted to three studies (Table 2b-2): Connolly et al35, 
Jaychandran, Meenapriya and Ganesan36 and Rekha et al.33. Connolly et al.35 were able 
to obtain a sensitivity and specificity of 89 and 57%, respectively, when using Raman 
spectroscopy for differentiation between salivary samples from patients with oral cancer 
and from healthy controls (Table 2b.2). In addition, according to this analysis, some 
specific spectral features of saliva components were assigned as responsible for the 
classification obtained – 870, 1126 (proteins), 1204 (phenylalanine), 1224, 1275, (starch), 
1409 (glycoproteins), and 1417 cm-1 (C=C bonds) (Table 2b-3). 
On the other hand, Jaychandran, Meenapriya and Ganesan36 report the following bands 
as establishing the difference between patients with oral cancer (or some form of oral 
epithelial dysplasia) and the control group: 444 (mucin), 752 (glycoproteins), 1158 and 
1525 cm-1 (lipids) (Table 2b-3). Nevertheless, a classification efficiency of 
approximately 91% was obtained between the two groups (Table 2b-2). 
A lower classification efficiency obtained between the groups was determined by Rekha 
et al.33 of approximately 55% (Table 2b-2). Although not statistically significant, this 
study found that the amino acid-associated (870, 986 cm-1), glycoproteins (918 cm-1), 
proline rich proteins (948, 969 cm-1), phenylalanine (1015 cm-1), starch III (1288 cm-1) 
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and starch I (1636 cm-1) bands appeared to be associated with the presence of OSCC 
(Table 2b-3). 
 
2b.5 Discussion 
Human saliva is considered a "mirror" of body health and plays an important role in the 
repair and lubrication of soft and hard tissues, formation and ingestion of the alimentary 
bolus, digestion, taste and control of the microbial population38. 
Schipper et al. determined, through mass spectroscopy, that the salivary collection 
method seems to be very important for the variability and concentration of proteins and 
substances detected in each type of saliva39. An interesting study examined the levels of 
parotid and submandibular/sublingual salivary IgA through ELISA (enzyme-linked 
immunosorbent assay) in response to experimental gingivitis in humans, where a 
statistically significant increase in the IgA secretion rate in stimulated parotid saliva was 
observed after 6 and 12 days without oral hygiene, not seen in resting parotid saliva40.  
The literature has also reported that Raman spectroscopy for saliva analysis can be applied 
for the detection of narcotics in forensic medicine and periodontal disease41,42. 
In terms of salivary nature, several factors can influence salivary secretion and 
composition, such as non stimulated and stimulated saliva collection. Salivary collection 
is basically termed non stimulated (resting) when no exogenous or pharmacological 
stimulation is present and termed stimulated when secretion is promoted by mechanical 
or gustatory stimuli or by pharmacological agents. When the secretion is stimulated 
mechanically, inert stimuli are commonly used (chewing of paraffin wax or rubber 
bands)43.  
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The studies identified in this systematic review were not conclusive or used only one form 
of salivary collection for analysis, consequently, limiting a more detailed analysis of the 
spectral profile of each type of sample. Calado et al. recently published an abstract in 
which a better and comprehensive analysis of the type of collection of saliva was 
performed44. In this study, stimulated saliva was considered as the sample type of choice 
for analysis with Raman spectroscopy, as it is more suited to the standard operating 
procedure for clinical applications and results in a more prominent Raman signal from 
the saliva samples. 
The physical state of the sample would also be a very important element in the process of 
instrumentation and analysis. Feng et al.31, Qiu et al.34, Connolly et al.35, Jaychandran, 
Meenapriya and Ganesan36 and Quian et al.37 used solid (dry) or liquid samples for 
analysis by SERS. Such methodologies using enhancement particles (SERS), or 
modifying the physical state of the saliva, add complexity to the sample preparation 
and/or resulting in indubitable loss of salivary quality when in a physical state other than 
the one of origin41,45. 
SERS is a special type of Raman spectroscopy, in which irregular or patterned metal 
substrates or metal nanocolloids are used for signal enhancement46-48. Typically, the best 
enhancement effect is achieved with silver induced SERS49. As a substance, silver holds 
antimicrobial properties and, consequently, may affect the sample under inspection, 
which could be the reason for the widespread use of silver nanoparticles in the studies 
reviewed. However, it is chemically quite reactive, and the stability and reproducibility 
of the silver substrates and colloids can also be an issue46,47. On the other hand, gold is 
preferred in microbe detection having the optimal excitation wavelength in the near-infra 
red region47.  
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In terms of spectral resemblance or peak compatibility among studies with SERS, some 
similarities in spectral features and profile were observed, such as cancer saliva proteins 
showing higher intensities at 1004, 1340, 1134 cm-1 31,32. However, the SERS studies 
found in this review did not show major similarities regarding the general spectral pattern, 
possibly due to the fact that they detect different histopathological entities. Also, the 
variability in intensity is an intrinsic property of SERS measurements. It is already known 
that the aggregation and adsorption mechanisms cause constant fluctuations in the 
intensity in a time-independent manner50. 
PCA-LDA was the method of choice for the statistical analysis of the obtained spectra. 
In Raman spectroscopy, PCA is used to reduce a mathematical matrix based on the 
spectral data of measured objects (in this case the individualised spectra), with a large 
number of variables (wavelength of each peak/band), while retaining the variability 
within the probabilistic data51. The LDA method, when used in conjunction with PCA, 
uses the PCA scores as latent variables to find a linear hyperplane that best classifies one 
or two groups of PCA scores51. 
PLSDA, another method of statistical analysis, can also represent a tool of classification. 
Similar to PCA-LDA, PLSDA is a supervised form of multivariate analysis which works 
as a linear classifier that aims to maximise the variance between groups and minimise the 
variance within groups. It is based on partial least squares regression (PLSR), a method 
used for constructing predictive models when the factors are many and highly collinear52.  
In a similar way, the use of SVM is considered an effective method for building a 
classifier. It aims to create a decision boundary between two classes that enables the 
prediction of labels from one or more feature vectors. This decision boundary, known as 
the hyperplane, is orientated in such a way that it best differentiates the identified classes. 
These closest points are called support vectors53. 
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Despite the widespread use of PCA-LDA for human saliva analysis through Raman 
spectroscopy of the studies reviewed, other studies have already demonstrated that 
PLSDA or SVM can also provide excellent or even superior classification efficiency to 
PCA-LDA between samples analysed by Raman spectroscopy, for example 90% 
accuracy for colon diagnosis54 and 96.72% sensitivity for lung cancer37.  
The precedent of previous studies employing PCA-LDA to categorise spectral profiles of 
samples could explain the continued preference over PLSDA or SVM in the reviewed 
studies, in spite of the similar statistical basis of these three different techniques. Notably, 
there have been no reports of a direct comparison of the three approaches applied to the 
same dataset.  
In terms of sensitivity and specificity, the studies involving Raman analysis of saliva for 
detection of oral cancer/oral dysplasia have revealed significant discrepancies related to 
the detection capabilities, even using the same statistical analysis method (PCA-LDA), 
the reported classification efficiency ranging from 55.4% to 91.3%33,36. The use of SERS 
did not seem improve this performance to any great extent, yielding sensitivity of 89% 
and specificity of 57% in the SERS study of Connolly et al.35, compared to 91.3% of 
classification efficiency in other studies36. 
Among the SERS studies that analysed saliva, independent of the tumour type, the highest 
sensitivity and specificity achieved were 95.08 and 100%, respectively37. The similarity 
of results obtained by conventional Raman and SERS analysis therefore brings into 
question the need or benefit of SERS for the analysis of saliva. Due to the lack of analysis 
in some of the SERS studies, the sensitivity and specificity could not be further correlated 
to use of a specific metal nanoparticle (gold or silver). However, the SERS incorporation 
in colloid state can usually reach a slightly better sensitivity55 as highlighted by Feng et 
al.31, yielding a diagnostic sensitivity of 91.9%.  
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Regarding the source wavelength, 785 nm was the most commonly used for saliva 
analysis, but no reasonable explanations have been addressed in order to clarify its use. 
This situation could be explained by the “convenience factor” of not having other laser 
lines available. Notably, the Raman scattering efficiency scales according to 
1/(wavelength)4, and so, the shorter the wavelength the better, but, at shorter wavelengths, 
Rayleigh and Mie scattering also increase, increasing the background, and the chance of 
being resonant with fluorophores also increases56.  
The fingerprint region selected by the studies reviewed was very variable. In Raman 
spectroscopy, the fingerprint region 400–1800 cm-1 can detect the majority of biological 
components of a sample. A smaller fingerprint range, consequently, can limit the 
information acquired from the sample in question57.  
In the case of SERS, different kinds of metallic enhancement material, silver, gold, or 
copper, on substrates or in colloidal form, can be used, enabling this technique to be 
applied in a Raman setup58. The enhancement effect derives from the resonant excitation 
of the surface plasmon of the nanoparticle, which varies according to the constituent 
metal, the nanoparticle size, and aggregation state59. This means that the optimum type 
of metal particle is directly correlated to the wavelength applied or vice-versa. However, 
no specific rationale governing choice of nanoparticle type/size or state was provided by 
the studies covered in this review. 
The reported spectral profiles of saliva are usually complex and show contributions of 
multiple chemical compounds. The spectral bands correlated with the salivary 
composition of all studies are suggestions based on available literature on specific 
components previously isolated and analysed. In the studies included in the analysis, 
peaks related to Amide I and Amide III of proteins were among the main biochemical 
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components associated with the differentiation between saliva samples of patients with 
OSCC or oral dysplasia and the control group. 
Many salivary proteins and glycoproteins have already been reported as biomarkers for 
the diagnosis of OSCC60. The current literature is rich in reports that correlate proteins 
such as c-erbB2, CA-125 and P53 as well as some antibodies, such CA15-3 antigen, in 
saliva to the development of OSCC and so act as biomarkers to detect this type of 
neoplasm61. In addition, other studies have also detected an overexpression of zinc-α-2-
glycoprotein in the saliva of patients through matrix-assisted laser desorption ionization-
quadrupole-time-of-flight (MALDI-Q-TOF) and mass spectrometry62. 
Results indicative of associations between C=C and C-H vibrations from the salivary 
Raman spectrum have also been previously reported in the clinical profile of epithelial 
cells or in the detection of lung cancer63. In addition, Feng et al. reported that those 
vibrational features are correlated with proteins that were involved in the salivary 
response of breast cancer patients32. The vibrational signals were seen to be stronger in 
benign breast tumour samples, indicating that the amount of proteins increases in the 
saliva samples from patients this type of lesion32.  
Specifically related to OSCC, biological vibration assignments from saliva can also be 
seen in some other Raman studies involving different types of oral samples. In vivo and 
ex vivo Raman studies, for example, have described the similar prominence of other 
similar protein Raman spectral bands in oral tissue such as 1126 and 1204 cm-1. They 
have also reported that the protein content of these samples was also responsible (in 86%) 
for the differentiation of dysplastic samples from controls64,65. Furthermore, Guze et al. 
have described other the prominence similar protein/glycoprotein bands in oral tissue 
specimens, such as 758 and 1288 cm-1 66. This study has also shown that peaks in the 
range 850–950 cm-1 (protein backbone vibrations) and 1200-1300 cm-1 (Amide III) were 
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more intense in the tumour region, particularly within the nucleus66. Results like these 
reinforce the importance of the protein content of saliva/oral tissues for the diagnosis 
process of these neoplasms as well as the Raman capability of detecting these alterations.  
Raman spectroscopy has already shown its versatility for the diagnosis of other types of 
cancers based on protein differentiation. Lyng et al. demonstrated the ability of Raman 
spectroscopy to classify cervical cancer based on relevant changes of essential proteins67. 
Sensitivity and specificity values could be calculated as high as 99.5% and 100% 
respectively for normal tissue and 98.5% and 99% respectively for invasive cervical 
carcinoma. Also, Raman spectroscopy was able to demonstrate that the secondary 
structures of serum proteins and the contents of amino acids can change during cancer 
colorectal progression68. 
It is important to highlight the fact that, even though Raman spectroscopy is a highly 
accurate and sensitive vibrational technique, the biochemical compositions correlated to 
the Raman vibrations of saliva have been assigned through the spectral profile of 
components acquired and present in the published literature. Raman spectroscopy, unlike 
other techniques such as mass spectroscopy or other molecular biology techniques, when 
used for salivary analysis, fully analyses the entire salivary molecular profile. The greatest 
advantage of Raman spectroscopy, often neglected by those working in the area of 
microscopy/molecular biology, is in the label free definition of saliva as a whole for the 
determination, through mathematical models, of the presence of early-stage OSCC (or 
dysplastic lesions) without any visible clinical and/or histopathological alterations, 
bringing possibilities for the development of technologies derived for application in vivo 
not only in the diagnosis of OSCC but also for biopsy guidance for example. 
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2b.5 Conclusion 
The current systematic review serves as a basis for a more complete methodological 
approach to salivary samples by means of Raman spectroscopy for future investigations, 
besides signaling its promising application in the oral cancer diagnosis process, even in 
the face of differences in the instrumentation setups and statistical analysis applied. 
Regarding the sample collection process, the nature/collection of the saliva samples from 
each study was not highlighted as an important factor for the adopted methodologies nor 
its correlation with the results obtained. However, new research indicates that stimulated 
salivary samples appear to have more diagnostic potential in terms of the number of 
biological components present and of greater clinical applicability for analysis by Raman 
spectroscopy according to the results obtained44. In addition, it is expected that SERS 
methodologies are more costly for a possible routine clinical application. In the same way, 
drying the sample prior to analysis undeniably results in a loss of salivary component 
quality. 
The most used wavelength for application of Raman technology was 785 nm according 
to the great majority of the studies examined. Also, it was confirmed that PCA-LDA was 
the most applied statistical method for analysis of the salivary spectrum, able to obtain 
values in sensitivity, specificity and/or classification efficiency higher than 90% when in 
the diagnosis of OSCC. 
The peaks/bands correlated with the salivary components such as proteins, glycoproteins 
and lipids appeared to be altered and they were possibly associated with the presence of 
OSCC/oral epithelial dysplasia in all the studies reviewed.  
Notable, however, is the inconsistency of the methodologies employed to date, and there 
is need for a systematic approach to optimisation of analysis protocols, to establish a 
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standard Raman setup for saliva samples as well as to better clarify factors correlated to 
the sampling procedure, such as type of collection, degradation and etc. 
Finally, once more clearly elucidated, an optimised methodology based on salivary 
analysis through Raman spectroscopy may contribute to the implementation of this 
technique in routine clinical diagnosis.  
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Chapter 3: Raman measurement optimisation for saliva 
analysis 
 
3.1 Introduction  
Raman spectroscopy may be able to holistically analyse saliva by giving a unique 
biochemical profile. This study aims to use Raman spectroscopy in the clinic to screen 
and diagnose OSCC and potential malignant oral lesions. This chapter had as its objective 
the determination of the best strategy to record Raman spectra from whole saliva for 
diagnostic purposes, keeping the liquid nature of the sample and without the use of 
nanoparticle enhancers. 
 
3.2 Methodology – Measurement optimisation 
 3.2.1 Water measurements 
Initially, measurements of water were performed to facilitate a future Raman set up for 
artificial saliva and real saliva. Ultrapure water was used for this initial stage. The Raman 
signal from water could be evaluated according to the noise aspect/appearance and 
spectral information (peaks), whether present. A low and a high magnification were used 
for each laser line; objectives 10X and 50X for the upright microscope and 10X and 60X 
(with a drop of water) for the inverted microscope. High wavenumbers were also recorded 
to make sure that the water content was visible for the respective laser line. A standard 
cuvette, a 96 well-plate (polystyrene) and a 96 well-plate with glass bottom no.1 (Thermo 
Fisher, around 0.17mm thickness) were used as substrates.  
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3.2.2 Artificial Saliva Preparation 
Attempting to mimic the biological behaviour of human saliva, artificial saliva was 
prepared according to the formula of Klimek et al.1, (Table 3-1) using high-purity 
chemicals and distilled water, at 28 ± 1°C. The pH of 6.8 to 7.5 was maintained by the 
manual addition of H3PO4. The order of addition followed the order of listing in the table. 
Furthermore, different concentrations of artificial saliva (0, 25, 50, 75 and 100% more 
concentrated, respectively based on the absolute concentration presented in the Table 3-
1) were prepared, aiming to overcome the natural “weak” spectral profile of saliva during 
the acquisition of the Raman spectra50. 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3-1: Chemical composition for 1000ml of Artificial Saliva according to Klimek et al.1 
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3.2.3 Raman spectral acquisition  
Optimisation of the different parameters required for Raman spectral acquisition was 
carried out using a HORIBA Jobin-Yvon HR-800 confocal Raman microspectrometer 
(Figure 3.1). 
 
 
 
 
 
 
 
 
 
Figure 3.1. The Horiba Jobin-Yvon LabRAM HR system used for the Raman spectral acquisition 
of the artificial saliva samples. 
 
The Raman spectra were recorded using two different wavelengths (532nm and 785nm), 
various objectives (10X, 50X and 60X) and a diffraction grating of 600 grooves/mm 
coupled with a charge couple device (CCD). Manual calibration of the grating was carried 
out using the 520.7cm-1 Raman line of crystalline silicon. Moreover, upright and inverted 
geometries were both tested and different substrates, including cuvettes, 96 well-plate 
(polystyrene) and 96 well-plate with no. 1 cover glass bottom. Raman spectra were 
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acquired in the 400 to 1800 cm−1 region with an integration time of 40 seconds per 
spectrum, and averaged over three accumulations. Dark current measurement and 
recording of the substrate and optics signal was also performed, for further corrections. 
3.2.4 Real saliva collection and centrifugal filtration 
A sample of human non stimulated whole saliva was collected from a healthy volunteer 
according to the procedure approved by ethical committee of Technological University 
Dublin (fully detailed in chapter 4, section 4.3.3). Following collection, 0.5 mL of the 
saliva sample was centrifugal-filtered using Amicon Ultra- 0.5ml centrifugal filter 
devices (Merck, Germany), according to the method demonstrated by Bonnier et al 2. In 
the case of centrifugally filtered devices, the 3 kDa device was employed, and 0.5 mL of 
the saliva was placed in the device and centrifuged at 14,000 g for 30 minutes. The filtrate 
was mostly composed of water and molecules smaller than 3kDa molecular weight, while 
the remainder of the saliva (concentrate) is retained in the filter device. The filter device 
was then placed upside down in a new Eppendorf and spun down at 1000g for 2 minutes. 
The resultant is a concentration by a factor of 10 for the remaining saliva, with a resultant 
concentrate volume of ~70 mL. 
3.2.5 Data Processing 
The data processing was carried out using Matlab (Mathworks, US) with the PLS-
Toolbox (Eigenvector Research Inc.) and in-house algorithms. The raw Raman spectra 
were first smoothed using a Savitsky-Golay filter (13 points, 9th order). The baseline 
correction was applied using the rubberband method, and the spectra were vector 
normalised aiming to reduce any variability caused by the fluctuation of excitation power. 
 
3.3 Results 
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3.3.1 Water measurements  
Upright geometry 
 For the initial experiments with water, a quartz cuvette (3.5 mL) completely filled with 
ultrapure water was used as a substrate to initially explore the optimisation of the Raman 
measurement protocol. A full range from 400cm-1 to 3800cm-1 was acquired through a 
10X objective, using 785nm as the laser source (Figure 3.2). The resulting spectrum 
obtained from water using a cuvette had a noisy aspect, which seemed to compromise the 
Raman signal from water (Figure 3.2). 
 
 
 
 
 
 
 
 
Figure 3.2: 785nm Raman full range spectrum of water in an upright geometry focused by a 10X 
objective using a quartz cuvette as substrate. 
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A second laser line (532 nm) was also used with the same set up above described. The 
Raman spectrum obtained from water was of very good quality with high signal to noise 
(Figure 3.3). It exhibits the two major water bands around 1640cm-1 and 3200-3400cm-
1. 
 
 
 
 
 
 
 
 
 
Figure 3.3: 532nm Raman full range spectrum of water in an upright geometry focused by a 
10X objective using a quartz cuvette as substrate. 
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into one of the wells to completely fill it. Again, a 10X objective was also used to acquire 
the Raman spectrum of water, using 532nm as laser source. Although not very evident in 
the high wavenumber region (Figure 3.4b), contamination from polystyrene can clearly 
be seen to contribute to the sample (water) spectrum (Figure 3.4a). This association to 
contamination of the spectrum by polystyrene features can be further confirmed in Figure 
3.5 showing the pure spectra of the polystyrene base of the 96 well-plate and water in the 
range 400-3800cm-1. 
The polystyrene contribution could be attributed to the fact that the focal depth of the 10X 
objective is often too long, in comparison to the well depth. Trying to minimise this 
contribution, a higher magnification (50X), and lower focal depth objective were also 
explored. The interference (polystyrene) could be apparently completely eliminated, 
resulting in a good quality water spectrum (Figure 3.6). 
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Figure 3.4: 532nm Raman spectrum of water in an upright geometry focused by a 10X objective using a 96 well-plate (polystyrene) substrate. (a) The fingerprint 
region (400-1800cm-1) and (b) the high wavenumber fingerprint (2500-3800cm-1) show the influence of polystyrene contributions to the spectrum.  
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Figure 3.5: 532nm Raman spectra of water in an upright geometry focused by a 10X objective using a 96 well-plate (polystyrene) substrate along with polystyrene 
spectrum. (a) fingerprint region and (b) high wavenumber region. 
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Figure 3.6: 532nm Raman spectrum of water in an upright geometry focused by a 50X objective using a 96 well-plate (polystyrene) substrate. (a) The fingerprint 
region (400-1800cm-1) and (b) the high wavenumber fingerprint (2500-3800cm-1) shows no influence from the background over the water spectrum. 
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The use of a lower magnification, such as 10X objective, increases the focal depth, 
consequently, making it possible to analyse larger working volumes. Therefore, in the 
case of saliva samples, the working volume provided by the 10X objective allows a 
complete scan of the sample. However, the increased working volume can also contribute 
to signal contamination from the substrate, as seen with polystyrene.  In contrast to this, 
the higher magnification (50X) avoids the contamination from background (polystyrene 
or other) due to the reduced focal depth of the objective lens.  
 
Inverted geometry 
As an alternative, the inverted geometry was investigated, as it has previously been 
reported to give optimal signals for serum measurement2. In an attempt to eliminate the 
high substrate interference from polystyrene seen in the upright measurements, a new 96 
well-plate glass bottom no.1 was then adopted for the inverted geometry. 
Using the inverted instrumentation configuration, the Raman signals from water using 
10X objective were initially acquired using the 785 nm laser source. The signal was in 
general very noisy and fluorescence compromised the spectral profile of water (Figure 
3.7). Also, the high wavenumber region did not show the bands related to water at this 
wavelength due to fluorescence influence and software autocorrection. 
The higher magnification (60X water immersion) was subsequently applied. The signal 
was clearly improved and the noise decreased, but the fluorescence interference 
remained, compromising the Raman signal (Figure 3.8). This sort of fluorescence 
response has also been reported in other studies, where this phenomenon was well 
documented as an effect from the substrate when 785 nm lasers are applied3,4. 
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Figure 3.7: 785nm full range Raman spectrum of water in an inverted geometry focused by a 
10X objective using 96 well-plate glass bottom no.1. 
 
 
 
 
 
 
 
 
Figure 3.8: 785nm full range Raman spectrum of water in an inverted geometry focused by a 
60X objective (water immersion) using 96 well-plate glass bottom no.1. 
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A 60X water immersion objective was applied to the inverted set up (Figure 3.9). Bonnier 
et al. have already demonstrated that when working in immersion using a 60X or 100X 
water immersion objectives, the working distance is increased to about 2 mm2. Thus, the 
60X objective coupled to water immersion might increase the signal resolution from 
saliva samples. 
 
 
 
 
 
 
 
 
 
Figure 3.9: 532nm Raman full range spectrum from 60X water immersion objective by itself. 
 
Keeping the higher magnification (60X water immersion objective), the 532 nm laser 
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which the focus of the water immersion objective had not yet reached the substrate; then, 
at different points as the focus was translated through the substrate (Figure 3.10). This 
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substrate at which the contribution of the glass as well as the water droplet on the 
immersion objective itself was minimised. 
 
 
 
 
 
 
 
 
 
Figure 3.10: 532nm Raman full range spectrum 60X water immersion objective, glass substrate, 
and 3 different focus points beyond the bottom of an empty well in inverted geometry, 
respectively.   
 
Once the optimum focus point was reached, different amounts of water were added (from 
0 to 70 µL) into the well in an attempt to find the minimum sample amount required for 
the set up proposed (Figure 3.11). The minimum amount was determined based on the 
water band intensity at 3400cm-1 as the water was added into the well (Figure 3.12).  
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Figure 3.11: 532nm Raman full range spectrum of an empty well and different amounts (10-70 
µL) of water in an upright geometry focused by a 60X water immersion objective using a 96 well-
plate glass bottom no.1 substrate. 
 
The intensity of water peak at 3400cm-1 reached its highest after 40 µL of water was 
added into the well. At this volume, the spectrum using the 60X water immersion in the 
upright geometry, the 532nm laser line, and a 96 well-plate glass bottom no.1 as substrate, 
was effective in eliminating any visible glass contribution from the water spectrum 
(Figure 3.13). The set up showed the feasibility of application for limited amounts of 
sample (saliva) as low as 40 µL 
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Figure 3.12: Raman intensity variation of different volume of water between 0-70 µL at 3400cm1 
in an upright geometry focused by a 60X water immersion objective using a 96 well-plate glass 
bottom no.1 substrate. 
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Figure 3.13: 532nm Raman full range spectrum of water in an inverted geometry focused by a 60X water objective using a 96 well-plate glass bottom no. 1 as 
substrate. 
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3.3.2 Artificial saliva measurements  
Artificial Saliva in different concentrations (Inverted Geometry) 
Following further analysis using inverted inverted geometry as the most suitable for liquid 
samples, different concentrations of artificial saliva were prepared aiming to obtain 
relevant Raman spectra signal which could not be detected with relevant biological signal 
information. The substrate (96 well-plate with glass bottom no. 1) and the previous 
wavelength (532nm) were adopted as this setup was demonstrated to be a suitable setup 
for saliva samples.   
The Raman spectral quality could be improved as long as the sample concentration was 
increased. Among five formulations, the spectral definition and relevant information 
(peaks) were more visible from artificial saliva when 75% (1:1.75) or more concentrated 
compared to lower concentrations (Figure 3.14).  
 
 
 
 
 
 
  
112 
 
400 600 800 1000 1200 1400 1600 1800
0
0.05
0.1
0.15
0.2
0.25
Raman shift(cm-1)
In
te
n
s
it
y
 (
A
rb
it
ra
ry
 u
n
it
s
)
 
 
Art. Saliva (1:1)
Art. Saliva (1:1.25)
Art. Saliva (1:1.5)
Art. Saliva (1:1.75)
Art. Saliva (1:2)
 
 
 
 
 
 
 
 
 
Figure 3.14: Off-set plot of 532nm Raman spectrum focused by a 60X objective onto a sample of artificial saliva 1:1, 1:1.25, 1:1.5, 1:1.75 and 1:2 ( or 0, 25%, 50%, 
75% and 100% more concentrated, respectively) in an inverted geometry focused by a 60X water objective using a 96 well-plate with glass bottom no. 1 as substrate.  
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785nm – laser line 
The information obtained from artificial saliva sample using a 785nm laser line could not 
show same relevant Raman spectral information compatible with the molecular 
composition of the artificial sample recorded when using a 532 nm laser line (Figure 
3.15).   
 
 
 
 
 
 
 
Figure 3.15: 785nm Raman spectrum focused by a 60X water objective onto a sample of artificial 
saliva in an inverted geometry using a 96 well-plate with glass bottom no. 1 as substrate. A noisy 
Raman signal was obtained with limited spectral information. 
 
3.3.3 Real Saliva 
A real stimulated whole saliva sample from a healthy donor (Technological University 
Dublin) was analysed by previous protocols applied in the artificial samples. Centrifugal 
filtration using 3kDa centrifugal filtering devices seemed to provide a relevant Raman 
signal revealing biomolecular information in the spectra valuable for future analysis for 
oral cancer detection (Figure 3.16). 
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Figure 3.16: 532nm raw Raman spectrum focused by a 60X water objective onto a sample of real 
saliva (around 75% more concentrated by centrifugal filtration) (blue) and a samples of real saliva 
not concentrated (before centrifugal filtration) (red)  in an inverted geometry focused by a 60X 
water objective using a 96 well-plate with glass bottom no. 1 as substrate.  
 
Moreover, the pre-processing data analysis can express the effectiveness of the protocol 
when comparing the pre-processed artificial concentrated saliva spectral profile to real 
saliva spectrum (Figure 3.17). 
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Figure 3.17: Off-set plot of Raman spectrum acquired from real saliva samples previously centrifuged using 3kDa devices in comparison to artificial saliva 1:2 (100% 
more concentrated) after pre-processing in an inverted geometry focused by a 60X water objective using a 96 well-plate with glass bottom no. 1 as substrate. Similarities 
can be seen between both spectra confirming the effectiveness of the standardisation protocol for real saliva samples. 
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Sample stabilisation study 
For a better understanding regarding sample stability, a pilot study regarding the effects 
of time on a saliva sample was also carried out. As the temperature effect from the Raman 
laser applied to the liquid saliva samples remains unknown in the current literature, one 
random stimulated saliva sample from a healthy volunteer (n=1) was analysed over one 
hour by the protocol established in this chapter, using the same substrate and 
instrumentation setup, and processing stages. A Raman spectrum was acquired every 2 
minutes over 1 hour, resulting in a total of 30 spectra.  
The plot of Raman spectra as a function of time shows the variance of the spectra obtained 
(Figure 3.18). Briefly, many of the peaks related to the biochemical composition of saliva 
decreased as the time passed. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.18: Raw Raman spectral changes of one liquid saliva sample over one hour. 
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The area under the curve of each spectrum was also calculated by the trapezoidal 
numerical integration method. Although showing noise variances, Figure 3.19 shows that 
the overall intensity of the Raman fingerprint of saliva has considerably decreased with 
time. Also, an off-set plot of each of the spectra over time (Figure 3.20) shows that the 
loss was basically restricted to protein bands.  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.19: Plot of the variation of the area under the curve over one hour. 
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Figure 3.20: Off-set plot highlighting spectral regions related to proteins and significant 
loss over time. 
 
According to the results obtained, the 10 first spectra, which represent the first 20 minutes, 
did not show any major spectral changes (degradation). After 20 minutes, the bands 
related to the biochemical profile of the sample had almost completely disappeared. These 
results can be due to possible degradation caused by the laser throughout the Raman 
acquisition process. It might be related to the fact that the laser can overheat the sample 
causing salivary protein degradation. 
These results complement and validate the current methodology, according to which only 
the first 10 saliva spectra of each sample can be safely used for Raman analysis.  
 
3.4 Discussion 
Vibrational spectroscopy techniques, such as Raman spectroscopy, hold the advantage of 
minimal sample preparation for analysis of biological samples. The methodology in this 
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current study aimed to optimise the Raman instrumentation and substrates rather than 
saliva preparation.   
The Klimek et al. formula of artificial saliva is considered the most similar to human 
saliva as it contains inorganic components as well as organic components, such as mucin1. 
Other formulae for artificial saliva preparation have also been used in different studies, 
although these formulations only contain inorganic components, which could represent a 
lack of biomolecular information for the Raman spectral recording5,7. 
It is very important to highlight the importance of this study in the vibrational 
spectroscopy field due to the effort in trying to find the best Raman instrumentation setup 
specifically for saliva analysis. The methodology proposed uses only different substrates 
and minimal sample preparation (as saliva was still kept in the liquid physical state) 
compared to other experiments, where enhancers were applied, such as nanoparticles; or 
the saliva sample was completely dried to facilitate the signal acquisition7,8,9. 
Although demonstrating the potential of saliva as a sample, most of the studies involving 
Raman microspectroscopy and saliva analysis on its own have dried the sample, resulting 
in a predictable biochemical information loss10,11. Studies have been carried out showing 
the saliva properties and Raman diagnostic capability for breast, nasopharyngeal and lung 
malignancies9,10,11. To diagnose nasopharyngeal cancer for example, the results suggested 
that the SERS signals attributed to proteins are significantly different between saliva from 
controls and nasopharyngeal cancer patients, and high diagnostic accuracy of 90.2% 
could be abtained8. Similarly, an accuracy of 82.47% and 80% were obtained when 
comparing saliva from healthy controls to saliva from patients with breast and for lung 
cancer, respectively7,8. However, all the methodologies performed in those studies 
involved preparation of enhancers (nano particles) that could be costly as well as difficult 
to translate to a clinical environment. 
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In summary, the Raman setup using the 532 nm laser line, 96 well-plate with glass bottom 
no.1 in an inverted microscope geometry, has been demonstrated to be effective for the 
measurement of artificial saliva, revealing significant biochemical spectral information 
from real saliva samples in an effective and less costly when in comparison to other 
techniques. In view of its potential for precise and rapid analysis of saliva, Raman 
spectroscopy can be used as a potential method for oral dysplasia diagnostics. 
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Chapter 4: Raman spectroscopic characterisation of non stimulated and 
stimulated human whole saliva: a new methodology. 
 
Chapter adapted from ‘Calado G, Behl I, Byrne HJ, Lyng FM. Raman spectroscopic 
characterisation of non stimulated and stimulated human whole saliva: a new 
methodology’ submitted for publication in Analyst (September/2019). 
 
Genecy Calado conducted all the experiment and data analysis, and was primary author 
of the article, with contributions and guidance from the other authors.  
 
4.1 Abstract 
Human saliva is a unique biofluid which can reflect the physiopathological state of an 
individual. The wide spectrum of molecules present in saliva, compounded by the close 
association of salivary composition to serum metabolites, can provide valuable 
information for clinical diagnostic applications through highly sensitive vibrational 
spectroscopic techniques such as Raman spectroscopy. However, the nature of saliva, in 
terms of collection and patient-related characteristics, can be considered factors which 
may strongly affect the Raman spectral profile of salivary samples and disrupt the search 
for specific salivary biomarkers in the detection of diseases. The main objective of this 
study, dealing with the processing of Raman spectra of saliva from 20 donors, 
concentrated by centrifugal filtration, was to highlight spectral features associated with 
the type of collection in an intra- and inter-patient patient approach. The methodology 
adopted for liquid saliva, showed consistency in the qualitative analysis of the groups, 
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confirming the reproducibility of this Raman spectroscopic approach. Using principal 
component analysis (PCA) and partial least squares – discriminant analysis (PLSDA), 
non stimulated saliva could be differentiated from stimulated saliva in both intra- and 
inter-patient analysis, with a classification efficiency of 77 and 87%, respectively. The 
bicinchoninic acid (BCA) assay showed a similar trend in terms of total protein 
concentration, showing a slight increase in stimulated saliva samples. These results are 
valuable in the process of developing and establishing Raman spectroscopy as a novel 
diagnostic tool in the future as well as controlling variabilities, in order to determine 
specific spectroscopic markers related to a multifactorial disease for diagnostic or follow-
up purposes. 
 
4.2 Introduction 
 
Saliva is considered a dynamic biological fluid that has a large range of constituents, 
including proteins, polypeptides, nucleic acids, electrolytes, and hormone1. It is 
categorised as an exocrine secretion of the salivary glands, which is hypotonic in nature, 
with a pH of 7.2–7.4, or in some conditions slightly acidic1. Whole saliva is unique and 
complex, both in its sources and composition. It consists not only of secretions from the 
three major salivary glands (parotid, submandibular and sublingual) and the minor glands, 
but also gingival crevicular fluid, oral mucosa transudate, secretions from nasal and 
pharyngeal mucosa, keratin debris and blood cells2,3. 
Interest in human saliva as a potential diagnostic and prognostic fluid is steadily 
increasing because it provides access not only to relevant oral but also systemic disease 
information4,5. Saliva has been identified as functionally equivalent to blood serum, 
reflecting the physiological state of the body, including hormonal, nutritional, and 
metabolic variations, for example6, and its composition can be linked with traditional 
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biochemical parameters which appear in the serum7. Salivary collection is usually 
considered as one of the easiest methods of collection of bodily fluids, due to its 
noninvasive nature, which also does not require specialised equipment or supervision. 
Further, saliva collection is usually a well accepted procedure, from the patients’ point of 
view, and is a cost-effective approach. Oral fluid sampling is also safe for both the 
operator and the patient and is amenable to repeated and voluminous sampling in short 
intervals of time. Considering these advantages, saliva is identified as a potential source 
of biological sample to be employed for specific patient as well as routine diagnostic 
screening8,9. 
It is very important, however, to highlight the fact that the composition of each saliva 
sample tends to vary and depend on the type of gland of origin and, consequently, the 
type of collection employed to obtain these samples10. Its composition differs according 
to the contribution of each gland in order to obtain the total unstimulated saliva secretion, 
and can vary from 65%, 23%, and 8% to 4% for the submandibular, parotid, and 
sublingual glands, for example11.  
When resting, without exogenous or chemical stimulation, non stimulated saliva is 
characterised by its low and continuous salivary flow, denoted basal unstimulated 
secretion, present in the form of a film that covers, moisturises, and lubricates the oral 
tissues. In contrast, stimulated saliva is produced by a range of mechanical, gustatory, 
olfactory, or pharmacological stimuli, and contributes to around 80% to 90% of daily 
salivary production12. 
Clinically, the most practical way to differentiate between non stimulated and stimulated 
saliva is usually by its salivary flow rate. In adults, normal total stimulated salivary flow 
ranges from 1 to 3 mL/min, low ranges from 0.7 to 1.0 mL/min, while hyposalivation is 
characterised by less than 0.7 mL/min13,14. In normal, non stimulated salivary function, it 
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ranges from 0.25 to 0.35 mL/min, low ranges from 0.1 to 0.25 mL/min, while 
hyposalivation is characterised by a salivary flow of less than 0.1 mL/min14. However, 
although widely adopted in clinics, the values denoted “normal” for stimulated and non 
stimulated salivary flow exhibit large biological variation14.  
Despite the complexity of the salivary milieu and the anatomy of salivary glands, the 
analysis of saliva and its different collection forms represent a promising approach to 
establishing potential biomarkers for several pathological conditions15. In this context, 
the scientific development of new technologies and associated “omics” approaches 
provide opportunities for the determination of new biomarkers for the diagnosis, staging, 
or prognosis of diseases16.  
Vibrational spectroscopy is one such evolving set of techniques which allows analysis of 
a multitude of biological samples, including saliva17-20. Recently, vibrational 
spectroscopic analysis of saliva has proven efficient to differentiate chronic periodontitis 
from aggressive periodontitis21, diagnose type 2 diabetes and psoriasis22, detect drugs23, 
and discriminate smoking from non-smoking patients24. Amongst the vibrational 
spectroscopic methods, Raman spectroscopy can be considered a unique non-invasive 
laser-based analytical technique that aids biochemical component analysis25. Raman 
spectroscopy is based on the molecular vibrations that are specific to certain types of 
biomolecules, including proteins, nucleic acids and lipids25. The Raman effect is based 
on vibration transitions under inelastic scattering of monochromatic light in visible, near 
ultraviolet or near infrared ranges. Raman spectroscopy can thus provide a characteristic 
fingerprint of the molecular vibrations that are specific to certain types of biomolecules, 
including proteins, nucleic acids and lipids25. Raman spectroscopy, in contrast to 
conventional biochemical methods, is a label-free and rapid technique, which usually 
requires only a small quantity of a sample without any preparation26. 
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It has been reported that Raman Spectroscopy of saliva can be used for narcotic usage 
detection27, for cancer diagnosis28,29, and in forensic medicine30. It is notable, however, 
that the current literature lacks technical information regarding the methodologies 
employed31. Thus, there is an urgent need for a systematic optimisation of analysis 
protocols governing Raman spectroscopy analysis of saliva samples. Most studies 
reported to date have focused on individual proteins under specific conditions, with the 
type of stimulation varying greatly32. Studies looking at protein changes in human saliva 
have typically analysed samples from individual glands, not whole saliva33. Notably, the 
literature is particularly scant on details regarding the sample collection protocols, and 
differentiation of stimulated and unstimulated production of saliva and on human whole 
saliva composition.  
In an attempt to establish a standard Raman spectroscopy protocol for analysis of saliva 
samples, as well as to better clarify factors correlated to the sampling procedure, such as 
type of collection, the aim of the present study was to develop, based on Raman spectra 
of saliva samples, a preanalytical workflow to highlight spectral features associated with 
intra- and inter-patient characteristics which could further help to extract specific salivary 
diagnostic signatures of systemic or local pathological conditions. 
 
4.3 Methodology 
4.3.1 Subjects  
Ethical approval to collect saliva samples from healthy donors was granted by the 
Technological University Dublin Research Ethics Committee (REC ref: 15/104). Written 
informed consent was obtained from each donor and the study was conducted in 
accordance with ethical principles founded in the Declaration of Helsinki.  
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4.3.2 Collection of saliva samples 
Saliva samples were collected by both non stimulated and stimulated techniques. In both 
techniques of saliva collection, all subjects were instructed to refrain from smoking, 
eating, drinking and tooth brushing for 1h prior to saliva collection. In each case, saliva 
was collected between 9:00 a.m. and 12:00 a.m., to minimise any interference of food. 
The participants rinsed their mouth with distilled water prior to collection for one minute, 
and waited five minutes before the collection commenced. 
Resting drooling (minimal oral movements), known as the non stimulated collection 
method, was used to collect about 2 mL of whole saliva from the oral cavity of healthy 
volunteers from Technological University Dublin. The saliva providers were asked to sit 
comfortably in an upright position and tilt their heads down slightly to pool saliva in the 
floor of the mouth. The first expectoration was discarded to eliminate food debris and 
unwanted substances which may contaminate the sample and cause analytical inaccuracy. 
Subsequently, the samples were expectorated into a pre-labelled, sterile, 15 mL plastic 
container (Nalgene, Eppendorf).  
Stimulated whole saliva was also collected, by asking the volunteers to chew on a tasteless 
piece of parafilm (5x5cm, 0.30 g; Parafilm ‘M’; American National CAL, Chicago, IL, 
USA). The first expectoration was discarded and the chewing-stimulated saliva was also 
expectorated into test tubes, every 30s for two minutes. During the saliva collection 
period, the subjects chewed at their natural pace.  
A total number of 30 saliva samples were collected from 20 volunteers. Non stimulated 
saliva and stimulated saliva were both collected from each of 10 of the donors, such that 
stimulated and non stimulated samples from the same donors could be compared. The 
remaining 10 samples were collected according to the stimulated protocol from 10 
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different donors, such that stimulated and non stimulated samples from different donors 
could be compared. From each sample (donor), 10 spectra were acquired. 
All salivary samples were aliquoted directly into 1 mL cryotubes and stored at -80°C, 
aiming to preserve the samples. They were further subjected to a freeze–thaw cycle to 
break down mucopolysaccharides34, consequently reducing viscosity and minimising 
pipetting errors. Before spectroscopic measurement, the saliva sample was allowed to rest 
for around 10 minutes to completely defrost in a 4 C° refrigerator. 
4.3.3 Centrifugal filtration of saliva samples 
Commercially available centrifugal filtration devices, Amicon Ultra- 0.5 mL (Millipore 
– Merck, Germany), with cut-off points at 3 kDa, were employed in this study. Reported 
by Bonnier et al., the centrifugal filtration methodology was then adapted to concentre 
the saliva samples, as they retain constituent components only above a size of 3 kDa, 
allowing much of the aqueous sample pass to the filtrate35. 
As indicated by the manufacturer, the ultrafiltration membranes in Amicon® Ultra-0.5 
devices “contain trace amounts of glycerine, which, as demonstrated by Bonnier et al.36, 
can contaminate spectral analysis. Washing of the centrifugal devices prior to saliva 
analysis was therefore carried out by spinning the Amicon Ultra-0.5 mL once with a 
solution of NaOH (0.1 M) followed by two rinses with Milli-Q water (Millipore Elix S). 
For both washing and rinsing, 0.5 mL of the respective liquid was added to the filters and 
the centrifugation was applied for 30 minutes at 14000g followed by a spinning with the 
devices upside down at 1000 × g for two minutes in order to remove any residual solution 
contained in the filter. 
For the sample concentration, 0.5 mL of saliva was placed in a 3K Centrifugal filtration 
device and centrifuged at 14 000 × g for 30 minutes. The filter devices were then placed 
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upside down in a new Eppendorf and spun down at 1000g for 2 minutes in order to collect 
the remainder of the saliva (concentrate) retained in the filter devices. The concentrating 
factor is of the order of 10, with a resultant concentrate volume of ~70 L. As a result, 
one fraction was obtained, representing proteins/components with a molecular weight 
higher than 3 kDa.  
4.3.4 Instrumentation 
A Raman Horiba Jobin Yvon LabRam HR 800, inverted, confocal Raman spectroscopic 
microscope was used to record the spectra from the concentrated saliva samples. The 
microscope has an automated xy stage and is coupled to a Peltier cooled CCD detector. 
A 50 mW diode laser with 532 nm wavelength was used, with a grating of 600 
grooves/mm, while the confocal hole was set at 100 m. A 96 well-plate with glass 
bottom (Thermo Fisher number 1, 0.17 mm thickness) was used as substrate. For the 
acquisition, 10 different regions were selected randomly using a 60X objective (MPLAN 
N Olympus, Japan), which also collected the backscattered light. The spectra were 
acquired over 3 accumulations, totalling 2 minutes per spectrum. A spectral fingerprint 
range from 400 to 1800cm-1 was recorded for further analysis. 
4.3.5 BCA assay 
Total protein concentration of 9 randomly selected saliva samples (3 non stimulated 
samples and 3 stimulated samples from the same donors, and 3 stimulated samples from 
different donors) was estimated via the bicinchoninic acid (BCA) protein assay (Micro 
BCA Protein Assay Kit - Thermo Scientific) by following the instructions of the 
manufacturer. The BCA assay is colorimetric based, giving a dark purple colour when 
two molecules of BCA chelate with protein and form a compound of the cuprous ion. The 
absorbance of the complex was measured at 562 nm using a microplate reader (Beckman 
Coulter Co.). BCA standard reagents A, B and C were freshly mixed in the ratio of 
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25:24:1. Bovine serum albumin (2 mg/ml) was used as a standard, with 13 working 
standards 0.5–2000 μg/mL. All the tubes (standards, test samples, and blank) were 
incubated at 37°C for 2 hours. After incubation, absorbance was measured at 562 nm 
against a reagent blank. The concentration of test samples was measured with reference 
to standards for further analysis. 
4.3.6 Data Analysis 
Pre-processing procedures 
The spectral data processing was carried out using Matlab (Mathworks, US) with the 
PLS-Toolbox (Eigenvector Research Inc.) and in-house algorithms. The raw Raman 
spectra were first smoothed using a Savitsky-Golay filter (13 points, 9th order). The 
baseline correction was applied using the rubberband method37, and the spectra were 
vector normalised, aiming to reduce any variability caused by the fluctuation of 
measurement conditions or instrumental parameters. 
 
Spectral correction method by non-negative least squares (NNLS) 
To deal with possible interferences from the background that may mask important 
biological features, the non-negative least squares method was used to remove glass 
and/or water residuals in the saliva spectra. This in-house model considers the spectral 
data obtained as linear functions resulting from the underlying saliva components and the 
water background and glass substrate38. It aims to reconstitute a vector x that explains the 
observed spectra as well as possible, based on known observations. So, given the spectra 
obtained and a set of known observations, such as a matrix of (1) 60 glass spectra and 60 
water spectra recorded from the model set samples considered in the study (see 
Supplemental Figure S1) and (2) a selection of 9 saliva components (from a pool of 11 
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components used to prepare artificial saliva according to the formula of Klimek et al.39), 
which were recorded at their maximum concentration in water (see Supplemental Figure 
S2, Figure S3 and Table S1) following the same parameters of instrumentation used for 
saliva samples; it is possible to find a nonnegative vector that estimates the contribution 
of these known observations to the spectra. The known observations are then multiplied 
by the nonnegative vector before being subtracted from the initial spectral matrix, 
correcting for both the glass and water contributions in saliva samples.  
This method of correction was also successfully applied for wax and glass removal in 
formalin fixed paraffin preserved tissues by Ibrahim et al.38. Also, a recent study has 
demonstrated the same versatility of the NNLS method for glass correction in oral 
cytological samples40. 
The formula of Klimek et al.39 was designed mainly to study dental erosion in in vitro 
models. Only 9 out of 11 saliva components were recorded due to their suitable chemical 
properties allowing a Raman signal to be acquired. Sodium chloride and monopotassium 
chloride were rapidly dissociated in water affecting the Raman spectra and essentially 
providing a spectrum corresponding to water. As a result, the individual spectra of these 
components were not considered. Also, due to the inability of the mucin component to 
adequately represent the glycoprotein/protein content in the saliva spectrum (see 
Supplemental Figure S2), the spectrum of an extra component (IgG – solubility 50 
mg/L), was also included in the unsupervised analysis (Supplemental Figure S2). This 
component was used to better understand the protein content of saliva through the analysis 
of the weight of each component used in NNLS, and was also used in the unsupervised 
analysis. Concomitantly, the spectral information of the constituents of artificial saliva 
was used for peak assignment in analysis the real saliva samples, where appropriate. 
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Statistical Analysis  
The pre-processed and corrected spectra of saliva samples were initially subjected to 
Principal Components Analysis (PCA) to allow an unsupervised evaluation of the 
variability existing in the data sets itself, as well as among non stimulated saliva and 
stimulated saliva.  
Furthermore, partial least squares discriminant analysis (PLSDA) was also used for 
further classification. Similar to PCA, PLSDA is a form of multivariate analysis which 
works as a linear classifier that aims to maximise the variance between groups and 
minimise the variance within groups, albeit in a supervised way. It is based on partial 
least squares regression (PLSR)41. Also, leave one patient out cross validation (LOPOCV) 
was applied by leaving out all the spectra from each patient (in this case, donor) in turn 
during the cross validation setoff the classifier. Saliva spectral datasets of both groups 
were mean centered to exclude any common variances.  
To further evaluate the performance of the PLSDA algorithm for differentiating between 
the three saliva groups, receiver operating characteristic (ROC) curves were also 
generated. Sensitivity was calculated from the fraction of in class spectra while the 
specificity was calculated from the fraction of not in class spectra for a given threshold. 
The cross validated ROC curves follow the same method, except the class predicted when 
the spectra are left out during cross validation is used. 
Data obtained from the BCA assay was subjected to statistical analysis (2 paired t-test) 
and p<0.05 was deemed to be significant. 
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4.4 Results 
As the intrinsic contribution of water from each sample and possible residual contribution 
from the glass in the finger print region (400-1800 cm-1) could interfere with the 
acquisition of the overall Raman spectra (Figure 4.1), those bands were removed  using 
the NNLS method. 
 
 
 
 
 
 
 
 
 
Figure 4.1: Raw Raman spectrum of a sample of saliva (blue spectrum), water spectrum (red 
spectrum) and glass coverslip no. 1 (orange spectrum). The blue rectangular region denotes the 
strong influence of water on the important protein finger-print range. The orange rectangular 
region denotes the possible finger-print range where there could be spectral glass contamination. 
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Due to the inability of mucin to account for the spectral profile in the protein regions in 
saliva (e.g. the Amide I region ~1500- 1800cm-1) (see Supplemental Figure 4.S5), IgG 
was included along with 9 saliva components to analyse the weight of the components in 
different saliva groups (see Supplemental Figure 4.S6). The weighted sum of all 
components was acquired by the combination of components associated with least 
residual error and it was compared to each corresponding group mean spectrum.  
Although the “fit” is still far from perfect, the inclusion of IgG in the spectral analysis 
significantly improves the correspondence, particularly in the region of the Amide I. In 
the non stimulated saliva samples, the least residual error showed that the component that 
best fit was IgG (glycoprotein) followed by mucin. In contrast, both groups of stimulated 
saliva samples (from same donors and different donors) had more contribution of mucin 
followed by IgG. These results support the use of IgG also for correction along with the 
other nine saliva components. 
After the required pre-processing and corrections, the mean Raman spectra of the groups 
analysed; (i) non stimulated saliva, (ii) stimulated saliva (from the same donors as the non 
stimulated samples) and (iii) the second group of stimulated saliva (different donors), can 
be seen in Figure 4.2. The major vibrational assignments for all three groups, based on 
literature data26,30,42,43, can be seen in Table 4-1. The NNLS correction model seems to 
confer a significant improvement, in this case, on the water and glass subtraction. 
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Figure 4.2: Mean Raman spectra of non stimulated saliva (blue), stimulated saliva from the same 
donors as non stimulated saliva (red), and stimulated saliva from different donors (orange). 
Spectra have been offset for clarity and the shading denotes standard deviation. 
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Table 4-1: Assignment of the main saliva proteins in the Raman bands to biomolecules26,30,42,43. 
Raman shift/cm-1 Major assignments 
502 S-S disulphide stretching band (collagen) 
654 Phenylalanine 
760 Tryptophan 
852 Proline/tyrosine 
878 Hydroxyproline 
938 Proline 
1003 Phenylalanine 
1032 Phenylalanine 
1127 C-N stretching (proteins) 
1208 Tryptophan 
1268 Amide III 
1340 Collagen 
1450 Proteins 
1552 Tryptophan 
1658 Amide I 
 
Qualitative analysis 
In terms of composition, it is clear that the saliva mean fingerprint from each sample set 
is dominated by the polypeptide backbone of protein, represented by the amide I, C-H 
deformation bands and aromatic ring breathing peaks at 1658 cm-1, 1450 cm-1 and 
1003cm-1, respectively. Based on the current literature, these bands can be related to 
various glycoproteins that are known to be constituents of saliva, especially mucin 
matrices43; when correlated to the panel of saliva components recorded and available (see 
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Supplemental Figure 4.S2), these peaks show compatibility with spectral features of 
IgG and mucin, reaffirming the high presence of glycoproteins/proteins. 
There are also some peaks, including those in the low wavenumber range of 400-550 cm-
1, that indicate the presence of saccharide. The salivary mucus is rich in 
mucopolysaccharides, also known as glycosaminoglycans, which can explain this 
possible assignment30. When linked to the components( present in Supplemental Figure 
4.S2), glucose, for example, shows similar spectral features, such as peaks at 422, 448 
and 520 cm-1, as does mucin (as it is also a protein with agglutination properties). 
Furthermore, considering again the saliva components used for NNLS correction (see 
Supplement Figure 4.S3), some peaks in this range could also potentially represent some 
salivary electrolytes (in other words the buffer content of saliva), such as sodium 
phosphate (540 cm-1), potassium phosphate (516 cm-1) and calcium chloride (480 cm-1).  
Saliva is also known for its high concentration of proline-rich proteins. These type of 
proteins are one of the major components of the saliva from the parotid and 
submandibular gland in humans but mainly secreted by the submandibular gland44. The 
Raman peaks at 852 cm-1, 878 cm-1 and 938 cm-1 are known to be correlated to proline 
presence and can also be easily assigned in the mean spectra of non stimulated saliva30. 
The bands at 760 cm-1, 1032 cm-1, 1208 cm-1 and 1340 cm-1 are bands related to a wide 
range of proteins and lipids. When compared to the panel of artificial saliva components 
used for correction, these peaks also show some correlation with spectral bands of IgG 
(glycoproteins). Furthermore, the 1127 cm-1 peak seems to be related to carbohydrate, 
very commonly found in the oral environment30. 
 
Unsupervised analysis of non stimulated saliva versus stimulated saliva  
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PCA was applied to gain more information on the differences between the non stimulated 
and stimulated saliva samples in general (Figure 4.3a and Figure 4.3b) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3: PCA of non stimulated and stimulated saliva from the same and different donors 
showing overlap between the groups according to PC1 in (a) 2D scatterplot and (b) 3D scatterplot. 
The PC2 axis shows, however, some degree of differentiation of the non stimulated saliva 
samples, as denoted by the blue ellipse. 
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PCA revealed a significant variance amongst the groups, indicating that the biochemical 
features of the saliva samples, either stimulated or non stimulated, from the same or 
different donors, leads to little or no differentiation with respect to the PC1 axis, (Figure 
4.3). Similar behaviour can be seen in a PCA of the dataset, following NNLS correction 
without IgG (Supplemental Figure 4.S2). However, with respect to the PC2 axis, the 
non stimulated saliva group seems to be more tightly aggregated, showing more 
biochemical homogeneity (Figure 4.3a).  
Although no clear differentiation of the sample types was achieved, the PC1 loading 
indicates that the variability across the samples could be correlated to protein (Figure 
4.4), featuring prominent protein bands such as 938 cm-1, 1004 cm-1, 1128 cm-1, 1384 cm-
1, 1450 cm-1, 1565 cm-1 and 1652 cm-1, mentioned previously in the qualitative analysis. 
The same behaviour could be seen in the PC1 loading where the NNLS correction did not 
include IgG (Supplemental Figure 4.S8). 
 
 
 
 
 
 
 
 
Figure 4.4: PC1 loading from PCA analysis. 
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The PC2 loading (Figure 4.5), for which a more clear differentiation of the non stimulated 
saliva samples was achieved, suggests that the higher intensity of the major negative 
peaks (1004, 1450, 1450 and 1669 cm-1) could be mostly assigned to higher concentration 
of glycoprotein/proteins in the non stimulated saliva, directly correlated to the Raman 
bands of IgG from the panel of components used in the NNLS correction (see 
Supplemental Figure S3). 
 
 
 
 
 
 
 
 
Figure 4.5: PC2 loading from PCA analysis. 
 
The inclusion of IgG to represent the glycoprotein content of saliva samples, although it 
does not significantly improve the discrimination power of PCA for the stimulated saliva 
samples, was considered important for the classification of the non stimulated samples 
due not only to the improved “fit” with this component but also due to a clearer 
discrimination according to PC2 (Supplemental Figure 4.S7), and was consequently 
used for in the supervised analysis.  
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The distribution of the different groups of saliva samples in PCA (Figure 4.3) suggests 
that non stimulated saliva seems to be, in an overall analysis, biochemically distinct 
(negative side of PC2), while stimulated saliva might represent a “mixture” of stimulated 
and non stimulated, composition-wise (spread across the negative and the positive side of 
PC2). Notably, the mean of the distributions of stimulated and non stimulated samples in 
PCA are offset, with respect to PC2, and therefore it is more appropriate to compare the 
mean spectra of the different groups to further analyse its composition. 
Stimulated and non stimulated saliva from the same donors showed very similar Raman 
spectral features when compared (Figure 4.6), apart from the spectral range around 1575 
cm-1 (glycoprotein related). Visually comparing the mean spectrum from each group 
(Figure 4.6), all the same major peaks are displayed in both, and in general the spectra 
appear very similar to each other.  
 
 
 
 
 
 
 
 
Figure 4.6: Mean spectra of non stimulated saliva and stimulated saliva from the same donors. 
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These differences in intensity are further confirmed when the mean spectra of the non 
stimulated saliva group was subtracted from the mean spectra of the stimulated saliva 
group (same donors) (Figure 4.7), showing again a higher presence of glycoproteins 
(1575 cm-1) associated with the stimulated saliva. 
 
 
 
 
 
 
 
Figure 4.7: Difference spectrum of non stimulated saliva mean spectrum subtracted from 
stimulated (same donors) mean spectrum. 
 
Supervised analysis of non stimulated saliva versus stimulated saliva – same donors 
PLSDA, along with LOPOCV method, was subsequently utilised as a classification 
algorithm employed to quantitatively differentiate stimulated from non stimulated saliva 
from the same donors. The resultant, cross validated, probability prediction plot indicates 
that it is possible to classify and separate the non stimulated saliva group from the 
stimulated saliva group, although they come from the same donors (Figure 4.8). In the 
same way, the confusion matrix obtained (in a balanced analysis of 100 spectra collected) 
indicates sensitivity and specificity of 77% and 78%, respectively (Table 4-2). 
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Figure 4.8: Cross validated probability prediction plot showing the discrimination between non 
stimulated saliva and stimulated saliva from the same donors. The discriminant (red line) is 
considered as the latent variable where the data best classifies.  
 
Table 4-2: Sensitivity and specificity from PLSDA classification between non stimulated saliva 
and stimulated saliva from the same donors. 
 
Based on the ROC curves (Figure 4.9a and Figure 4.9b), the classifier was able to obtain 
excellent discrimination between non stimulated saliva (AUC=0.844) and stimulated 
saliva (AUC=0.844). 
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Figure 4.9: ROC curves for (a) non stimulated saliva samples and (b) stimulated saliva samples 
from the same donors. AUC is a measure of accuracy of the classifier, (C) is calibrated and (CV) 
is the cross validated AUC. The red dots represent the calculated sensitivity and 1-specificity on 
the y and x axis, respectively.  
 
Supervised analysis of non stimulated saliva versus stimulated saliva – different donors 
As a second approach aiming to further classify these samples, the saliva samples from 
different donors were compared, non stimulated saliva samples from 10 donors (used in 
the first analysis), and stimulated from a new group of 10 different donors. Consistent 
with the analysis of samples from the same donors, only the intensity of some peaks 
seemed to change while the general spectral appearance of the salivary profile of the non 
stimulated and stimulated groups continued to be very similar (Figure 4.10). 
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Figure 4.10: Mean spectra of non stimulated saliva and stimulated saliva from different donors. 
 
Following the analysis with the same donors, similar differences in intensity could be 
further confirmed when the mean spectra of the non stimulated saliva group was 
subtracted from the mean spectra of the stimulated saliva group (different donors) (Figure 
4.11), showing this time a reduced presence of proteins (1575 cm-1) associated  with the 
stimulated saliva from different donors. It is, however, important to highlight a higher 
intensity on proline related peak (938 cm-1) associated with the non stimulated saliva.  
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Figure 4.11: Difference spectrum of non stimulated saliva mean spectrum subtracted from 
stimulated (different) mean spectrum. 
 
To further assess the accuracy of saliva spectra, spectral differences of non stimulated 
saliva and stimulated saliva from different donors were mean centered and also explored 
in detail by the PLSDA multivariate algorithm and LOPOCV. The cross validated 
probability prediction plot from the different donors (Figure 4.12) could show an 
efficient classification between the groups which was confirmed with sensitivity and 
specificity (in a balanced analysis of 100 spectra) of 88% and 86%, respectively (Table 
4-3).  
 
Table 4-3: Sensitivity and specificity from PLSDA classification between stimulated saliva and 
non timulated saliva from distinct donors. 
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Figure 4.12: Cross validated probability prediction plot showing the discrimination between non 
stimulated saliva and stimulated saliva from different donors. 
 
The ROC curve plot for the second analysis showed that the classifier had an even better 
accuracy (AUC=0.8550) for both classes (non stimulated and stimulated) of samples from 
different donors (Figure 4.13a and Figure 4.13b).  
 
 
 
 
 
 
Figure 4.13: ROC curves for (a) non stimulated saliva samples and (b) stimulated saliva samples 
from distinct donors.  
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In terms of estimation of the total concentration of proteins, the BCA assay results did 
not show a significant difference between the non stimulated saliva samples and the 
stimulated saliva samples from the same donors (p = 0.584) or different donors (p = 
0.370). However, the mean concentration of total proteins was slightly increased in 
stimulated saliva from the same donors (Figure 4.14a) and different donors (Figure 
4.14b). 
 
 
 
 
 
 
Figure 4.14: BCA assay showing the mean total protein concentration (µg/mL) and standard 
deviation (error bars = 95% confidence intervals) according to the different types of saliva in the 
same donors (a) and different donors (b). 
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chewing paraffin wax or by gustatory stimulation by applying acetic acid in the mouth 
followed by collection of saliva1,45.  
Few reports have explored the effect of stimulation on human whole saliva composition. 
Most studies have focused on individual proteins under specific conditions, with the type 
of stimulation varying greatly. In an attempt to use non stimulated saliva to detect juvenile 
idiopathic arthritis, despite small divergences, no differences in the protein salivary status 
between patients and the control group were found46. Studies looking at protein changes 
in human saliva have typically analysed samples from individual glands, not whole saliva 
and many of these studies did not account for important variables, such as intra- and inter-
patient differences47. Nevertheless, protein concentration is known to be influenced by 
type of stimulation, glandular source, etc 48.  
Discriminating chemometrically between non stimulated whole saliva and stimulated 
whole saliva is an important step to confirm and standardise the applicability of Raman 
spectroscopy for diagnostic purposes. To the best of our knowledge, this is the first study 
of its kind to compare the composition of stimulated and non stimulated saliva based on 
the Raman spectral features as well as the individual spectral biochemical fingerprint 
based on an intra- and inter-patient approach. 
The spectral components of saliva are complex, and have contributions from multiple 
constituent chemical species. For both saliva types, the spectra are dominated by water, 
proteins and electrolytes. These results consequently correlate with several literature 
sources, where the cited majority chemical components of saliva in the highest 
concentrations are electrolytes, mucus, antibacterial compounds, and various enzymes, 
and water49-51. 
151 
 
As part of the preprocessing procedure, water can be removed using NNLS fitting, using 
spectra of constituents of a known artificial saliva formulation. It was noted however, that 
the combined spectra of the formulation did not account well for the protein content 
evident in the saliva spectra, and thus IgG was added to the mix of constituents. Also, it 
is important to highlight the fact that the artificial saliva formulation of Klimek et al., 
although representing a comprehensive mixture of saliva components, might not be 
representative enough for the complex spectroscopic band assignment, as this formula 
was primarily created to see the in vitro effects of dental erosion39. This explains the need 
for IgG as the salivary glycoprotein representative for improvement of the spectral fit (see 
Supplemental Figure 4.S5 and 4.S6).  
When comparing the two different saliva groups, the qualitative analysis (spectral 
composition) of non stimulated saliva and stimulated saliva initially showed that, in both 
the intra-patient and inter-patient approach, the mean spectra of the different saliva groups 
had similar features. From the intra-patient approach, these results would be expected due 
to the fact that each saliva sample had the same donor source, despite being collected in 
a different way, which would mean a minimal variation in terms of biological 
composition of these samples. Thus, the same behaviour would also be expected from the 
inter-patient analysis due to the essential components of saliva being still quite similar 
even when collected from different individuals50. 
Generally the intensity of some bands, as seen in the mean spectra of each group, changed, 
and this is understandable since the relative contribution of the chemical species in saliva 
will likely change with each donor and can even change within the same donor throughout 
the day 30. Besides, it is important to highlight the fact that, for example, the proline band 
at 938 cm-1 had a higher intensity in the non stimulated group which could be explained 
by the major contribution of the submandibular gland in non stimulated samples as 
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compared to stimulated samples44. However, differences such as the higher intensity of 
glycoprotein related peaks, such as those at 1575 cm-1, in the difference spectra of the 
groups can suggest that stimulated saliva also contain valuable protein contributions in 
its composition for possible clinical analysis. 
It is already known that the average daily flow of whole saliva varies in healthy 
individuals between 1 and 1.5 L and the type of collection/stimulation. Percentage 
contributions of the different salivary glands during unstimulated flow are 20% from 
parotid, 65% from submandibular, 7% to 8% from sublingual, and less than 10% from 
numerous minor glands. Stimulated high flow rates drastically change the percentage 
contributions from each gland, with the parotid contributing more than 50% of total 
salivary secretions52.These different contributions might be responsible for the 
overlapping distribution of the stimulated saliva samples with the non stimulated saliva 
samples in PCA. 
Since the structure and composition of saliva is complex, and given that the spectral 
profile from different groups based on stimulation and non stimulation are very similar, 
it was necessary to develop a more sophisticated and robust diagnostic model based on 
PCA and PLSDA by utilising the entire spectrum to determine the most diagnostically 
significant spectral features for classification of the saliva. However, there is of course a 
potential for a large variety of contaminants in any saliva sample due to the eating habits 
of a particular donor48, but these interferences do not appear to affect the spectroscopic 
signature. 
In an unsupervised analysis, PCA did not provide a clear differentiation between the 
different saliva samples regardless of NNLS correction with IgG. However, PC1 of both 
analyses has shown that the slight differences in spectral profiles could be attributed to 
bands at 1004, 1128, 1450, 1655 cm-1. As expected, these bands seem to correspond to 
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the bond stretching of νs (C-C) of phenylalanine and Amide I which could be used to 
identify salivary proteins43. These results are also consistent with contributions from 
mucin and IgG (glycoproteins) spectral features from the recorded components, providing 
confirmation of such assignments.  
Furthermore, the overall spectral profile of stimulated saliva seemed to have more 
influence from peaks at 938, 1442-50 cm-1 which could be correlated to proline and lipids 
in comparison to non stimulated samples from different donors. These results indicate 
that proline-rich proteins which are found in abundance in non stimulated saliva, can be 
subject to inter-patient variation in salivary composition. However, a possible association 
with calcium chloride and urea, according to our own panel of components, may open a 
possibility that Raman spectroscopy was able to detect possible differences in the 
microbiome of stimulated saliva, as urea is a resultant component of bacterial 
proliferation in the oral environment; and calcium chloride (present in the acquired 
pellicle) could be a result of the mechanical action during collection54. 
PCA showed that stimulated saliva was quite diverse (as mixture of both stimulated and 
non stimulated components), whereas non stimulated saliva was more homogeneous (or 
pure). According to the PC2 loading, non stimulated saliva also seemed to be strongly 
influenced by a peak at 1669 cm-1, to which amino acids could be correlated55. On the 
other hand, the difference spectra of both groups could highlight the higher concentration 
in other glycoproteins in stimulated saliva52. 
To further complement the Raman spectral analysis, the BCA assay results seemed to be 
consistent with the fact that there are no major differences in the protein concentration of 
the two types of saliva samples. Although not statistically significant, stimulated samples 
had a slightly increased protein concentration in comparison to the non stimulated 
samples. This result is in accordance with some variability in intensity of some protein 
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peaks, such as 1575 cm-1 seen in the difference spectrum. Ultimately, BCA results were 
able to confirm the rich general content of protein in saliva samples but could not 
differentiate the two groups based on protein concentration specifically. This could be 
attributed not only to the inter-patient issues but perhaps also attributed to the reduced 
number of samples used in this biochemical test. 
Several factors may modify the salivary concentration. Thus, the composition of 
unstimulated saliva is different from stimulated saliva (which is more similar in 
composition to plasma)56. For example, an increase in the salivary flow rate, obtained by 
stimulation with acidic food, increases the concentrations of sodium, chloride and 
bicarbonate and decreases the concentration of salivary potassium and phosphate, 
compared with unstimulated saliva57. 
Stimulated saliva has certain drawbacks as the foreign substances which stimulate the 
saliva tend to modify the pH and the water phase of salivary secretion. However, for 
practical reasons, stimulated saliva samples may be preferred over non stimulated saliva 
samples, as these can be collected in higher volumes and considerably faster than non 
stimulated saliva samples or when in a clinical environment1. Not surprisingly, the 
proteomic profile of stimulated saliva samples has been reported to be diluted when 
compared with non stimulated saliva samples, which is why non stimulated saliva 
samples are preferred for proteomic analysis of saliva58,59. Others studies, however, have 
reported the salivary protein content increased with stimulated saliva samples60. 
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4.6 Conclusion 
The field of salivary diagnostics has undeniable translational and clinical potential. 
Continuing advancements in vibrational spectroscopy technologies have revealed 
unprecedented insights toward understanding salivary composition as part of the body’s 
overall health. Correct interpretation and utilization of this information may be useful not 
only for identifying local and systemic disorders but also, perhaps, to aid in the treatment 
strategies. 
Raman spectroscopy can be of real interest for diagnostic purposes in case of complex 
diseases with multiple confounding factors. This is even more the case for salivary 
extracts whose biochemical composition may be affected by several conditions, not only 
the type of collection but also comorbidities related to complex diseases. 
The qualitative results show that the specificity of the Raman signature of liquid saliva 
samples and its potential ability to be used as an identification technique for diagnostic 
purposes in the future due to its reproducibility even in different conditions of collection 
and considering inter-patient (donor) variability.  
In an unsupervised analysis, PCA was not able to differentiate the different saliva 
samples, showing minimal changes inherent to individual saliva composition. However, 
it did indicate that non stimulated saliva was significantly more biochemically 
homogeneous, compared to stimulated saliva. 
The good sensitivity and specificity obtained by PLSDA revealed that, even with high 
spectral similarities correlated to the salivary composition, the classifiers could provide 
differentiation between the groups, mainly between non stimulated samples and 
stimulated samples from different donors. 
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With the help of a standardised collection procedure and protocol, the use of salivary 
samples for Raman spectroscopy can be a promising diagnostic method that can allow a 
novel non invasive and cost-effective approach. Also, having set guidelines standardising 
the procedure, as the method proposed by this study, could resolve any confounding 
issues between studies and alleviate some of the inherent variability among individuals 
and populations when using saliva samples for Raman spectroscopic clinical analysis. 
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Chapter 4: Supplemental 
 
Supplemental 1 
 
 
 
 
 
 
 
 
 
 
Figure 4.S1: 60 Pre-processed spectra of ultrapure water (a) and glass coverslip no. 1 (b) for NNLS correction 
a) b) 
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Supplemental 2 (part 1) 
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Supplemental 2 (part 3) 
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Supplemental 2 (part 4) 
 
 
 
 
 
 
 
 
Figure 4.S2: 9 artificial saliva components according to the formula of Klimek et al.39 recorded individually plus IgG. 
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Supplemental 3 
 
 
 
 
 
 
 
 
 
 
Figure 4.S3: Raman spectra from 9 saliva components plus IgG used as reference for NNLS 
correction for water and glass and selected bands used for reference in the mathematical 
correction process. 
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Supplemental 4 
 
Table 4-S1: Saliva components used as reference for NNLS correction for water and glass and 
the maximum solubility of each component in water according to the supplier (Sigma Aldrich). 
Saliva Components  Maximum solubility indicated by the 
supplier (at room temperature) 
Urea 1 g/mL 
Calcium chloride 219.1 g/L 
Ascorbic Acid 176 g/L 
Glucose 133 mg/mL 
Ammonium chloride 100 mg/mL 
Sodium thiocyanate 1,000 g/L 
Monopotassium phosphate 22.6 g/100 mL 
Disodium phosphate 7.7 g/100 ml 
Mucin 20 mg/mL 
 
 
 
 
  
172 
 
Supplemental 5 
 
 
 
 
 
 
 
Figure 4.S5: Non stimulated mean spectrum and spectrum of the weighted components without IgG (components’ fit) after NNLS correction (a); stimulated (same 
donors) mean spectrum and spectrum of the weighted components (components’ fit) after NNLS correction (b); and stimulated (different donors) mean spectrum and 
spectrum of the weighted components (components’ fit) after NNLS correction (c). 
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Supplemental 6 
 
 
 
 
 
 
 
 
Figure 4.S6: Non stimulated mean spectrum and spectrum of the weighted components including IgG (components’ fit) after NNLS correction (a); stimulated (same 
donors) mean spectrum and spectrum of the weighted components including IgG (components’ fit) after NNLS correction (b); and stimulated (different donors) mean 
spectrum and spectrum of the weighted components plus IgG (components’ fit) after NNLS correction (c). 
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Supplemental 7 
 
 
 
 
 
 
 
 
Figure 4.S7: PCA of non stimulated and stimulated saliva from same (a) and different donors (without IgG) showing general misclassification and, consequently, 
non-differentiation, by PC1 perspective. 3D plot corroborates the misclassification (b). PC2 axis shows, however, sort of differentiation of non stimulated saliva 
samples, as denotes the blue ellipse. 
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Figure 4.S8: PC1 loading from analysis without IgG. 
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Chapter 5: Raman spectroscopy for identification of potential 
malignant oral lesions and oral squamous cell carcinoma 
through saliva analysis 
 
5.1 Introduction  
It is undeniable that oral squamous cell carcinoma (OSCC) causes significant rates of 
mortality and morbidity in patients diagnosed with this type of tumour, especially when 
discovered late in the course of the disease onset and/or progression. In a clinical context, 
OSCC can be considered in terms of a “natural history”, which originates from non-
aberrant keratinocytes which are chronically exposed to a stimulus that disrupts their 
homeostasis, leading to epithelial hyperplasia, dysplasia of different degrees, carcinoma 
in situ (CIS) and ultimately invasive carcinoma, which can give rise to the generation of 
remote metastases1, with the consequent clinical manifestations. 
The 2005, the World Health Organisation defined a three-tier classification system of 
epithelial dysplasia grades of potential malignant oral lesions (PMOL) as mild, moderate 
and severe2. This is based on the architectural and cytological alterations, whereby, in 
mild dysplasia, the architectural disturbances, with cytological atypia, are present only in 
the lower third of the epithelium. In moderate dysplasia, the criteria stipulate that 
architectural disturbance extends into the middle third of the epithelium, but the degree 
of cytological atypia may require upgrading the classification to “severe dysplasia”. In 
severe dysplasia, architectural disturbances are observed in greater than two thirds of the 
epithelium, with cytological atypia which now can also include CIS, characterised by full 
thickness or almost full thickness of epithelial architectural disturbance in the viable cell 
layers accompanied by pronounced cytological atypia2,3. 
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More recently, in an attempt to simplify the clinical application of this grading system, 
the Working Group coordinated by the WHO Collaborating Centre for Oral Cancer also 
recommended a 2-tier classification of low risk (hyperplasia and mild dysplasia) and high 
risk (moderate, severe and CIS)4. Thus, in the more recent evolution of the WHO grading 
system (2017), features of “squamous hyperplasia (acanthosis and basal cell 
hyperplasia)” and “CIS”, considered in the 2005 WHO classification, have been removed 
from the oral epithelial dysplasia grading5. The term CIS is now used synonymously with 
severe dysplasia. Some cytological/cellular features in the 2005 WHO classification have 
been dropped, while others have now been included in the new classification. For 
example, the “increase in nuclear size” has been dropped, while the architectural feature 
“loss of epithelial cell cohesion” has been included in 2017 WHO diagnostic criteria6. 
However, the biological significance of this system needs to be validated in longitudinal 
studies to explore its value in the prediction of malignant transformation risk of oral 
epithelial dysplasia.   
The grading for oral epithelial dysplasia (PMOLs with histopathological epithelial 
dysplasia present), has always been considered one of the most ill-defined and unfocused 
fields in oral and maxillofacial pathology and, unfortunately, the new WHO grading does 
not seem to improve this scenario6. Added to this, the histopathological classification as 
such is prone to inter- and intra-observer errors and, in some situations, the progression 
of dysplasia is not a linear process, so the degree of dysplasia attributed is not necessarily 
a predictor for malignant transformation7. Furthermore, although it is accepted that 
PMOLs are statistically more likely to progress to cancer, the actual mechanisms are still 
poorly understood and it is not inevitable that a dysplastic lesion will progress to cancer. 
Hence, there are still no clear molecular markers which enable us to distinguish lesions 
that may progress from those that will not7. 
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From a diagnostic perspective, researchers postulate that blood-derived molecules could 
potentially influence the molecular constituency of oral fluids8,9,10. This suggests that 
circulating biomarkers absorbed by the salivary glands may possibly alter the biochemical 
composition of saliva. Consequently, whole saliva may contain complex but 
characteristic molecular information capable of communicating an individual’s current 
state of health11.  
Based on the results obtained from healthy volunteers to differentiate the two types of 
saliva collection in Chapter 4, Raman spectroscopy may be able to integrally analyse 
saliva, giving a faithful and distinct biochemical profile and be used to clinically screen 
and diagnose OSCC and PMOL. This chapter explores the use of Raman spectroscopy to 
discriminate between mild, moderate and severe dysplasia as well as high and low 
dysplasia grades based on the spectral profile of saliva samples through partial least 
squares discriminant analysis (PLSDA) for possible clinical application of this technique 
in the near future.  
 
5.2 Methodology  
5.2.1 Ethics and volunteer questionnaire  
Ethical approval to collect saliva samples from healthy donors was granted by the Dublin 
Institute of Technology (now Technological University Dublin) Research Ethics 
Committee (REC ref: 15/104) (Appendix I), as mentioned in chapter 4. A medical and 
oral health status questionnaire was also used to obtain further information regarding 
biological factors that could potentially influence the analysis (Appendix II). Some of 
the data will be further exploited in chapter 6, to better understand the influence of 
individual/clinical factors, such as smoking and alcohol consumption.  
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Ethical approval was also obtained from the St James' Hospital/Dublin Dental University 
Hospital Research Ethics Committee to collect saliva samples from patients with 
histopathologically diagnosed PMOL/OSCC (REC ref: 2013/23/05) (Appendix III). 
Written informed consent was obtained from each donor and the study was conducted in 
accordance with ethical principles founded in the Declaration of Helsinki. 
5.2.2 Collection of saliva samples 
Due to the practicality of the method in the clinical environment and the results obtained 
in chapter 4, stimulated saliva collection was the methodology of choice for patient 
samples. Stimulated whole saliva was collected, pre-processed, stored and concentrated 
following the same procedures elucidated in Stimulated saliva collection in chapter 4 
(section 4.3.2). 
In total, saliva samples of 45 patients were collected and included; of which 18 were mild 
oral epithelial dysplasia, 17 moderate oral epithelial dysplasia, 6 severe oral epithelial 
dysplasia/carcinoma in situ and 4 invasive OSCC (Table 5-1). To counter-balance the 
study, 45 saliva samples from healthy volunteers (controls) were collected (Table 5-2). 
The average age for the patients was 63 ±12.8 years while that of the controls was 34 ± 
10.49 years. Regarding gender, 46.66% (n=21) of the patients were female and 53.33% 
(n=24) were male, while 33.33% (n=15) of the healthy volunteers were male and 66.66% 
(n=30) were female. 
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Table 5-1: Information on patients’ clinical profile. 
Patient  Gender Age Histopathological diagnosis 
1  F 54 Moderate dysplasia 
2 M 62 Moderate dysplasia 
3 M 70 Moderate dysplasia 
4  M 65 Moderate dysplasia 
5 F 68 Mild dysplasia 
6 F 72 OSCC 
7 F 71 Moderate dysplasia 
8 F 91 OSCC 
9 F 50 CIS 
10 F 59 Mild dysplasia 
11 F 56 Mild dysplasia 
12 F 65 Moderate dysplasia 
13 F 49 Moderate dysplasia 
14 M 63 Moderate dysplasia 
15 M 63 OSCC 
16 M 73 Mild dysplasia 
17 F 70 Mild dysplasia 
18 M 77 Mild dysplasia 
19 M 80 Mild dysplasia 
20 F 40 Mild dysplasia 
21 F 48 Mild dysplasia 
22 M 80 Moderate dysplasia 
23 M 35 Moderate dysplasia 
24 F 72 CIS 
25 F 70 Severe dysplasia 
26 M 55 Mild dysplasia 
27 F 73 Mild dysplasia 
28 M 74 Mild dysplasia 
29 F 34 Severe dysplasia 
30  M 73 Mild dysplasia 
31 F 67 Mild dysplasia 
32 M 69 Mild dysplasia 
33  F 64 Moderate dysplasia 
34 M 62 Mild dysplasia 
35 M 45 Moderate dysplasia 
36 M 61 Severe dysplasia 
37 F 86 Moderate dysplasia 
38 M 66 Moderate dysplasia 
39 M 58 Moderate dysplasia 
40 M 71 Moderate dysplasia 
41 M 52 OSCC 
42 M 49 Moderate dysplasia 
43 M 61 Severe dysplasia 
44 F 60 Mild dysplasia 
45  M 63 Mild dysplasia 
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Table 5-2: Relevant information on healthy volunteers. 
Healthy volunteers (controls) Gender Age 
1 M 30 
2 F 27 
3 F 39 
4 F 35 
5 M 27 
6 F 38 
7 F 27 
8 F 29 
9 M 34 
10 F 27 
11 F 32 
12 M 31 
13 F 32 
14 F 32 
15 F 38 
16 F 27 
17 M 33 
18 F 41 
19 F 29 
20 F 50 
21 M 28 
22 M 34 
23 F 40 
24 F 31 
25 M 70 
26 M 32 
27 F 56 
28 F 35 
29 F 26 
30 M 27 
31 F 26 
32 M 30 
33 F 27 
34 M 30 
35 F 63 
36 M 32 
37 F 29 
38 M 65 
39 F 25 
40 F 25 
41 F 32 
42 F 26 
43 F 27 
44 M 29 
45 F 32 
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5.2.3 BCA assay 
Total protein concentration of stimulated saliva samples of 9 patients (3 mild, 3 moderate 
and 3 severe/CIS) was estimated by the bicinchoninic acid (BCA) protein assay (Micro 
BCA Protein Assay Kit - Thermo Scientific). This assay was performed as described in 
section 4.3.5 in chapter 4.   
5.2.4 Instrumentation 
Following the methodology proposed in chapter 3, a confocal Raman Horiba Jobin Yvon 
LabRam HR 800 Raman (inverted) microspectroscope was used to record the spectra 
from the concentrated saliva samples from patients and healthy volunteers. The 
instrument and setup properties, and substrate choice, were applied as described in section 
4.3.4 in chapter 4. For every sample, 10 different random regions (within the sample area) 
were spectrally recorded such that the depth (z axis) was kept constant, as explained in 
chapter 3.  
5.2.5 Data Analysis 
The data analysis was carried out using Matlab (Mathworks, US) with the PLS-Toolbox 
(Eigenvector Research Inc.) and in-house algorithms. The spectral preprocessing and 
correction steps have been described in Pre-processing procedures section 4.3.6 in 
chapter 4. 
In the same way as the data analysis of chapter 4, PLSDA with leave one patient out cross 
validation (LOPOCV) was used to build the classifier and discriminate the samples 
according to dysplasia grade and/or presence of malignancy. 
Similar to chapter 4, ROC curves were also graphed for each class tested. The accuracy 
was measured by the area under the curve (AUC), so the closer the curve towards the left 
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and the border, the more accurate the classifier. Conversely, the close to its diagonal 
(baseline), the higher the misclassification rate and the lower the accuracy. 
The data obtained from the BCA assay was subjected to 2 paired t-test to compare values 
across two groups, or one-way analysis of variance (ANOVA) to compare values across 
three groups (with Tukey post hoc, if needed). p<0.05 was deemed to be significant. 
 
5.3 Results 
Analysis of saliva samples from healthy volunteers and from patients with PMOL and 
OSCC   
The mean spectra from saliva of the healthy volunteers and of the patients with mild, 
moderate, severe (which also includes CIS) oral epithelial dysplasia and OSCC, as 
expected, appeared to be very similar (Figure 5.1), demonstrating the need for more 
sophisticated multivariate analysis techniques, such as PLSDA, to discriminate the 
presence of different dysplasia grades and the presence of OSCC or not. 
 
 
 
 
 
 
 
184 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1: Mean Raman spectra of control, mild, moderate, severe oral epithelial dysplasia and 
OSCC. The spectra have been off set for clarity and shading denotes standard deviation. 
 
Firstly, to detect the presence or not of dysplasia, a general model involving the entire 
dataset (450 spectra from healthy volunteers and 450 spectra from patients, which 
included PMOLs and OSCC) was created. The results from the PLSDA classification 
show a very good discrimination based on the two classes assigned, as seen through the 
cross validated probability predicted plot (Figure 5.2). This was further ratified by the 
sensitivity and specificity of the classifier (Table 5-3).  
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Figure 5.2: Cross validated probability prediction plot showing the discrimination between the 
control group and the PMOLs/OSCC group. 
 
Table 5-3: Sensitivity and specificity from PLSDA classification between control group and 
PMOLs/OSCC group. 
 
 
In an attempt to better understand the classification obtained, the cross validated 
probability prediction plot was then patient-coloured to identify any possible clinical 
correlation to the misclassification (outliers) present (Figure 5.3). In this perspective, 
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mild dysplasia samples that were clinically regressing after biopsy or removal of 
aetiological factors (such as smoking/alcohol consumption) and one sample of mild 
epithelial dysplasia from semi-labial mucosa seemed to be the reason for misclassification 
towards the controls.  
 
 
 
 
 
 
 
 
Figure 5.3: Cross validated probability prediction plot showing the discrimination between the 
control group and the PMOLs/OSCC group coloured by sample. Red ellipse denotes mild 
dysplasia samples that were clinically regressing after biopsy and/or removal of aetiological 
factors. Blue ellipse denotes one sample of mild epithelial dysplasia located in semi-labial 
mucosa.   
 
The results from the ROC curves reveal an excellent degree of accuracy (AUC=0.9211) 
for discrimination of both groups by the classifier (Figure 5.4). 
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Figure 5.4: ROC curves for (a) control group and (b) PMOLs /OSCC group from Raman analysis 
of saliva samples.  
 
To better evaluate the factors responsible for the discrimination between the different 
classes, the latent variable (LV-1), responsible for 24.70% of the variance, was plotted 
(Figure 5.5). Positive peaks, mostly correlated to oral dysplasia in general, were observed 
at 938 (proline rich proteins12), 1004, 1450 and 1655 cm-1 (proteins and glycoproteins13). 
The major bands on the negative of LV-1 were observed to be at 1375 and 1342 cm-1 
(amino acids/acetates13). 
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Figure 5.5: LV-1 of PLSDA model which included control group and oral dysplasia/OSCC 
group.  
 
Although not statistically significant (p = 0.1537), the BCA assay showed an increase in 
total protein concentration in the oral dysplasia/OSCC group in general when compared 
to the control group, complementing the results from the Raman analysis (Figure 5.6). 
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Figure 5.6: BCA assay showing the mean total protein concentration (µg/mL) and standard 
deviation (error bars = 95% confidence intervals) of saliva samples from the control group and 
from the oral dysplasia/OSCC group.  
 
Aiming to better analyse the capability of discrimination of the classifier, four extra 
models were created to better visualise the differentiations between the control group and 
the different dysplasia grades or OSCC. 
The model dedicated to discriminating control saliva samples (n=45) from mild dysplasia 
saliva samples (n=18), exhibited the same trend of differentiation as the general model. 
The cross validated probability predicted plot (Figure 5.7a) showed a noticeable 
differentiation, while the differentiating LV-1 (Figure 5.7b) exhibited primarily the same 
features as that of the general model. The ROC curves (Figure 5.8a and Figure 5.8b) 
complemented those results by showing a good accuracy (AUC=0.8348) for both groups 
obtaining also a very good specificity, although a substantially reduced sensitivity of 63% 
(Table 5-4). 
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Figure 5.7: Plot of the (a) cross validated probability prediction and (b) PLSDA LV-1 showing the discrimination between the control group (n=45) and the mild 
epithelial dysplasia group (n=18). 
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Figure 5.8: ROC curves of the control group (n=45) (a) and the mild epithelial dysplasia group (n=18) (b). 
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Table 5-4: Sensitivity and specificity from PLSDA classification between the control group and 
the mild dysplasia group. 
 
 
The second model was designed to differentiate the control group (n=45) from the 
moderate epithelial dysplasia group (n=17). Once more, PLSDA could provide good 
specificity, albeit with a low sensitivity (Table 5-5). The cross validated probability 
prediction plot (Figure 5.9a) shows similar differentiation, based on the same LV-1 
characteristics cited before (Figure 5.9c), with the exception of the peak at 1000 cm-1. 
Also, the ROC curves (Figure 5.10a and Figure 5.10b) showed good accuracy 
(AUC=0.72690) for both classes. 
 
Table 5.5: Sensitivity and specificity from PLSDA classification between the control group and 
the moderate dysplasia group. 
 
 
 
  
Sensitivity (%) 63% 
Specificity (%) 87% 
Sensitivity (%) 58% 
Specificity (%) 78% 
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Figure 5.9: Plot of the (a) cross validated probability prediction and (b) PLSDA LV-1 showing the discrimination between control group (n=45) and the moderate 
epithelial dysplasia group (n=17). 
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Figure 5.10: ROC curves of the control group (n=45) (a) and the moderate epithelial dysplasia group (n=17) (b). 
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When differentiating the control group (n=45) from the severe dysplasia group (n=6), 
PLSDA resulted in relatively poor discrimination, that can be seen by the cross validated 
probability prediction plot (Figure 5.11a) and good specificity (Table 5-6). However, 
LV-1 (Figure 5.11b), responsible for 21.53% of the variance, showed the same bands as 
those found in the lower grade dysplasia groups, including the peaks at 783 (nucleic 
acid/surgar13,14), 1382 (amino acids), 1557 and 1707 cm-1 (acetates/amino acids14). 
Furthermore, the ROC curve (Figure 5.12a and Figure 5.12b) still showed excellent 
discriminant power of the classifier, albeit with a poor sensitivity of 59%.  
 
Table 5-6: Sensitivity and specificity from PLSDA classification between the control group and 
the severe dysplasia group. 
 
 
 
 
 
 
  
Sensitivity (%) 59% 
Specificity (%) 83% 
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Figure 5.11: Plot of the (a) cross validated probability prediction and (b) PLSDA LV-1 showing the discrimination between the control group (n=45)  and the severe 
epithelial dysplasia group (n=6).  
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Figure 5.12: ROC curves of the control group (n=45) (a) and the severe epithelial dysplasia group (n=6) (b)  
 
a) b)  
198 
 
Finally, the PLSDA results from the discrimination between control (n=45) and OSCC 
(n=4) showed no visible separation in the cross validated probability prediction plot 
(Figure 5.13a). The LV-1 (Figure 5.13b), responsible for 16.01% of variance, showed a 
similar pattern to the LVs of the previous models, with major intensity differences, this 
time, on the negative side and a higher influence of the peak 671 cm-1 (nucleic 
acid/sugars13) on the positive side. However, the ROC curves (Figure 5.14a and Figure 
5.14b) still showed good accuracy (AUC=0.7133) for both classes and the specificity was 
high, although the sensitivity was low (Table 5-7). 
 
Table 5-7: Sensitivity and specificity from PLSDA classification between the control group and 
the OSCC group. 
 
 
 
 
  
Sensitivity (%) 50% 
Specificity (%) 88% 
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Figure 5.13: Plot of the (a) cross validated probability prediction and (b) PLSDA LV-1 showing the discrimination of the control group (=45) and the OSCC group 
(n=4). 
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Figure 5.14: ROC curves of the control group (=45) (a) and the OSCC group (n=4) (b).  
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Analysis of dysplasia grade (WHO classification) 
To assess whether it affects the classification efficiency, the oral epithelial dysplasia 
groups, classified according to the WHO criteria (2017), were compared to each other, to 
evaluate the sensitivity of the Raman technique over the histopathological grading given 
to each sample/group. In a primary qualitative analysis, based on the mean spectra of the 
different groups of dysplasia (Figure 5.15), differences could not be noticed, calling for 
a supervised analysis, such as PLSDA. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.15: Mean Raman spectra of mild, moderate and severe/CIS oral epithelial dysplasia 
groups. The spectra have been off set for clarity and shading denotes standard deviation. 
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In a more complex approach, PLSDA was applied to the three classes at once: mild 
(n=18), moderate (n=17) and severe (n=6). A very low sensitivity but good specificity 
was observed for the mild dysplasia group, while, in contrast, the discrimination of 
moderate and severe dysplasia groups yielded high sensitivity although with poor 
specificity (Table 5-8).The cross validated probability prediction plot (Figure 5.16a) did 
not show any separation by the discriminant analysis, while LV-1 (Figure 5.16b), 23.88% 
of variance, showed the same spectral features as those cited in the LV-1 of the general 
model (Figure 5.5).  
 
Table 5-8: Sensitivity and specificity from PLSDA classification between the mild, moderate and 
severe/OSCC groups. 
 
 
The ROC curves (Figure 5.17a and Figure 5.17b) did not show a high degree of accuracy 
in general, the highest accuracy being achieved for the severe/CIS group (Figure 5.17c). 
 
 
 
 
  Mild Moderate Severe/CIS 
Sensitivity (%)  30 72 77 
Specificity (%)  74 20 38 
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Figure 5.16: (a) cross validated probability prediction and (b) PLSDA LV-1 plot showing the discrimination between the three classes.
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Figure 5.17: ROC curves for the (a) mild, (b) moderate and (c) severe oral epithelial dysplasia groups. 
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By plotting the means of the scores on LV-1 of each PMOL sample (Figure 5.18), the 
analysis could show that there is a degree of progression detected by Raman spectroscopy, 
in terms of variability amongst the three grades of dysplasia from saliva samples, mainly 
between the mild and higher grades. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.18: Mean (each PMOL sample) of PLSDA scores of LV-1. 
 
The results from BCA assay (Figure 5.19) did not show any statistical difference 
(p=0.428313). However, the general levels of protein indicated a similar tendency of 
progression visualised by the increase of the mean total protein concentration at higher 
dysplasia grades. 
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Figure 5.19: BCA assay showing the mean total protein concentration (µg/mL) and standard 
deviation (error bars = 95% confidence intervals) from saliva samples of control, mild, moderate 
and severe/CIS groups.  
 
Analysis of dysplasia grade (binary classification) 
In an attempt to achieve a better classification based on the results of the previous section, 
analysis according to the new suggested WHO binary grading analysis was also 
performed. However, no discrimination could be seen based on the cross validated 
probability prediction plot (Figure 20a); although LV-1 showed similar spectral features 
to those seen previously, with no new spectral features apparent (Figure 5.20b). Also, 
the classifier showed a low accuracy for both classes (Figure 5.21). Nevertheless, it is 
important to highlight that the sensitivity of this model was considerably higher (Table 
5-9). 
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Figure 5.20: Plot of the (a) cross validated probability prediction and (b) PLSDA LV-1 showing the discrimination between low and high dysplasia groups. 
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Figure 5.21: ROC curves of (a) low and (b) high dysplasia groups. 
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Table 5-9: Sensitivity and specificity from PLSDA classification between low and high dysplasia 
groups. 
 
 
OSCC analysis 
PLSDA was also applied to examine the differences between the PMOLs (n=41) and 
OSCC (n=6) groups. Taking into consideration all the data from the oral epithelia 
dysplasia (410 spectra) and OSCC (40 spectra), PLSDA was not able to find statistical 
discrimination of these two groups. This can be seen through the results of the cross 
validated probability prediction plot (Figure 5.22a), the ROC curves (Figure 5.22b and 
Figure 5.22c) and the sensitivity (Table 5-10). For the same reason, LV-1 was not 
generated for this analysis. 
 
Table 5-10: Sensitivity and specificity from PLSDA classification between PMOLs and OSCC. 
 
 
  
Sensitivity (%) 72% 
Specificity (%) 33% 
Sensitivity (%) 37% 
Specificity (%) 83% 
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Figure 5.22: Plot of the (a) cross validated probability prediction showing the discrimination between the classes and ROC curves of (b) dysplasia and (c) OSCC 
groups.  
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It should be noted that, in this exploratory, proof of concept study, the patient numbers 
are rather limited, and when subdivided into grades, even more so, and notably, they 
become unbalanced with respect to the control dataset, which can impact the data analysis 
protocol15. In an attempt to evaluate the groups in a more realistic way, PLSDA was once 
more applied to differentiate saliva samples from oral epithelial dysplasia and OSCC 
groups. However, in order to balance the dataset sizes, a new matrix with spectra of saliva 
samples of oral dysplasia was randomly created through the use of random integers 
generation (Matlab), taking into account that at least one patient data of these generated 
numbers should be from each dysplasia grade, mild (n=1), moderate (n=1) and severe/CIS 
(n=1), and the last observation should be randomly selected by the algorithm from any of 
the remaining data. To keep the model consistent, this randomisation process was 
performed five consecutive times to ensure the consistency of the results. 
In this approach, PLSDA was able to show clear discrimination between saliva samples 
from PMOLs and OSCC groups, as apparent in the cross validated probability prediction 
plot (Figure 5.23a), and the model showed good sensitivity and specificity (Table 5-11) 
when differentiating saliva samples from OSCC and oral epithelial dysplasia groups. The 
LV-1 (Figure 5.23b), responsible for 37.74% of the variance, described by negative 
peaks at 1376 and 1489 cm-1 (amino acids13). Other negative peaks for this analysis, also 
associated to the presence of OSCC, were observed at 481, 668, 537, 758, 852 (nucleic 
acid/sugars13) and 1655 cm-1 (amino acids14). Notably, the spectral profile of LV-1 is 
significantly different from most of the previous LVs, in which the classification seemed 
to be based on the protein content. The ROC curves (Figure 5.24a and Figure 5.24b) 
also show excellent accuracy (AUC=0.8025) for both classes. 
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Figure 5.23: Plot of the (a) cross validated probability prediction and (b) PLSDA LV-1 showing 
the discrimination between the dysplasia and OSCC groups. 
 
Table 5-11: Sensitivity and specificity from PLSDA classification between PMOLs and 
OSCC groups in a paired analysis. 
Sensitivity (%) 75% 
Specificity (%) 72% 
a) 
b) 
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Figure 5.24: ROC curves of (a) dysplasia and (b) OSCC groups in a paired analysis 
  
a) b) 
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5.4 Discussion and conclusions 
PMOLs are usually associated with a variable rate of malignant progression, with the 
detection of oral epithelial dysplasia by tissue biopsy remaining the gold standard in 
guiding management6. However, many grading systems, including the current one 
proposed by WHO, have been put forward in an attempt to obtain objectivity in grading 
oral epithelial dysplasia. Despite these efforts, variability and subjectivity remains 
unresolved. 
Diagnosing any oral dysplastic lesion is vital to provide an early treatment and 
consequently better prognosis. As shown by the general PLSDA model, Raman 
spectroscopy could provide, through the salivary profile of patients, this discrimination 
with an excellent degree of accuracy. The results from PLSDA have shown this 
differentiation can primarily be attributed to higher levels of glycoproteins and proteins. 
Some proteomic studies have already reported elevated levels of salivary defensin-1 as 
an indication for the detection of OSCC, since higher concentrations of salivary defensin-
1 were detected in patients with OSCC compared with healthy controls, for example16. In 
another study, soluble CD44 was elevated in the majority of patients with OSCC and 
distinguished cancer from benign disease with a high specificity17. Furthermore, a well-
known panel of proteins, such as p53 and growth factor proteins, are widely reported to 
be present in higher concentrations in the presence of oral dysplasia18,19. 
Compared to the general analysis, the dysplasia grade analysis results obtained through 
PLSDA did not show, in a general perspective, very good discrimination, even using two 
different grading systems to analyse the saliva spectra. However, it is important to note 
that, when good sensitivity/accuracy was achieved, the models seemed to correlate the 
spectral changes with amino acids. These results are consistent with previous studies 
which reported markedly higher levels of salivary concentration of leucine, isoleucine, 
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tryptophan, valine, threonine, histidine, alanine and phenylalanine in OSCC patients than 
in healthy individuals20. 
In the OSCC analysis, it was possible to observe that, in a paired analysis, the 
discrimination obtained by PLSDA could be associated with the content of sugars. 
Nucleic acids have been already reported in saliva by some researchers, i.e. circulating 
tumour DNA, which is cell-free DNA of 180–200 base pairs in length that sheds from 
tumour cells into the circulatory system and has been detected in various bodily fluids, 
including saliva21. 
Also, different and important factors should be taken in consideration when using 
machine learning systems or classifiers. As observed in the different analyses, the results 
had a broad range in terms of accuracy/sensitivity/specificity and seemed to be influenced 
by sample dataset size and balance. The potential impact of these factors on the PLSDA 
modelling process was therefore explored. Following the same protocol of analysis as the 
results section of this chapter, the initial model containing the whole set of controls (n=45) 
and patients (n=45) was tested in different situations of parity and number (Figure 5.25), 
whereby the sensitivity and specificity of the original analysis was kept for reference (and 
standard deviations by 95% confidence interval based on the distribution of the confusion 
matrix from the analysis) and other situations, including randomly decreasing the 
dimension of the patient group, or matching the numbers of both classes; or even 
increasing artificially the patient data to reach parity with the control data.  
When the patient data was reduced, the number of controls were retained (n=45), and 
different reduced dimensions were tested: 12, 8, and 4 patients. These dimensions were 
strategically selected to mimic the reduced numbers of some of the patient data subsets, 
for example OSCC (n=4). When paired by decreasing the dimensions of both classes, the 
data number was determined by the smallest group (4 patients with OSCC, requiring then 
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4 from the other classes – totalling 12). Also, the final composition of each matrix (control 
or patients) was determined random integers generation algorithm in each round.  
In a similar way, when artificially increased, the same algorithm was applied to select the 
uniform composition of each grade (having at least 4 patients for each class) and 
randomly increased making sure that each subset (mild, moderate, severe/CIS and OSCC) 
appeared at least three times (n=36), leaving the 9 remaining observations (needed to 
complete the 45) to be again randomly selected by the algorithm. In this case, the controls 
were all retained (n=45). 
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Figure 5.25: Bar-graph showing simulations of analyses involving the dataset from controls and patients. The first two columns (L-R) represent the original sensitivity 
(blue) and specificity (red) from the original model associated with standard deviations acquired based on the Clopper-Pearson confidence interval (95%) over the 
distribution of the PLSDA confusion matrix. The rest of the columns represent different situations in which the patient data could be reduced, matched by decreasing 
the control data or matched by artificially increasing the patient data. In these cases, the sensitivity, specificity and standard deviation of each situation were acquired 
by the average of these values throughout 5 rounds of PLSDA analysis (where the dimension of the classes was randomised by using of random integers generation 
algorithm).  
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In the case of the analyses in which the dimension of the group was decreased (or matched 
by decreasing the patient data), the values for sensitivity and specificity were obtained by 
taking the average percentage value of five consecutive analyses where each patient data 
(or control, in case of decreasing the control data) was randomly selected, by random 
integers generation algorithm (Matlab), to compose the matrix in question before 
analysis. The standard deviation, in these analyses, was obtained based on the values of 
discrepancies during the five rounds of analysis. 
These analyses were performed to mimic the situation of the data available to this study, 
in which the dimensions of the control group is larger than the patient group, such that 
having an extremely unbalanced dataset could somehow lower the power of disease 
detection of the multivariate analysis. Matching the data (by decreasing the controls) 
somewhat underestimates the sensitivity/specificity, while artificially increasing the 
patient data (to match with the number of controls) overestimates these values, although, 
without major analytical discrepancies.  
In fact, when the multivariate analysis was applied with a reduced number of “diseased” 
samples in comparison to a fixed number of control samples, the values of sensitivity 
tended to decrease, as the analysis found it more difficult to assimilate the small number 
of observations as true positives, while the true negatives (directly correlated to the 
specificity) had no major discrepancies. This scenario could be important to infer that 
matching group dimensions or even artificially increasing the small groups to match with 
the general dimensions of the classes could show a less detrimental impact on the 
classification than a scenario where the dimensions are not matched.  
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Figure 5.26: Representative LV-1s from each PLSDA analysis simulation involving the dataset 
of controls and patients according to the average of sensitivity and specificity of each. 
 
The validity of the “simulated” approach was investigated by examination of the 
consistency of the LV-1 of the respective analyses (Figure 5.26). The similarities of the 
LVs indicates (taken from the most representative analysis, amongst the five rounds, in 
terms of the average sensitivity and specificity values) that the PLSDA analyses, although 
providing different values for sensitivity and specificity, based its classifications on 
similar spectral components (peaks), the peaks of which were also previously highlighted 
in the results section of this chapter (Figure 5.5). However, it is important to highlight 
that the LV-1 obtained from a “naturally” balanced PLSDA analysis (controls decreased 
to meet the number of patients’ data - control 12 vs. 12 PMOL/OSCC) was the most 
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different LV-1 to the original model (Control 45 vs. PMOL/OSCC 45); while the 
artificially increased (Control 45 vs. PMOL/OSCC artificially increased 45) had more 
spectral similarities, in terms of intensity, with the original results. 
These observations could open a precedent to fully evaluating PLSDA analysis and how 
the group dimensions can influence the general results. Further analyses were also 
performed following the same experimental principles of group dimension and parity 
used for the analysis of the entire data. This time, the analyses followed the classes in the 
analysis of controls vs. each PMOL/OSCC (Figure 5.27), the analysis of WHO dysplasia 
grade (Figure 5.28) and PMOLs vs. OSCC (Figure 5.29). No simulations were 
performed using the binary dysplasia classification (low and high dysplasia) due to the 
high number already present in each class seen in the results section of this chapter, in the 
results section (binary classification). 
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Figure 5.27: Bar-graph showing simulations of analyses involving the dataset from controls and the different dysplasia grades (WHO classification). The first three 
columns (L-R) represent the original sensitivity (blue) and specificity (red) from the original model associated with standard deviations acquired based on the Clopper-
Pearson confidence interval (95%) over the distribution of the PLSDA confusion matrix. The rest of the columns represent different situations where the patients’ data 
(separated each dysplasia grade) could be reduced, paired by decreasing the number of controls or paired by artificially increasing the number of patients’ data. In 
these cases, the sensitivity, specificity and stand deviation of each situation were acquired by the average of these values throughout 5 rounds of PLSDA analysis 
(where the dimension of the classes were randomised by using of random integers generation algorithm). 
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Figure 5.28: Bar-graph showing simulations of analyses involving the dataset from patients 
according to each dysplasia grade. The first three columns (whole data) represent the original 
sensitivity (blue) and specificity (red) from the original model associated with standard deviations 
acquired based on the Clopper-Pearson confidence interval (95%) over the distribution of the 
PLSDA confusion matrix. The rest of the columns represent different situations where the 
different classes could have different dimensions, paired by decreasing the number of larger 
dimension classes (mild and moderate), or paired by artificially increasing the number of the 
smaller classes (moderate and severe/CIS). In these cases, the sensitivity, specificity and standard 
deviation of each situation were acquired by the average of these values throughout 5 rounds of 
PLSDA analysis (where the dimension of the classes was randomised by using the random 
integers generation algorithm). 
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Figure 5.29: Bar-graph showing simulations of analyses involving the dataset from patients with 
PMOLs vs. OSCC. The first two columns (whole data) represent the original sensitivity (blue) 
and specificity (red) from the original model associated with standard deviations acquired based 
on the Clopper-Pearson confidence interval (95%) over the distribution of the PLSDA confusion 
matrix. The rest of the columns represent different situations where the different classes could 
have different dimensions, paired by decreasing the number of the larger dimension class 
(PMOL), or paired by artificially increasing the number of the smaller class (OSCC). In these 
cases, the sensitivity, specificity and standard deviation of each situation were acquired by the 
average of these values throughout 5 rounds of PLSDA analysis (where the dimension of the 
classes was randomised by using the random integers generation algorithm). 
 
These further experimental test/results seemed to follow the same pattern of 
sensitivity/specificity values among the PLSDA analyses. Some of the poor values 
initially obtained in the results section of this chapter can now be clearly explained and 
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associated with the sample size and the paired/unpaired conditions. The smaller the size 
of the sample, the harder it is to build a representative model21. Even with an 
underestimation, an analysis approach in which the larger dimension classes were reduced 
to produce parity/balance, seemed to be a better analytical approach in comparison to 
PLSDA analyses with small dimension/unpaired classes. However, this new overview 
regarding group dimension, which could for example be performed by artificially 
increasing a small patient dataset, might represent a new alternative to overcome these 
usual analytical problems, as the spectral results from the LV-1s comparison show that 
the classifications with artificially increased data was provided based on a very similar 
spectral profile and, consequently, similar biochemical composition. 
Finally, it should also be noted that all the analysis explored here were based on results 
from the histopathological diagnosis provided by the hospital pathologists following 
associated grading systems. The severity of dysplasia is arrived at based on the grading 
of dysplasia in the lesion in question. However, it has been established that dysplasia 
grading suffers from intra- and inter-observer variability23 and thus the classifications of 
the “gold standard” should in themselves be open to question. 
Finally, other factors that can have influence on the Raman spectrum and classification 
will be further explored in chapter 6. 
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Chapter 6: Influence of patient factors and potential 
confounding factors on Raman spectroscopic classification 
through saliva analysis 
 
6.1 Introduction 
Following from the analysis in chapter 5, clinical features and/or patient factors that might 
represent an influence on the statistical classification using Raman spectroscopy are now 
explored. As discussed in detail in section 1.2.2 of chapter 1, it has long been accepted 
that tobacco consumption, including smokeless tobacco, and heavy alcohol consumption 
are the principal aetiologic factors for the development of oral cancer1 and it has also been 
demonstrated that they can have a synergistic effect1-3. In addition, a variety of suspected 
risk factors such as chronic irritation, poor oral hygiene, viral infection, occupational 
exposure, malnutrition and genetic factors, have also been correlated to the development 
of oral cancer4,5.  
Beyond those factors inherent to the disease itself, there are several others that can 
influence the salivary profile of an individual. The amount and composition of secreted 
human saliva depends on factors such as flow rate, circadian rhythm, type and size of the 
salivary gland, type of the stimulus, diet, drugs, age, sex, blood type, physiological status, 
and several others6. 
As the study of chapter 5 was based on heterogeneous groups of healthy volunteers and 
patients of different gender, age, habits and medical histories, the aim of this chapter was 
to discern whether these factors have any influence on the classification using Raman 
spectroscopy.  
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6.2 Methodology 
6.2.1 Ethics, saliva collection and volunteer questionnaire  
Ethical approval for collection of saliva samples healthy volunteers (collected in FOCAS 
Research Institute, Technological University Dublin) and patients with potentially 
malignant lesions or OSCC (from Dysplasia Clinic at Dublin Dental University Hospital) 
is fully detailed in section 5.2.1 from chapter 5. 
A medical and oral health status questionnaire was also used to obtain further information 
regarding biological factors that can influence the analysis classification, such as gender, 
age, and others, to better understand these variances over the classifier (Appendix III). 
A stimulated whole saliva collection method was used, as described in section 4.3.2 of 
this thesis. 
6.2.2 Raman Spectroscopic Instrumentation 
The Raman spectroscopic instrument and recording setup have been described in section 
4.3.4 of chapter 4. The spectra acquired for chapter 5 were used for this study. 
6.2.3 Data analysis 
Metadata on the healthy volunteers (control) and patients included in chapter 6 is provided 
in Table 6-1 and Table 6-2, respectively. This was used to divide all healthy volunteers 
(control) and patients, regardless of histopathological diagnosis, into groups according to 
gender, smoking habits, alcohol consumption and site of the lesion for the patient group. 
The spectra acquired for the study of chapter 5, were analysed using PLSDA with 
LOPOCV, as described in section 5.2.5. 
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Table 6-1: Information on healthy volunteer (control) factors. 
Healthy volunteer (control)  Gender Age Smoking  Alcohol Consumption 
1 M 30 No No 
2 F 27 No Yes/0-2 units per week 
3 F 39 No Yes/0-7 units per week 
4 F 35 No Yes/0-8 units per week 
5 M 27 No Yes/0-30 units per 
week 
6 F 38 No Yes/25 units per week 
7 F 27 No Yes/Occasionally  
8 F 29 No Yes/2 units week 
9 M 34 No Yes/25 units per week 
10 F 27 No Yes/20 units per week 
11 F 32 No No 
12 M 31 Yes Yes  
13 F 32 Yes Yes  
14 F 32 Yes/2 
cpw 
Yes/2 per week 
15 F 38 No No 
16 F 27 No Yes/0-1 
17 M 33 Yes  Yes/4 units per week 
18 F 41 No No 
19 F 29 No Yes/0-2 units per week 
20 F 50 No Yes 
21 M 28 No Yes/2 units per week 
22 M 34 No No 
23 F 40 No No 
24 F 31 No Yes/0-1 per week 
25 M 70 Yes Yes  
26 M 32 No Yes/1unit per month 
27 F 56 No Yes/5 units per week 
28 F 35 No No 
29 F 26 No Yes/0-2 units week 
30 M 27 No Yes/10 units per week 
31 F 26 Yes/2cpd Yes/4 units per week 
32  M 30 No No 
33  F 27 No No 
34 M 30 No Yes/3 units week 
35 F 63 No Yes/11 units per week 
36 M 32 No Yes/1 unit per week 
37 F 29 No No 
38 M 65 No Yes/8 units per week 
39 F 25 No Yes/2 units per week 
40 F 25 No Yes/1 unit per week 
41 F 32 No No 
42 F 26 Yes/4cpd  Yes/6 units per week 
43 F 27 No No 
44 M 29 No No 
45 F 32 No No 
n/a, information was not available; cpd, cigarettes per day; cpw, cigarettes per week. 
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Table 6-2: Information on patient factors and clinical features. 
Patient  Gender Age Smoking  Alcohol Consumption Site of Lesion 
1 F 54 Ex-smoker Yes/7 units per week Buccal mucosa 
2 M 62 No No Gingiva  
3 M 70 5 cpd Yes/minimal Buccal mucosa 
4 M 65 Ex-smoker Yes/8 units per week Gingiva 
5 F 68 No Yes/10 units per week Tongue 
6 F 72 No Yes/2 units per week Gingiva  
7 F 71 Ex-smoker Yes/12 units per week Buccal mucosa 
8 F 91 No Yes/2 units per week Floor of mouth 
9 F 50 No Yes/10 units per week Tongue 
10 F 59 10 cpd Yes/4 units per week Buccal mucosa 
11 F 56 Ex-smoker Yes/12 units per week Tongue 
12 F 65 No  n/a Tongue 
13 F 49 Ex-smoker n/a Tongue/ buccal mucosa 
14 M 63 15 cpd Yes/15 units per week Buccal mucosa 
15 M 63 Ex-smoker Yes/14 units per week Tongue 
16 M 73 30 cpd No Floor of mouth 
17 F 70 Ex-smoker Yes/6-7 units per week Hard palate 
18 M 77 Ex-smoker Yes/2 units per week Labial mucosa 
19 M 80 Ex-smoker No  Tongue 
20 F 40 Ex-smoker No Buccal mucosa 
21 F 48 No Yes/1 units per week Buccal mucosa 
22 M 80 Ex-smoker No Buccal mucosa 
23 M 35 Ex-smoker Yes/5-10 units per 
week 
Alveolus 
24 F 72 15 cpd Yes/10 units per week Floor of mouth 
25 F 70 No Yes/1 units per week Gingiva 
26 M 55 25-30 cpd Yes/8 units per week Alveolus 
27 F 73 Ex-smoker Yes/8 unitsper week Tongue 
28 M 74 Ex-smoker n/a Buccal mucosa 
29 F 34 No No Tongue 
30 M 73 No Yes/1 unit per week Tongue 
31 F 67 20 cpd No Soft palate 
32 M 69 60 cpd Yes/60 units per week Tuberosity 
33 F 64 20 cpd Yes/6 units per week Soft palate 
34 M 62 Ex-smoker Yes/8 units per week Tongue 
35 M 45 No No n/a 
36 M 61 3-4 cpd No Labial mucosa 
37 F 86 No No Palate 
38 M 66 20 cpd No Tongue 
39 M 58 20-30cpd Yes/100 units per 
week 
Buccal mucosa 
40 M 71 No No Gingiva 
41 M 52 5 cpd Yes/80 units per week Floor of mouth 
42 M 49 No No Labial mucosa 
43 M 61 20 cpd Yes/6 units per week Tongue 
44 F 60 10 cpd Yes/10 units per week Floor of mouth 
45 M 63 Ex-smoker Yes/20 units per week  Tongue 
n/a, information was not available; cpd, cigarettes per day; cpw, cigarettes per week. 
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It is important to highlight that the PLSDA analyses of the factors/clinical features were 
performed using paired dimension classes (by decreasing the dimension of larger higher 
group data randomly, as detailed in chapter 5). Each statistical analysis was performed 
five times for the different factors, in order to ensure the consistency of the results . 
 
6.3 Results 
6.3.1 Gender 
Taking into consideration the clinical information from the entire dataset of healthy 
volunteers and patients (Table 6-1 and Table 6-2), the analysis was paired according to 
the smallest group available (15 males from control group) and the data organised 
according to gender into: females from control group (n=15), males from control group 
(n=15), females from patient group (n=15) and males from patient group (n=15). The 
PLSDA did not show any statistical influence of the gender of the groups, which was 
further confirmed through the cross validated probability prediction plot (Figure 6.1). 
However, some outliers (misclassification) could be seen in the control group in 
comparison to the patient group, perhaps due to the higher variability of healthy 
volunteers samples and the smaller variability of PMOLs/OSCC saliva samples. The 
sensitivity and specificity obtained by this model was generally poor, and illustrated in 
Table 6-3.  
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Figure 6.1: Cross validated probability prediction plot showing no discrimination between the 
female controls, male controls, female patients and male patients. 
 
Table 6-3: Sensitivity and specificity from PLSDA classification when differentiating the 
different genders from group control and patients. 
 Female 
(control) 
Male  
(control) 
Female 
(patients) 
Male 
(patients) 
Sensitivity (%) 37 55 56 38 
Specificity (%) 44 48 72 69 
 
In terms of ROC curves, the PLSDA results did not show classification based on gender, 
indicating poor accuracy for all the classifiers (Figure 6.2).  
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Figure 6.2: ROC curves for (a) male controls, (b) female controls, (c) male patients and (d) 
female patients classification.  
 
To further understand the influence of gender on the whole dataset, the scores of PLSDA 
latent variables, LV-1 and LV-2, for detection of PMOLs/OSCC (from chapter 5) were 
plotted (Figure 6.3a) and then re-coloured according to the gender profile of each 
variable (Figure 6.3b). This further reveals the lack of influence of the gender on the 
classification of dysplastic samples. 
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Figure 6.3: Scores of controls and patients on the latent variables from the PLSDA model (a) 
further coloured according to gender (b).  
 
6.3.2 Age 
Any potential influence of age on the classification was also analysed, as it could be a 
possible clinical feature with some reasonable impact over the classification. To match 
with the age average of OSCC incidence and salivary profile changes, a group with five 
a) 
b) 
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classes was created to explore possible interferences on the classification: healthy 
individuals below 30 years of age (n=4), healthy individuals between 30 and 50 years of 
age (n=4), healthy individuals above 50 years of age (n=4), patients 50 years of age or 
below (n=4) and patients above 50 years of age (n= 4). These group dimensions were 
determined by the number of the smallest age group available (4 controls above 50 years 
of age) and, due to the absence of patients below 30 years of age, the patients were only 
divided into two groups. 
Some differentiation could be noticed through the cross validated probability prediction 
plot (Figure 6.4). When LV-1 was plotted (Figure 6.5), the spectral profile responsible 
for this differentiation was very similar to the one presented in chapter 5 (Figure 5.5) 
which further confirmed that the differentiation could be attributed to the dysplastic 
profile of these samples and not due to the age. Nevertheless, PLSDA results did not show 
significant statistical results, as poor sensitivity and specificity was generally obtained for 
each class (Table 6-4).   
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Figure 6.4: Cross validated probability prediction plot showing the discrimination between the 
different age groups from controls and patients. 
 
 
 
 
 
 
 
 
Figure 6.5: LV-1 of PLSDA model which included the different age groups. 
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Table 6-4: Sensitivity and specificity from PLSDA classification when differentiating healthy 
individuals (control) and patients in the different age groups. 
 Above 50yo 
(control)  
30-50yo 
(control) 
Below 30yo 
(control) 
50 or 
below 
(patients) 
 Above 50 
(patients) 
Sensitivity 
(%) 
50 57 3 62 47 
Specificity 
(%) 
66 85 58 86 85 
 
Also, the ROC curves (Figure 6.6) showed no significant accuracy of the different 
classifiers: controls below 30 years of age (AUC= 0.5492), controls between 30 and 50 
years of age (AUC=0.7173), controls above 50 years of age (AUC=0.2748), patients 50 
years of age or below (AUC=0.8523) and patients above 50 years of age (AUC=0.8083). 
These results seem to reflect the high capability of the analysis in detecting the dysplastic 
samples rather than the different age groups. 
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Figure 6.6: ROC curves for the classification of (a) individuals below 30 years of age, (b) 
between 30 and 50 years of age and (c) above 50 years of age, (d) patients at 50 years of age or 
below and (e) patients above 50 years of age. 
a) b) 
c) d) 
e) 
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Furthermore, the scatter plot of the scores of LV-1 and LV-2 based on the PLSDA 
discrimination of dysplastic samples (Figure 6.7), when re-coloured for the different age 
groups (Figure 6.7), did not show a major influence of the age on the analysis.  
 
 
 
 
 
 
 
 
Figure 6.7: Scores of controls and patients on the latent variables from PLSDA model further 
coloured according to the different groups of age. 
 
6.3.3 Smoking 
According to the smoking status of the controls in Table 6-5, a PLSDA according to four 
classes, smoker controls (n=7), non smoker controls (n=7), smoker patients (n=7) and non 
smoker patients (n=7) was also conducted. The PLSDA results showed no clear 
classification amongst the different groups, according to the cross validated probability 
prediction plot (Figure 6.8). Also, the sensitivity and specificity of this model was 
considered poor, albeit with a sensitivity of 66% for non smoker controls (Table 6-5). 
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Figure 6.8: Cross validated probability prediction plot showing the discrimination between 
smokers and non smokers from controls and patients. 
 
Table 6-5: Sensitivity and specificity from PLSDA classification when differentiating 
smoker and non smoker individuals from control and patient group. 
 Non smokers 
(control)  
Smokers 
(control) 
Non smokers 
(control) 
Smokers 
(patients) 
Sensitivity (%) 61 54 44 31 
Specificity (%) 51 78 74 77 
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Although, there was no clear classification, it was noticeable that the smoker control and 
patient groups seemed to exhibit a high degree of misclassification, which could represent 
a possible influence for the differentiation of smoking and the dysplastic profile of the 
samples from smoker patients. 
For this reason, PLSDA was first performed separately for the controls, to examine the 
possible cause of this misclassification. The PLSDA results showed low classification 
sensitivity (68%) and specificity (60%) when differentiating these two categories. 
Although low, this differentiation could be visualised through the cross validated 
probability prediction plot (Figure 6.9a). The LV-1, responsible for 27.54 % of the 
variability, indicated that the classification seemed to be mainly associated with peaks at 
789 and 1696 cm-1 in the positive side (Figure 6.9a). Most importantly, the peaks that 
could be correlated to smoking habit (negative side) could be seen at 1003 (Phenylalanine, 
C-C skeletal), 1125 (υ (C-C) skeletal of acyl backbone in lipid), 1448 (CH2CH3 
deformation) and 1659 cm-1 (disulfide bonds).  
 
 
 
 
 
 
Figure 6.9: Plot of the (a) cross validated probability prediction showing the discrimination 
between non-smokers and smokers and (b) PLSDA LV-1. 
a) b) 
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Furthermore, the ROC curves showed low accuracy (AUC=0.6171) of the classifiers for 
smokers and non smokers (Figure 6.10).  
 
 
 
 
 
 
Figure 6.10: ROC curves for saliva samples of controls (a) non smokers and (b) smokers. 
 
Also, to ensure that smoking was not a habit that could influence the classification in the 
patient data, a PLSDA of smoking as a clinical factor was also performed using the patient 
data. Knowing the complexity of the interaction between smoking habits and the salivary 
profile/state, the analysis of smoking habits for the patient data was performed using 
different classes: No-smokers (n=12), ex-smokers (n=12) and smokers (n=12) (this could 
not be performed with the data of controls due to the absence of declared ex-smokers 
within the healthy volunteers). When analysed by PLSDA, the cross validated probability 
prediction plot did not show a clear differentiation between the different groups (Figure 
6.11a). Also, when LV-1 was plotted, the small differences that could be detected by this 
method showed that the spectral profile was very similar to those cited in the LV-1 for 
controls (Figure 6.11b), with the exception of the peak at 921 cm-1 (C-C stretch/Proline). 
Also, the groups exhibited very poor sensitivity for either of the classes (Table 6-6). 
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Figure 6.11: Plot of the (a) cross validated probability prediction showing the discrimination 
between non-smokers, ex-smokers and smokers; and (b) PLSDA LV-1 from patients’ saliva 
samples. 
 
Table 6-6: Sensitivity and specificity from PLSDA classification when differentiating no-
smokers, ex-smokers and smokers amongst the patient group. 
 Non-smokers Ex-smokers Smokers 
Sensitivity (%) 58 56 32 
Specificity (%) 52 75 72 
 
 
In terms of accuracy, the ROC curves, in Figure 6.12, provided low values for all 
classifiers: non-smokers (AUC=0.5631), ex-smokers (AUC=0.6241) and smokers 
(AUC=0.5979). 
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Figure 6.12: ROC curves for the classification of (a), no-smokers, (b) ex-smokers and (c) 
smokers. 
 
Although the results show no clear influence of smoking on the classification, the LV-1 
and LV-2 scores from PLSDA of the controls and patients were also plotted and coloured 
by smoking status to further understand the source of the variance (Figure 6.13). When 
visualised, the LV-1 and LV-2 scatter plot exhibits a tendency to differentiate patients 
(independent of smoking status) and smokers (control), from non smokers from the 
control group. This fact, however, might re-inforce the importance of smoking for the 
classification of saliva samples. 
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Figure 6.13: Scores of controls and patients on the latent variables from PLSDA model further 
coloured according to the smoking status. 
 
6.3.4 Alcohol consumption 
The alcohol consumption within the control group had a significant range. Simplifying 
the analysis, as the data numbers were not large, they were organised in four classes: 
alcohol consuming controls (n=12), non-alcohol consuming controls (n=12), alcohol 
consuming patients (n=12) and non-alcohol consuming patients (n=12). According to the 
PLSDA results, no significant discrimination was evident, as sensitivity and specificity 
were very poor across the different groups (Table 6-7), and this was further validated by 
the cross validated probability prediction plot (Figure 6.14). The ROC curves (Figure 
6.15) further ratified the results, showing a very low accuracy for all classifiers. 
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Figure 6.14: Cross validated probability prediction plot showing the discrimination between 
alcohol and non-alcohol consuming individuals from control groups and patient group. 
 
Table 6-7: Sensitivity and specificity from PLSDA classification when differentiating between 
alcohol and non-alcohol consuming individuals from control groups and patient group. 
 No-alcohol 
consuming 
(control) 
Alcohol 
consuming 
(control) 
No-alcohol 
consuming 
(patients) 
No-alcohol 
consuming 
(patients) 
Sensitivity (%) 64 41 30 50 
Specificity (%) 40 51 63 69 
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Figure 6.15: ROC curves for the classification of (a) alcohol consuming controls, (b) no alcohol 
consuming control, (c) alcohol consuming patients and (d) no alcohol consuming patients. 
 
The scores of LV-1 and LV-2 from the PLSDA of the whole data involving controls and 
patients to differentiate dysplastic lesions did not show any influence of alcohol 
consumption on the classification (Figure 6.16). 
 
 
a) b) 
c) d) 
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Figure 6.16: Scores of the between alcohol and non-alcohol consuming individuals from control 
group and patient group on the latent variables from PLSDA model. 
 
6.4 Discussion 
The findings of this chapter suggest that no clear influence on classification by PLSDA 
was evident, based on the following factors: gender, age and alcohol consumption. It is 
important, however, to observe that the PLSDA for the different age groups could show 
a tendency of differentiation based on the presence of dysplasia and not due to the age 
difference, as denoted by the LV-1 (Figure 6.5) from this analysis. 
The risk of developing oral cancer has been shown to be related to both the intensity and 
duration of exposure to both alcohol and smoking8. The pathogenetic mechanisms behind 
alcohol-associated carcinogenesis in OSCC remain unclear, as alcohol is not 
carcinogenic. However, there is increasing evidence that a major part of the tumour-
promoting action of alcohol might be mediated via its first, toxic and carcinogenic 
metabolite acetaldehyde8. 
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In vitro studies have repeatedly shown that alcohol enhances the penetration of tobacco 
associated carcinogens across the oral mucosa9. Squier et al. showed that alcohol has the 
capacity to eliminate the lipid component of the barrier present in the oral cavity that 
surrounds the granules of the epithelial spinous layer, and short‐term exposure to 15% 
alcohol increased the permeability of human ventral tongue mucosa, which could account 
for the synergic correlation between alcohol and smoking with the development of 
OSCC9. 
In saliva, salivary microbial production is supposed to be one of the major sources of 
acetaldehyde from ethanol8. This fact could be a biologically plausible mechanism to 
explain the synergistic and multiplicative manner by which the attributable cancer risks 
of alcohol and smoking act. However, the results obtained by PLSDA in this chapter were 
not able to point out any classification over the spectral profile of saliva and alcohol 
consumption.  
It is already known that some acute effects depend on a direct action of ethanol and 
formation of reactive oxygen species and fatty acid ethyl esters10. This fact might be able 
to explain the absence of any major classification. Also, most of the salivary changes, 
with significant changes in parotid saliva secretion and its composition (which may 
perpetuate and compound ethanol-induced injury), can be only associated with chronic 
alcohol ingestion11. This situation could not be seen in the data presented here, however. 
From the results obtained in this chapter, it is not apparent that factors other than the 
degree of dysplasia can influence the Raman classification of saliva samples. Although 
not statistically significant, smoking habit was seen to slightly impact the classification 
of data based on the distribution present on the cross validated probability prediction plot 
(Figure 6.8) and the scores of LV-1 and LV-2 plot (Figure 6.13). These results, 
reinforced by the spectral features provided by LV-1 from controls, are consistent with 
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other Raman studies in which researchers have shown that the saliva from smokers, 
especially stimulated saliva, not only contains significantly more proteins in oxidised 
form with increased disulfide bridges, that reduces protection for oral epithelium, but also 
could present changes in protein (mucin) conformation12. 
It is important to highlight that a lower impact of smoking habits over the model 
classification was seen when the patient data was analysed by itself. However, the plot of 
the scores of LV-1 and LV-2 (Figure 6.13) based on the classification of controls and 
dysplastic samples suggest that smoking might influence the classification. This could be 
attributed to the fact the smoking is an aetiological factor in developing epithelial oral 
dysplasia, and hence biochemical changes occurring in saliva of smokers could be similar 
to those patients with these lesions, whether smokers or not 13. 
While it has been reported that age related physiological changes can be discriminated 
with Raman spectroscopy14, the results obtained in this chapter did not show any 
statistical differences between the three age groups. This might be explained by the fact 
that most of the salivary changes in elderly individuals are primarily correlated only with 
the salivary flow rate13. The use of centrifugal filtration might partially even out the 
concentration of saliva components analysed, once the same amount of sample is used 
before spectral acquisition. 
Other patient factors and clinical features which have not been considered, due to the lack 
of metadata, can still have some influence on the Raman classification. These would 
include the presence or absence of HPV and candida status of the donor/patient and the 
degree of differentiation in OSCC lesions. 
Finally, these results suggest that it is very important when analysing saliva samples from 
individuals with or without oral pathologies to consider them in the context of different 
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factors and clinical features, highlighting the need for large scale studies with more 
representative dimensions. 
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Chapter 7: Conclusions and future work 
 
7.1 Conclusions 
The main objective of this thesis was to assess the potential of Raman spectroscopy in 
detecting oral epithelial dysplasia and OSCC through the analysis of saliva samples. The 
first two chapters presented an introduction to the thesis; Chapter 1 had a strong emphasis 
on OSCC, oral dysplasia and saliva, while the chapter 2a placed the emphasis on Raman 
spectroscopy and its importance in diagnostics, mainly oral cancer diagnosis. Integrating 
the first two chapters, chapter 2b aimed to clarify the current state-of-art through a 
systematic review the available and published methodology related to Raman spectral 
analysis of saliva for oral cancer detection, emphasising instrumental, analytical and 
sample parameters. The systematic review indicated that the 785 nm laser line was the 
most applied wavelength and PCA-LDA was the most commonly used method for 
multivariate analysis. The main salivary components possibly associated with the 
presence of OSCC were proteins and lipids. The measurement of saliva samples in the 
liquid physical state, and with no addition of enhancers for SERS, was also highlighted 
as a better approach. However, in terms of sampling protocols, some issues still needed 
to be addressed, as no differentiation was generally made between stimulated and non 
stimulated saliva. 
In chapter 3, the aim was to establish the best instrumentation method to be applied to 
saliva samples, minimising as much as possible the sample preparation steps and, 
consequently, loss of saliva integrity. Regarding the most suitable wavelength, 532nm as 
laser line has shown the best results in terms of spectral quality and resolution. Moreover, 
an inverted geometry associated with a glass bottomed 96 well-plate (no.1 coverslip 
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thickness) with x60 objective provided a cleaner spectral signal and may be adopted as a 
high throughput method for use in a clinical application. Also, concentration of the saliva 
by >75% has been shown to be effective in overcoming the inherent weakness of the 
spectral signatures of the constituent components of saliva in the liquid form, ratifying 
the use of centrifugal filtration to concentrate real saliva samples.  
Chapter 4 addressed the capability of Raman microspectroscopy to differentiate the saliva 
based on the collection methodology and intrinsic salivary composition. The Raman 
profiles from the groups of stimulated saliva and non stimulated saliva showed that, 
although having differences regarding concentration, both types of saliva collections can 
be used for diagnosis purposes without major differences. However, the stimulated type 
can be used as a more efficient technique for sample collection, as the non stimulated 
method would represent a time consuming procedure to be applied in the clinical 
environment (45 minutes for non stimulated saliva collection compared to 15 minutes for 
stimulated saliva collection). Regarding the multivariate analysis, PLSDA could provide 
a classification of good sensitivity for both types of sample, with the highest sensitivity 
reached when classifying samples from different donors (88%). The feasibility of Raman 
microspectroscopy for classification of non stimulated and stimulated samples confirms 
its capability for detection of biochemical changes that may also be applied to 
differentiate saliva samples from individuals with oral cancer/potentially malignant 
lesions and saliva samples from healthy individuals. 
In chapter 5, saliva samples from a cohort of patients with OSCC and different grades of 
dysplasia (mild, moderate and severe) were assessed through Raman spectroscopy and 
multivariate analysis (PLSDA with LOPOCV). The results demonstrated that dysplastic 
samples, in general, could be discriminated from control (healthy volunteers saliva 
samples) with an outstanding accuracy (AUC=0.9444)1. However, the results involving 
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discrimination of the oral epithelial dysplasia saliva samples did not show the same high 
performance, although better results were obtained for higher grade oral epithelial 
dysplasia samples and in cases where the matrices had the same dimensions (either 
artificially increased or paired by decreasing the numbers) before the statistical analysis. 
Chapter 6 investigated other factors which could have an influence on saliva samples and, 
consequently, on the Raman spectral discrimination. The results showed that that no clear 
classification could be seen based on gender, age, smoking habits and alcohol 
consumption. However, smoking habits seemed to somehow influence the data, mainly 
when comparing controls to patients. 
 
7.2 Clinical relevance and other considerations  
From a clinical perspective, there is a constant interest in saliva as an alternative 
diagnostic sample and Raman spectroscopy as diagnostic aid. However, several factors 
need to be evaluated and further elucidated surrounding both approaches before its 
clinical application. In salivary analysis as such, a correct standardisation regarding 
collection, storage and processing is the foundation for a reproducible and faithful 
technique. Saliva has been successfully applied in other studies to diagnose OSCC/oral 
potential malignant lesions2-4. Keeping the natural physical state of saliva (liquid) is 
indubitably crucial to preserve possible salivary markers that might be substantial to the 
detection of oral cancer. In chapter 3, beyond other aspects, the centrifugal filtration can 
not only preserve the sample in its liquid state but can also represent a cheaper method of 
“enhancing” the major components of saliva than, for example, nanoparticle enhancers. 
Also, saliva samples and the Raman technique, when combined, could not only represent 
a tool for a dental/medical qualified professional but also a screening method that can be 
258 
 
performed by a non dental/medical qualified person, optimising the time of diagnosis and 
improving the prognosis.    
7.3 Future perspectives 
Taking into consideration the different approaches related to Raman analysis of saliva 
samples in the current literature, the methodology proposed by the current study seems to 
be highly flexible for a future clinical application. However, the number of saliva samples 
used for these analyses were comprised of 55 healthy controls and 45 patients. Also, in 
general terms, a limitation of this study was that the controls and patients were not 
completely matched in terms of age, gender, etc. A more comprehensive study of larger 
scale5 may not only result in more effective classifiers (mainly for classification of the 
different dysplasia grades) but could also better demonstrate the influence of variables 
such as age, smoking, alcohol consumption, and so on. Also, a better insight could be also 
obtained from a longitudinal study where dysplastic lesions had transformed into OSCC 
or regressed to complete absence of dysplasia. As morphology is not a predictor of 
malignant transformations, Raman spectroscopy could help identifying molecular bonds 
that are common to several biomolecules through a spectral analysis of the saliva samples 
in a holistic or more complete way, usually required for the subtle biochemical changes 
in dysplasia/cancer6. 
In terms of sample preservation, saliva samples have always been a hot topic of discussion 
in terms of reproducibility. Raman spectroscopy, as mass spectrometry, might need a 
more tailored methodology for saliva collection and saliva processing. However, the less 
sample preparation required the higher the chances of a future clinical application of the 
technique in question. The results have shown a wide variety of instrumentation setups 
and sample collections. Nevertheless, other factors such as the use of protease inhibitors 
for saliva conservation and the effects of laser irradiation on sample degradation could 
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also be important for the reproducibility required before the technique could be accepted 
as a diagnostic tool7,8. 
Also, the intimate relationship of the salivary glands to the local vascular system network 
and its reflection in the saliva profile represents an unknown that still has to be better 
analysed when saliva is used as a diagnostic sample. Defining the properties that are 
strictly correlated to systemic diseases and those that are strictly correlated to local 
pathologies is not only essential, but they might represent the missing scientific 
“breakthrough” for the permanent establishment of saliva as a diagnostic sample.   
Finally, it is difficult to compare the studies involving Raman spectroscopy of saliva 
samples, as the sample collection and preservation, instrumentation, processing of the 
spectra and data analysis differ between different studies9. The disparities in 
methodologies, unfortunately, widen the steps in bringing Raman spectroscopy closer to 
a formal clinical application.  
However, despite the acknowledged limitations, this current study was successful in 
establishing new foundations for saliva concentration, Raman spectrum acquisition, 
processing and Raman data analysis. The standardisation of Raman methodology for 
saliva analysis represents a reliable and reproducible pathway to be translated into clinics. 
Also, the advantages associated with the Raman technique, such as its label-free and non-
invasive nature; along with the rich biomolecular information of saliva samples suggest 
great potential for the future of the oral medicine diagnostic field. 
 
 
 
 
260 
 
References 
1. Hajian-Tilaki K. Receiver Operating Characteristic (ROC) Curve Analysis for Medical 
Diagnostic Test Evaluation. Caspian J Intern Med. 2013;4(2):627–635. 
2. Connolly JM, Davies K, Kazakeviciute A, Wheatley AM, Dockery P, Keogh I, Olivo 
M. Non-invasive and label-free detection of oral squamous cell carcinoma using saliva 
surface-enhanced Raman spectroscopy and multivariate analysis. Nanomedicine. 2016 
Aug;12(6):1593-601. doi: 10.1016/j.nano.2016.02.021. Epub 2016 Mar 23. 
3. Rekha P, Aruna P, Brindha E, Koteeswaran D, Baludavid M, Ganesan S. Near-infrared 
Raman spectroscopic characterization of salivary metabolites in the discrimination of 
normal from oral premalignant and malignant conditions. J Raman Spectrosc. 2015, 
47:763-772.S.  
4. Jaychandran S, Meenapriya PK, Ganesan S. Raman Spectroscopic Analysis of Blood, 
Urine, Saliva and Tissue of Oral Potentially Malignant Disorders and Malignancy-A 
Diagnostic Study. Int J Oral Craniofac Sci 2016, 2(1): 011-014.  
5. Beleites C, Neugebauer U, Bocklitz T, Krafft C, Popp J. Sample Size Planning for 
Classification Models. Analytica Chimica Acta, 2013,760:25–33. 
6. Jermyn M, Desroches J, Aubertin K, St-Arnaud K, Madore WJ, De Montigny E, Guiot 
MC, Trudel D, Wilson BC, Petrecca K, Leblond F. A review of Raman spectroscopy 
advances with an emphasis on clinical translation challenges in oncology. Phys Med Biol. 
2016 Dec 7;61(23):R370-R400. Epub 2016 Nov 2. 
7. Golatowski C, Salazar MG, Dhople VM, Hammer E, Kocher T, Jehmlich N, Völker 
U. Comparative evaluation of saliva collection methods for proteome analysis. Clin Chim 
Acta. 2013;18;419:42-6. doi: 10.1016/j.cca.2013.01.013. Epub 2013 Feb 
261 
 
8. Mohamed R, Campbell JL, Cooper-White J, Dimeski G, Punyadeera C. The impact of 
saliva collection and processing methods on CRP, IgE, and Myoglobin immunoassays. 
Clin Transl Med. 2012;1(1):19. Published 2012 Sep 5. doi:10.1186/2001-1326-1-19 
9. Calado G, Behl I, Daniel A, Byrne HJ, Lyng FM. Raman spectroscopic analysis of 
saliva for the diagnosis of oral cancer: a systematic review. Translational Biophotonics. 
Accepted for publication in August/2019. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
262 
 
 
Appendix I – Participant consent and Ethical approval from DIT (now TU Dublin) 
 
Participant Information Leaflet  
(HEALTHY VOLUNTEERS) 
 
Names of researchers:  
  Prof Fiona Lyng, Dublin Institute of Technology 
  Mr Genecy Calado, PhD student, Dublin Institute of Technology 
 
Title of study: 
“Investigation of saliva samples using Raman spectroscopy” 
 
Introduction 
We have a mouth cancer research project which has been funded by Science without Borders and 
we would be grateful for your assistance. 
 
Mouth cancer ranks as the 15th most common cancer in the world and 10th most frequent in males. 
It accounts for ~2.1% of total cancer cases worldwide. The 5 year survival rate is approximately 
80% for early stage disease but only approximately 20% for late stage disease and patients often 
present with advanced disease.  Early detection of mouth cancer or pre-cancer greatly increases 
the chances for successful treatment. Bio fluids such as blood, urine, and saliva can provide 
information about human health and are being widely investigated for clinical diagnosis of various 
diseases including oral cancers.  
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The purpose of our study is to investigate whether a novel technology using Raman spectroscopy 
can identify cancer or pre-cancer in a patient from a sample of their saliva. Raman spectroscopy 
is a form of laser technology which can produce a unique biochemical fingerprint of a sample 
when the light is shone on it and analysed.  In the future, we would like to apply this technology 
to saliva samples taken from mouth cancer patients. We would first like to develop the methods 
using saliva from healthy volunteers.  
 
You have been invited to take part as a healthy volunteer. Our study requires a sample of saliva. 
 
You are completely at liberty to refuse to participate.  
 
What will happen if I take part? 
If you decide to take part, after rinsing your mouth with water, you will provide a saliva sample 
into a plastic container. The sample will frozen at -80oC and will subsequently be analysed using 
Raman spectroscopy. 
The samples and results will be anomymised and coded, so that they will not be identifiable as 
coming from you. The data will be transferred and stored on a single encrypted computer in the 
Dublin Institute of Technology. The samples will be destroyed 5 years after completion of the 
study. This is because Raman technology is relatively new and developing all the time, and we 
would like the opportunity to take advantage of any new developments in the Raman 
spectroscopy field in the near future. The data will only be available to the research team and 
will not be made available to any third parties. It will not be used for any other research other 
than that for which you have consented.    
 
Possible benefits of the study.  
There are no direct benefits to yourself, other than knowing that you have contributed to 
scientific research on mouth cancer prevention.  
 
Possible risks to participants and after effects  
There are no risks or side effects from donating a saliva sample.  
 
What will happen to the results of the study 
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This project will contribute to a PhD (doctorate) degree and the results of the study will be 
published in scientific journals and presented at scientific meetings, with due consideration to 
confidentiality.    
 
Confidentiality of information 
Your identity will remain entirely confidential. Your name will not be published and will not be 
disclosed to anyone outside the study team. Your data and sample will be coded and anonymised 
and once this has been done, it will be transferred and stored securely on a dedicated, encrypted 
computer in the Dublin Institute of Technology and thereafter will not be traceable back to 
yourself. 
 
Voluntary participation 
We stress that you are NOT obliged to take part. If, after agreeing to assist in our mouth cancer 
research, you wish to withdraw from the study, all your samples and data will be destroyed.  
 
Permission  
Ethical approval has been obtained from Dublin Institute of Technology. 
 
Further information and how to take part 
The procedures will be explained to you, any questions that you have answered, and an 
informed consent form must then be signed by you if you agree to take part in this study.  
 
Contact details of researchers 
Prof. Fiona Lyng 
Focas Research Institute 
Dublin Institute of Technology, Kevin St 
Tel 01 4027972 
 
 
This study is covered by standard institutional indemnity insurance. 
Nothing in this document restricts or curtails your rights. 
The researchers declare no conflict of interest. 
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CONSENT FORM  
(HEALTHY VOLUNTEERS) 
 
Names of researchers:  
  Prof Fiona Lyng, Dublin Institute of Technology 
  Mr Genecy Calado, PhD student, Dublin Institute of Technology 
 
Title of study: 
“Investigation of saliva samples using Raman spectroscopy” 
 
BACKGROUND:  
Our research involves the use of Raman technology to try to develop a new technique for early 
detection of mouth cancer and pre-cancer using saliva (see accompanying Patient Information 
Leaflet). To help us to develop the methods we need to take some saliva samples from healthy 
volunteers. We are asking your permission for a saliva sample.   
Your data will be anonymised, coded, confidential, securely stored and will not be disclosed to 
third parties.  
 
Voluntary participation 
We stress that you are NOT obliged to take part. If, after agreeing to assist in our mouth cancer 
research, you wish to withdraw from the study, all samples and data will be destroyed 
 
DECLARATION: 
I have read, or had read to me, this consent form and the accompanying Patient Information 
Leaflet. I have had the opportunity to ask questions and all my questions have been answered 
to my satisfaction. I freely and voluntarily agree to be part of this research study, though without 
prejudice to my legal and ethical rights. I understand I may withdraw from the study at any time.  
I have received a copy of this agreement.   
 
Participant’s Name ……………………………………………………….. 
 
Contact Details:……………………………………………………….. 
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………………………………………………………………………………………… 
 
Participant's Signature:…………………………………………………Date:………………… 
 
Nothing in this document restricts or curtails your rights. 
 
________________________________________________________ 
 
 
I ………………………………………….. the Researcher : 
 
I have explained the nature and purpose of this research study, the procedures to be undertaken 
and any risks that may be involved. I have offered to answer any questions and fully answered 
such questions. I believe that the participant understands my explanation and has freely given 
informed consent. 
 
Investigator’s Signature:………………………………………  Date:………… 
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Participant Form 
Raman Micro-spectroscopic study of oral cancer 
Name: Ms. Isha Behl & Mr.Genecy Calado  
Supervisors: Prof.s Fiona Lyng and Hugh J. Byrne 
 
Volunteer Number: __________ 
Date of Birth: ___/___/____ 
Gender:        Male      Female 
Ethnicity1:  White Irish or other White Background  Black or Black Irish - 
African or other Black Background         Asian or Asian Irish - Chinese or other Asian 
Background 
Note: 
______________________________________________________________________ 
______________________________________________________________________
_____ 
 
A) HABITS 
1) Alcohol consumption:  
a) How many units per week:         
b) Time of last consumption: 
2) Tobacco consumption: 
a) Consumption in which form:         Cigarettes           Cigar          Narquile 
(Shish)  
Others: _________________ 
b) How many/much per day: 
c) Time of last consumption: 
3) Sexual preferences: 
a) Sexual Orientation:         Heterosexual         Homosexual         Bisexual 
b) Number of partners in last 3 months: 
 
1 According to Central Statistics Office, Ireland 
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4) Oral Hygiene: 
a) Brushing:               Yes              No 
                                      If yes so, how many times per day:                    Last brushing: 
 b) Mouthwash:             No               Yes, Name:   
                    If yes so, how many times per day:                    Last 
consumption: 
 e) Flossing:         Yes              No 
If yes so, how often:                    Last flossing: 
 f) Periodontal disease:        Gingivitis           Periodontitis          Unknown  
   Others: ___________________ 
g) Dry mouth:        Yes               No 
If yes, reason: ________________ 
 f) How regularly do you see a dentist/oral hygienist? 
   When last visited:_________________ 
 
B) MEDICAL CONDITION 
1) Any known disease:        No              Yes, 
_____________________________________ . 
2) Medication (last consumption): 
3) How do you consider your current state of health?         
      Excellent         
      Good      
      Fair       
      Poor   
Annex I -  
269 
 
Volunteer Number: __________ 
Date of collection: ___/___/____        Time: _______ 
 
PHYSICAL EXAMINATION: 
 
 
 
SAMPLE COLLECTION: 
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Appendix III – Participant consent and Ethical approval from Dublin Dental 
University Hospital. 
Patient Information Sheet 
PATIENTS ATTENDING DYSPLASIA CLINIC 
 
“Identification of high risk-oral precancerous lesions using Raman technology” 
 
Introduction  
As academics in Trinity College Dublin, and the Dublin Institute of Technology, we engage in 
scientific research. One particular area of our interest is mouth cancer and precancer 
research. We have a mouth cancer research project which has been funded by Science 
Foundation Ireland and we would be grateful for your assistance. 
 
You are attending the Dysplasia Clinic because you have a white patchin your mouth called a 
leukoplakia The diagnosis of leukoplakia is made by inspecting the area visually, and if necessary, 
by taking a sample (a biopsy), of the tissue and looking at it under a microscope, to confirm the 
diagnosis. The biopsy test is very good at reaching a diagnosis and telling us if there are any 
abnormal cells in the sample. Unfortunately, however, at this time, we cannot predict with any 
certainty which of these leukoplakias will become cancers in the future, although we know that 
about one in twenty will.   
 
Raman spectroscopy is a new form of laser technology which can produce a unique biological 
fingerprint (like a bar code in the supermarket) of cells in a biopsy sample when the light is shone 
on it and analysed.  It has already been used on cervical smears (the smear test for cancer of the 
cervix in women) and can identify high-risk, precancerous cells. We should like to apply this 
technology to samples of leukoplakias taken from the mouths of our patients, to see if we can 
identify high-risk, precancerous cells, so that we can provide a treatment aimed at preventing 
the leukoplakia turning into a mouth cancer.  
 
We ask you to consent to having a “brush biopsy” of the leukoplakia to analyse with the laser 
technology. This involves scraping the area to remove a superficial layer of cells.  In addition, we 
would like to take a saliva sample as saliva can provide important information about human health 
and is being researched as an indicator of various diseases including oral diseases. 
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You are completely at liberty to refuse to participate. Refusal to participate 
will not affect your treatment, or future management, in any way. 
 
What happens to the tissue I donate to the study? 
The brush biopsy cells and the saliva sample will be processed in the laboratory so that the 
samples can be analysed with the Raman laser. We will also carry out staining 
(immunocytochemistry) on the brush biopsy cells to look at different proteins. In addition, we 
will need to record some limited clinical details, after access to your clinical file. 
 
The samples and results, and clinical details will be anonymised and coded, so that they will not 
be identifiable as coming from you. The data and samples will be transferred and stored in the 
Dublin Institute of Technology, the data on a single encrypted computer. The code will remain 
in the Dental Hospital. The samples will be destroyed 5 years after completion of the study. This 
is because Raman technology is relatively new and developing all the time, and we would like 
the opportunity to take advantage of any new developments in the Raman laser field in the near 
future. The data will only be available to the research team and will not be made available to 
any third parties. Only members of the clinical team, when you attend the clinic in the Dublin 
Dental University, will be allowed access to your clinical files. The data and samples will not be 
used for any other research other than that for which you have consented.    
 
Possible benefits of the study. 
If we can identify high-risk lesions and treat these lesions early, we may be able to prevent the 
lesions progressing to cancer. Oral leukoplakias are often quite extensive and since we cannot 
predict which one in twenty will become cancers, it is difficult to justify extensive operations to 
remove every lesion completely, since this treatment would be unjustified in nineteen out of 
twenty cases. If this technology proves effective, we can justify more extensive surgical 
treatment in selected patients, with an aim to prevent these lesions developing into mouth 
cancer in the future. Mouth cancer is a particularly nasty disease because the treatment for 
established mouth cancer is an extensive mouth and neck surgical operation, which is both 
disfiguring and may involve visible scarring and complex reconstructive surgery afterwards. 
 
Possible risks to participants and after effects  
There are no more risks than if you were not in the research study. The “brush biopsy” will 
only cause minimal, if any, discomfort and will leave no scar. 
 
Location of research: Dublin Dental School and Hospital and Dublin Institute of Technology. 
What will happen to the results of the study 
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This project will contribute to a PhD (doctorate) degree and the results of the study will be 
published in scientific journals, with due consideration to confidentiality.    
 
Confidentiality of information 
Your identity will remain entirely confidential. Your name will not be published and will not be 
disclosed to anyone outside the study team. Your data and sample will be coded and anonymised 
and once this has been done, it will be transferred and stored securely on a dedicated, encrypted 
computer in the Dublin Institute of Technology and will not be traceable back to yourself, without 
the code, which will remain secure in the Dublin Dental University Hospital 
 
Voluntary participation 
We stress that you are NOT obliged to take part. If, after agreeing to assist in our mouth cancer 
research, you wish to withdraw from the study, all samples and data will be destroyed.  
 
Permission  
Ethical approval has been obtained from the Faculty Research Ethics Group – Faculty of Health 
Sciences, Trinity College Dublin. Granted October 2016. 
 
Further information and how to take part 
The procedures will be explained to you, any questions that you have answered, and an 
informed consent form must then be signed by you if you agree to take part in this study.  
 
Contact details of researchers 
Prof. Stephen Flint and Prof Fiona Lyng 
C/O Department of Oral and Maxillofacial Surgery, Oral Medicine and Oral Pathology 
Dublin Dental School & Hospital, Lincoln Place, Dublin 2 
Tel: 01 6127200.  
 
This study is covered by standard institutional indemnity insurance. 
Nothing in this document restricts or curtails your rights. 
The researchers declare no conflict of interest 
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CONSENT FORM 
PATIENTS ATTENDING DYSPLASIA CLINIC 
 
Names of researchers:  
 
Prof. Stephen Flint (Dublin Dental University Hospital) 
  Prof Fiona Lyng (Dublin Institute of Technology) 
 
Title of study: 
 
“Identification of high risk-oral precancerous lesions using Raman technology” 
  
BACKGROUND:  
Our research involves the use of sophisticated laser technology to try to identify lesions in the 
mouth that are high risk for becoming cancer, in order that we can treat these lesions with a view 
to preventing them becoming cancerous (see accompanying Patient Information Leaflet). We ask 
permission to take and analyse a “brush biopsy” sample and a saliva sample.   
Your data, and any clinical information, will be anonymised, coded, confidential, securely stored 
and will not be disclosed to third parties.  
 
Voluntary participation 
We stress that you are NOT obliged to take part. If, after agreeing to assist in our mouth cancer 
research, you wish to withdraw from the study, all samples and data will be destroyed.  
 
DECLARATION: 
I have read, or had read to me, this consent form and the accompanying Patient Information 
Leaflet. I have had the opportunity to ask questions and all my questions have been answered 
to my satisfaction. I freely and voluntarily agree to be part of this research study, though without 
prejudice to my legal and ethical rights. I understand I may withdraw from the study at any time.  
I have received a copy of this agreement.   
 
Patient’s Name ……………………………………………………….. 
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Contact Details:……………………………………………………….. 
………………………………………………………………………………………… 
 
Participant's Signature:…………………………………………………Date:………………… 
 
Nothing in this document restricts or curtails your rights. 
 
 
 
I ………………………………………….. the Researcher : 
 
I have explained the nature and purpose of this research study, the procedures to be undertaken 
and any risks that may be involved. I have offered to answer any questions and fully answered 
such questions. I believe that the participant understands my explanation and has freely given 
informed consent. 
 
Investigator’s Signature:………………………………………  Date:………… 
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Appendix IV – Publications and Conference presentations 
Conference Presentations: 
2015 - 6th Annual Graduate Research Symposium, Dublin, Ireland (Poster); 
2016 - 40th annual symposium of the Microscopy Society of Ireland, Dublin, Ireland 
(Poster); 
2016 - SPEC Conference, Montreal, Canada (Poster); 
2016 - Brazilian Society for Oral Pathology and Oral Medicine, Manaus, Brazil (Poster); 
2017 - 2017 British Society for Oral Medicine Annual Scientific Meeting, Dublin, Ireland 
(Poster); 
2017 - 40th annual symposium of the Microscopy Society of Ireland (Poster), Dublin, 
Ireland; 
2018 - SPEC, Glasgow, UK (Poster Presentation); 
2018 – International Association of Oral Pathologists (IAOP) and American Academy of 
Oral and Maxillofacial Pathology joint Annual Meeting 2018, Vancouver, canada (Oral 
presentation); 
2018 - International Association for Dental Research/PER General Session – London, 
England (Oral presentation); 
2019 - Microscopy Society of Ireland, Dublin, Ireland (Oral Presentation); 
2019- British Society for Oral Medicine Annual Scientific Meeting, Dublin, Ireland, 
(Poster)*; 
2019 – Portuguese Dental Association Conference, Lisbon, Portugal (Oral Presentation); 
276 
 
*RCSI award for best poster presentation 
 
Publications: 
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Full-article: Isha Behl, Genecy Calado, Ola Ibrahim, Alison Malkin, Stephen Flint, Hugh 
J. Byrne and Fiona M. Lyng. Development of methodology for Raman 
microspectroscopic analysis of oral exfoliated cells. Anal. Methods, 2017;9:937.  
 
Abstract: Genecy Calado, Isha Behl, Ola Ibrahim, Stephen Flint, Hugh J. Byrne and Fiona 
M. Lyng. DEVELOPMENT OF METHODOLOGIES FOR RAMAN SPECTRAL 
ANALYSIS OF HUMAN SALIVA FOR DETECTION OF ORAL CANCER. Oral 
Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology 
124(2):e142 
 
Abstract: Isha Behl, Genecy Calado, Ola Ibrahim, Alison Malkin, Stephen Flint, Hugh J. 
Byrne and Fiona M. Lyng. A STUDY OF ORAL EXFOLIATED CELLS USING 
RAMAN MICROSPECTROSCOPY. Oral Surgery, Oral Medicine, Oral Pathology, Oral 
Radiology, and Endodontology 124(2):e144 · August 2017 
 
Abstract:  Dr. Calado Genecy, Ms. Isha Behi, Dr. Marina Leite Pimentel, Dr. Sheila 
Galvin, Dr. Stephen Flint, Prof. Hugh J Byrne, Prof. Fiona Lyng, RAMAN SPECTRAL 
STUDY OF SALIVA: A NEW TOOL FOR DETECTION OF MALIGNANT AND 
PREMALIGNANT ORAL LESIONS, Oral Surgery, Oral Medicine, Oral Pathology and 
Oral Radiology. 2019;128;(1):e90.  
 
 
 
 
- Accepted for publication: 
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